date generated: 2024-03-12
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
| x | |
|---|---|
| 5_8S_rRNA | -0.7235362 |
| 7SK | 0.0792128 |
| A1BG | -0.8697311 |
| A1BG.AS1 | 0.2565051 |
| A2M | 1.2525086 |
| A2M.AS1 | 0.8703520 |
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2612 |
| num_genes_in_profile | 16514 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8299 |
| num_profile_genes_not_in_sets | 8215 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used:
GMT file of genesets: ReactomePathways_2023-09-01.gmt| Gene sets metrics | |
|---|---|
| num_genesets | 2612 |
| num_genesets_excluded | 1149 |
| num_genesets_included | 1463 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Cohesin Loading onto Chromatin | 10 | 1.15e-05 | -0.801 | 1.07e-04 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 7.71e-22 | -0.777 | 2.82e-20 |
| Formation of a pool of free 40S subunits | 100 | 1.03e-37 | -0.742 | 2.16e-35 |
| SARS-CoV-1 modulates host translation machinery | 36 | 2.55e-14 | -0.733 | 6.92e-13 |
| Ribosomal scanning and start codon recognition | 58 | 8.19e-22 | -0.728 | 2.92e-20 |
| Viral mRNA Translation | 88 | 5.17e-32 | -0.725 | 4.45e-30 |
| Peptide chain elongation | 88 | 1.09e-31 | -0.721 | 8.00e-30 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 2.30e-39 | -0.720 | 1.12e-36 |
| Translation initiation complex formation | 58 | 3.70e-21 | -0.716 | 1.26e-19 |
| Selenocysteine synthesis | 92 | 2.02e-32 | -0.714 | 1.97e-30 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 2.41e-38 | -0.713 | 5.89e-36 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 3.17e-21 | -0.711 | 1.10e-19 |
| Eukaryotic Translation Termination | 92 | 4.28e-32 | -0.710 | 3.92e-30 |
| Eukaryotic Translation Elongation | 93 | 8.51e-32 | -0.703 | 6.56e-30 |
| Establishment of Sister Chromatid Cohesion | 10 | 1.23e-04 | -0.701 | 8.41e-04 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 2.21e-31 | -0.695 | 1.54e-29 |
| Cap-dependent Translation Initiation | 118 | 2.18e-38 | -0.689 | 5.89e-36 |
| Eukaryotic Translation Initiation | 118 | 2.18e-38 | -0.689 | 5.89e-36 |
| PINK1-PRKN Mediated Mitophagy | 21 | 7.32e-08 | -0.678 | 1.12e-06 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 5.41e-31 | -0.669 | 3.44e-29 |
| Expression and translocation of olfactory receptors | 25 | 1.03e-08 | 0.661 | 1.81e-07 |
| SARS-CoV-2 modulates host translation machinery | 49 | 3.30e-15 | -0.650 | 9.10e-14 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 1.22e-32 | -0.644 | 1.28e-30 |
| Nonsense-Mediated Decay (NMD) | 114 | 1.22e-32 | -0.644 | 1.28e-30 |
| Selenoamino acid metabolism | 114 | 8.23e-32 | -0.636 | 6.56e-30 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 2.59e-30 | -0.628 | 1.58e-28 |
| Mitophagy | 28 | 1.50e-08 | -0.618 | 2.53e-07 |
| Common Pathway of Fibrin Clot Formation | 11 | 4.86e-04 | 0.607 | 2.66e-03 |
| Formation of ATP by chemiosmotic coupling | 16 | 3.99e-05 | -0.593 | 3.01e-04 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 1.17e-03 | -0.593 | 5.58e-03 |
| Olfactory Signaling Pathway | 29 | 3.34e-08 | 0.592 | 5.26e-07 |
| Influenza Viral RNA Transcription and Replication | 135 | 4.32e-30 | -0.568 | 2.53e-28 |
| Cellular response to starvation | 148 | 2.33e-31 | -0.554 | 1.55e-29 |
| Translation | 292 | 1.17e-59 | -0.553 | 8.54e-57 |
| Cristae formation | 29 | 4.03e-07 | -0.544 | 5.61e-06 |
| Complex I biogenesis | 51 | 2.08e-11 | -0.542 | 4.68e-10 |
| Respiratory electron transport | 93 | 3.66e-19 | -0.537 | 1.22e-17 |
| Receptor Mediated Mitophagy | 11 | 2.12e-03 | -0.535 | 8.88e-03 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 113 | 1.39e-22 | -0.532 | 5.37e-21 |
| Mitochondrial translation | 94 | 5.59e-19 | -0.531 | 1.82e-17 |
| Mitochondrial translation termination | 88 | 8.14e-18 | -0.530 | 2.53e-16 |
| Mitochondrial translation elongation | 88 | 1.10e-17 | -0.528 | 3.36e-16 |
| Mitochondrial translation initiation | 88 | 1.13e-17 | -0.528 | 3.37e-16 |
| Influenza Infection | 154 | 3.36e-29 | -0.523 | 1.76e-27 |
| Formation of Fibrin Clot (Clotting Cascade) | 20 | 5.36e-05 | 0.522 | 3.94e-04 |
| Branched-chain amino acid catabolism | 21 | 3.89e-05 | -0.519 | 2.95e-04 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 12 | 1.96e-03 | -0.516 | 8.34e-03 |
| Beta-catenin phosphorylation cascade | 17 | 2.42e-04 | -0.514 | 1.46e-03 |
| Regulation of expression of SLITs and ROBOs | 162 | 1.86e-29 | -0.513 | 1.01e-27 |
| Laminin interactions | 30 | 1.54e-06 | 0.507 | 1.94e-05 |
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Cohesin Loading onto Chromatin | 10 | 1.15e-05 | -0.801000 | 1.07e-04 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 7.71e-22 | -0.777000 | 2.82e-20 |
| Formation of a pool of free 40S subunits | 100 | 1.03e-37 | -0.742000 | 2.16e-35 |
| SARS-CoV-1 modulates host translation machinery | 36 | 2.55e-14 | -0.733000 | 6.92e-13 |
| Ribosomal scanning and start codon recognition | 58 | 8.19e-22 | -0.728000 | 2.92e-20 |
| Viral mRNA Translation | 88 | 5.17e-32 | -0.725000 | 4.45e-30 |
| Peptide chain elongation | 88 | 1.09e-31 | -0.721000 | 8.00e-30 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 2.30e-39 | -0.720000 | 1.12e-36 |
| Translation initiation complex formation | 58 | 3.70e-21 | -0.716000 | 1.26e-19 |
| Selenocysteine synthesis | 92 | 2.02e-32 | -0.714000 | 1.97e-30 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 2.41e-38 | -0.713000 | 5.89e-36 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 3.17e-21 | -0.711000 | 1.10e-19 |
| Eukaryotic Translation Termination | 92 | 4.28e-32 | -0.710000 | 3.92e-30 |
| Eukaryotic Translation Elongation | 93 | 8.51e-32 | -0.703000 | 6.56e-30 |
| Establishment of Sister Chromatid Cohesion | 10 | 1.23e-04 | -0.701000 | 8.41e-04 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 2.21e-31 | -0.695000 | 1.54e-29 |
| Cap-dependent Translation Initiation | 118 | 2.18e-38 | -0.689000 | 5.89e-36 |
| Eukaryotic Translation Initiation | 118 | 2.18e-38 | -0.689000 | 5.89e-36 |
| PINK1-PRKN Mediated Mitophagy | 21 | 7.32e-08 | -0.678000 | 1.12e-06 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 5.41e-31 | -0.669000 | 3.44e-29 |
| Expression and translocation of olfactory receptors | 25 | 1.03e-08 | 0.661000 | 1.81e-07 |
| SARS-CoV-2 modulates host translation machinery | 49 | 3.30e-15 | -0.650000 | 9.10e-14 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 1.22e-32 | -0.644000 | 1.28e-30 |
| Nonsense-Mediated Decay (NMD) | 114 | 1.22e-32 | -0.644000 | 1.28e-30 |
| Selenoamino acid metabolism | 114 | 8.23e-32 | -0.636000 | 6.56e-30 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 2.59e-30 | -0.628000 | 1.58e-28 |
| Mitophagy | 28 | 1.50e-08 | -0.618000 | 2.53e-07 |
| Common Pathway of Fibrin Clot Formation | 11 | 4.86e-04 | 0.607000 | 2.66e-03 |
| Formation of ATP by chemiosmotic coupling | 16 | 3.99e-05 | -0.593000 | 3.01e-04 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 1.17e-03 | -0.593000 | 5.58e-03 |
| Olfactory Signaling Pathway | 29 | 3.34e-08 | 0.592000 | 5.26e-07 |
| Influenza Viral RNA Transcription and Replication | 135 | 4.32e-30 | -0.568000 | 2.53e-28 |
| Cellular response to starvation | 148 | 2.33e-31 | -0.554000 | 1.55e-29 |
| Translation | 292 | 1.17e-59 | -0.553000 | 8.54e-57 |
| Cristae formation | 29 | 4.03e-07 | -0.544000 | 5.61e-06 |
| Complex I biogenesis | 51 | 2.08e-11 | -0.542000 | 4.68e-10 |
| Respiratory electron transport | 93 | 3.66e-19 | -0.537000 | 1.22e-17 |
| Receptor Mediated Mitophagy | 11 | 2.12e-03 | -0.535000 | 8.88e-03 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 113 | 1.39e-22 | -0.532000 | 5.37e-21 |
| Mitochondrial translation | 94 | 5.59e-19 | -0.531000 | 1.82e-17 |
| Mitochondrial translation termination | 88 | 8.14e-18 | -0.530000 | 2.53e-16 |
| Mitochondrial translation elongation | 88 | 1.10e-17 | -0.528000 | 3.36e-16 |
| Mitochondrial translation initiation | 88 | 1.13e-17 | -0.528000 | 3.37e-16 |
| Influenza Infection | 154 | 3.36e-29 | -0.523000 | 1.76e-27 |
| Formation of Fibrin Clot (Clotting Cascade) | 20 | 5.36e-05 | 0.522000 | 3.94e-04 |
| Branched-chain amino acid catabolism | 21 | 3.89e-05 | -0.519000 | 2.95e-04 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 12 | 1.96e-03 | -0.516000 | 8.34e-03 |
| Beta-catenin phosphorylation cascade | 17 | 2.42e-04 | -0.514000 | 1.46e-03 |
| Regulation of expression of SLITs and ROBOs | 162 | 1.86e-29 | -0.513000 | 1.01e-27 |
| Laminin interactions | 30 | 1.54e-06 | 0.507000 | 1.94e-05 |
| APC truncation mutants have impaired AXIN binding | 14 | 1.27e-03 | -0.497000 | 5.82e-03 |
| AXIN missense mutants destabilize the destruction complex | 14 | 1.27e-03 | -0.497000 | 5.82e-03 |
| Signaling by AMER1 mutants | 14 | 1.27e-03 | -0.497000 | 5.82e-03 |
| Signaling by APC mutants | 14 | 1.27e-03 | -0.497000 | 5.82e-03 |
| Signaling by AXIN mutants | 14 | 1.27e-03 | -0.497000 | 5.82e-03 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 1.27e-03 | -0.497000 | 5.82e-03 |
| cGMP effects | 14 | 1.81e-03 | 0.481000 | 8.01e-03 |
| CTNNB1 S33 mutants aren’t phosphorylated | 15 | 1.28e-03 | -0.480000 | 5.82e-03 |
| CTNNB1 S37 mutants aren’t phosphorylated | 15 | 1.28e-03 | -0.480000 | 5.82e-03 |
| CTNNB1 S45 mutants aren’t phosphorylated | 15 | 1.28e-03 | -0.480000 | 5.82e-03 |
| CTNNB1 T41 mutants aren’t phosphorylated | 15 | 1.28e-03 | -0.480000 | 5.82e-03 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 1.28e-03 | -0.480000 | 5.82e-03 |
| Signaling by GSK3beta mutants | 15 | 1.28e-03 | -0.480000 | 5.82e-03 |
| The citric acid (TCA) cycle and respiratory electron transport | 160 | 1.68e-25 | -0.478000 | 7.01e-24 |
| Mitochondrial Fatty Acid Beta-Oxidation | 34 | 1.66e-06 | -0.475000 | 2.04e-05 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 13 | 3.10e-03 | -0.474000 | 1.25e-02 |
| Mitotic Telophase/Cytokinesis | 13 | 3.22e-03 | -0.472000 | 1.29e-02 |
| Eicosanoid ligand-binding receptors | 13 | 3.37e-03 | 0.470000 | 1.33e-02 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 1.80e-27 | -0.469000 | 7.96e-26 |
| Attenuation phase | 23 | 1.03e-04 | -0.468000 | 7.13e-04 |
| HIV elongation arrest and recovery | 32 | 4.99e-06 | -0.466000 | 5.25e-05 |
| Pausing and recovery of HIV elongation | 32 | 4.99e-06 | -0.466000 | 5.25e-05 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 7.73e-03 | -0.464000 | 2.70e-02 |
| Alpha-protein kinase 1 signaling pathway | 11 | 7.79e-03 | -0.463000 | 2.71e-02 |
| rRNA processing in the nucleus and cytosol | 190 | 3.19e-28 | -0.463000 | 1.50e-26 |
| NF-kB is activated and signals survival | 13 | 3.83e-03 | -0.463000 | 1.49e-02 |
| Cytosolic tRNA aminoacylation | 24 | 9.07e-05 | -0.462000 | 6.35e-04 |
| FOXO-mediated transcription of cell death genes | 15 | 2.03e-03 | -0.460000 | 8.54e-03 |
| rRNA processing | 200 | 7.53e-29 | -0.457000 | 3.67e-27 |
| Mitochondrial protein import | 63 | 4.69e-10 | -0.454000 | 9.40e-09 |
| E3 ubiquitin ligases ubiquitinate target proteins | 44 | 2.04e-07 | -0.453000 | 2.95e-06 |
| Regulation of BACH1 activity | 11 | 9.45e-03 | -0.452000 | 3.10e-02 |
| mRNA Splicing | 210 | 3.90e-29 | -0.448000 | 1.97e-27 |
| mRNA Splicing - Major Pathway | 202 | 8.84e-28 | -0.446000 | 4.04e-26 |
| Citric acid cycle (TCA cycle) | 22 | 3.01e-04 | -0.445000 | 1.78e-03 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 29 | 3.74e-05 | -0.442000 | 2.86e-04 |
| mRNA Splicing - Minor Pathway | 50 | 8.36e-08 | -0.438000 | 1.25e-06 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 3.50e-05 | -0.437000 | 2.74e-04 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 3.50e-05 | -0.437000 | 2.74e-04 |
| Suppression of phagosomal maturation | 13 | 6.66e-03 | -0.435000 | 2.36e-02 |
| Peroxisomal protein import | 56 | 1.88e-08 | -0.434000 | 3.12e-07 |
| Formation of RNA Pol II elongation complex | 56 | 2.00e-08 | -0.434000 | 3.26e-07 |
| RNA Polymerase II Transcription Elongation | 56 | 2.00e-08 | -0.434000 | 3.26e-07 |
| Defective B3GALTL causes PpS | 35 | 1.10e-05 | 0.429000 | 1.04e-04 |
| tRNA Aminoacylation | 42 | 1.79e-06 | -0.426000 | 2.15e-05 |
| Glyoxylate metabolism and glycine degradation | 24 | 3.06e-04 | -0.426000 | 1.79e-03 |
| O-glycosylation of TSR domain-containing proteins | 36 | 1.10e-05 | 0.423000 | 1.04e-04 |
| Protein ubiquitination | 63 | 6.81e-09 | -0.422000 | 1.21e-07 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 9.22e-03 | -0.417000 | 3.06e-02 |
| ERBB2 Activates PTK6 Signaling | 11 | 1.66e-02 | 0.417000 | 4.81e-02 |
| Crosslinking of collagen fibrils | 18 | 2.39e-03 | 0.413000 | 9.98e-03 |
| Adrenaline,noradrenaline inhibits insulin secretion | 22 | 7.90e-04 | 0.413000 | 3.98e-03 |
| Chaperone Mediated Autophagy | 20 | 1.41e-03 | -0.412000 | 6.34e-03 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 6.83e-04 | -0.409000 | 3.52e-03 |
| Protein localization | 154 | 2.14e-18 | -0.409000 | 6.80e-17 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 6.18e-03 | -0.408000 | 2.23e-02 |
| IRAK2 mediated activation of TAK1 complex | 10 | 2.60e-02 | -0.407000 | 6.95e-02 |
| APC-Cdc20 mediated degradation of Nek2A | 23 | 7.79e-04 | -0.405000 | 3.95e-03 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 10 | 2.68e-02 | -0.405000 | 7.06e-02 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 3.60e-06 | -0.404000 | 4.06e-05 |
| Translesion synthesis by POLK | 17 | 4.11e-03 | -0.402000 | 1.57e-02 |
| Translesion synthesis by REV1 | 16 | 6.08e-03 | -0.396000 | 2.21e-02 |
| Signaling by ROBO receptors | 201 | 3.69e-22 | -0.396000 | 1.38e-20 |
| RORA activates gene expression | 18 | 3.63e-03 | -0.396000 | 1.42e-02 |
| Processing of Capped Intron-Containing Pre-mRNA | 278 | 9.22e-30 | -0.395000 | 5.19e-28 |
| Late endosomal microautophagy | 31 | 1.49e-04 | -0.394000 | 9.76e-04 |
| Folding of actin by CCT/TriC | 10 | 3.17e-02 | -0.392000 | 8.01e-02 |
| Membrane binding and targetting of GAG proteins | 14 | 1.11e-02 | -0.392000 | 3.53e-02 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 1.11e-02 | -0.392000 | 3.53e-02 |
| HSF1 activation | 26 | 5.69e-04 | -0.390000 | 2.99e-03 |
| Prolactin receptor signaling | 10 | 3.30e-02 | -0.389000 | 8.22e-02 |
| Mitochondrial tRNA aminoacylation | 21 | 2.02e-03 | -0.389000 | 8.52e-03 |
| VLDLR internalisation and degradation | 15 | 9.34e-03 | -0.388000 | 3.09e-02 |
| Translesion synthesis by POLI | 17 | 5.82e-03 | -0.386000 | 2.14e-02 |
| RNA Polymerase II Pre-transcription Events | 77 | 5.37e-09 | -0.385000 | 9.71e-08 |
| mTORC1-mediated signalling | 24 | 1.16e-03 | -0.383000 | 5.52e-03 |
| Processing of SMDT1 | 15 | 1.06e-02 | -0.381000 | 3.40e-02 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 19 | 4.16e-03 | -0.380000 | 1.59e-02 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 2.10e-05 | -0.379000 | 1.73e-04 |
| HIV Transcription Elongation | 42 | 2.10e-05 | -0.379000 | 1.73e-04 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 2.10e-05 | -0.379000 | 1.73e-04 |
| Metabolism of RNA | 695 | 2.08e-64 | -0.378000 | 3.04e-61 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 30 | 3.55e-04 | -0.377000 | 2.02e-03 |
| EPHA-mediated growth cone collapse | 23 | 1.83e-03 | 0.375000 | 8.03e-03 |
| SUMOylation of transcription cofactors | 44 | 1.66e-05 | -0.375000 | 1.43e-04 |
| Cytoprotection by HMOX1 | 58 | 1.01e-06 | -0.371000 | 1.35e-05 |
| Methylation | 12 | 2.61e-02 | -0.371000 | 6.96e-02 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 22 | 2.68e-03 | -0.370000 | 1.10e-02 |
| Formation of the Early Elongation Complex | 33 | 2.58e-04 | -0.368000 | 1.54e-03 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 2.58e-04 | -0.368000 | 1.54e-03 |
| Peroxisomal lipid metabolism | 25 | 1.48e-03 | -0.367000 | 6.64e-03 |
| SARS-CoV-1-host interactions | 93 | 1.07e-09 | -0.366000 | 2.08e-08 |
| Metalloprotease DUBs | 19 | 5.83e-03 | -0.365000 | 2.14e-02 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 51 | 7.42e-06 | -0.363000 | 7.44e-05 |
| Cell-extracellular matrix interactions | 18 | 8.10e-03 | 0.361000 | 2.78e-02 |
| Pexophagy | 11 | 3.94e-02 | -0.359000 | 9.53e-02 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 3.18e-02 | -0.358000 | 8.01e-02 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 3.18e-02 | -0.358000 | 8.01e-02 |
| Nitric oxide stimulates guanylate cyclase | 18 | 8.65e-03 | 0.358000 | 2.91e-02 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 21 | 4.71e-03 | -0.356000 | 1.77e-02 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 5.30e-02 | -0.353000 | 1.22e-01 |
| Assembly Of The HIV Virion | 16 | 1.44e-02 | -0.353000 | 4.32e-02 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 63 | 1.27e-06 | -0.353000 | 1.64e-05 |
| Dectin-1 mediated noncanonical NF-kB signaling | 58 | 3.44e-06 | -0.352000 | 3.90e-05 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 52 | 1.16e-05 | -0.352000 | 1.07e-04 |
| Transcription of the HIV genome | 67 | 6.88e-07 | -0.351000 | 9.32e-06 |
| Interleukin-10 signaling | 27 | 1.62e-03 | 0.351000 | 7.17e-03 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 19 | 8.24e-03 | -0.350000 | 2.79e-02 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 19 | 8.24e-03 | -0.350000 | 2.79e-02 |
| Metabolism of amino acids and derivatives | 315 | 1.71e-26 | -0.349000 | 7.36e-25 |
| Degradation of the extracellular matrix | 113 | 1.82e-10 | 0.347000 | 3.86e-09 |
| Intrinsic Pathway of Fibrin Clot Formation | 12 | 3.76e-02 | 0.347000 | 9.20e-02 |
| Defective CFTR causes cystic fibrosis | 57 | 6.33e-06 | -0.346000 | 6.52e-05 |
| Anchoring fibril formation | 15 | 2.06e-02 | 0.345000 | 5.80e-02 |
| Degradation of AXIN | 53 | 1.38e-05 | -0.345000 | 1.21e-04 |
| Regulation of Complement cascade | 30 | 1.08e-03 | 0.345000 | 5.16e-03 |
| Peptide ligand-binding receptors | 77 | 1.68e-07 | 0.345000 | 2.46e-06 |
| NIK–>noncanonical NF-kB signaling | 57 | 6.72e-06 | -0.345000 | 6.87e-05 |
| Elevation of cytosolic Ca2+ levels | 13 | 3.14e-02 | 0.345000 | 8.00e-02 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 3.16e-02 | 0.344000 | 8.00e-02 |
| Defective EXT2 causes exostoses 2 | 13 | 3.16e-02 | 0.344000 | 8.00e-02 |
| STAT3 nuclear events downstream of ALK signaling | 10 | 5.94e-02 | -0.344000 | 1.32e-01 |
| Voltage gated Potassium channels | 19 | 9.46e-03 | 0.344000 | 3.10e-02 |
| Ubiquitin-dependent degradation of Cyclin D | 50 | 2.61e-05 | -0.344000 | 2.08e-04 |
| Degradation of cysteine and homocysteine | 14 | 2.60e-02 | -0.344000 | 6.94e-02 |
| HDMs demethylate histones | 21 | 6.43e-03 | -0.344000 | 2.31e-02 |
| Regulation of Apoptosis | 51 | 2.20e-05 | -0.344000 | 1.80e-04 |
| APC/C:Cdc20 mediated degradation of Securin | 64 | 2.03e-06 | -0.343000 | 2.39e-05 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 1.53e-05 | -0.343000 | 1.33e-04 |
| Regulation of PTEN mRNA translation | 11 | 4.88e-02 | -0.343000 | 1.14e-01 |
| Vpu mediated degradation of CD4 | 50 | 2.92e-05 | -0.342000 | 2.31e-04 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 5.00e-02 | -0.341000 | 1.17e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 23 | 4.64e-03 | -0.341000 | 1.74e-02 |
| NCAM1 interactions | 32 | 8.47e-04 | 0.341000 | 4.24e-03 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 6.24e-02 | -0.340000 | 1.37e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 11 | 5.08e-02 | -0.340000 | 1.17e-01 |
| alpha-linolenic acid (ALA) metabolism | 11 | 5.08e-02 | -0.340000 | 1.17e-01 |
| Basigin interactions | 22 | 5.85e-03 | 0.339000 | 2.14e-02 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 4.77e-05 | -0.339000 | 3.53e-04 |
| Receptor-type tyrosine-protein phosphatases | 13 | 3.45e-02 | 0.339000 | 8.56e-02 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 2.46e-03 | -0.337000 | 1.02e-02 |
| Early Phase of HIV Life Cycle | 14 | 3.00e-02 | -0.335000 | 7.77e-02 |
| Association of TriC/CCT with target proteins during biosynthesis | 34 | 7.50e-04 | -0.334000 | 3.82e-03 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 18 | 1.45e-02 | -0.333000 | 4.32e-02 |
| Diseases associated with O-glycosylation of proteins | 54 | 2.40e-05 | 0.332000 | 1.95e-04 |
| HIV Life Cycle | 145 | 5.41e-12 | -0.332000 | 1.34e-10 |
| Vif-mediated degradation of APOBEC3G | 52 | 3.86e-05 | -0.330000 | 2.94e-04 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 69 | 2.20e-06 | -0.330000 | 2.56e-05 |
| Class A/1 (Rhodopsin-like receptors) | 141 | 1.48e-11 | 0.329000 | 3.38e-10 |
| Negative regulation of NOTCH4 signaling | 54 | 2.84e-05 | -0.329000 | 2.26e-04 |
| p75NTR signals via NF-kB | 16 | 2.28e-02 | -0.329000 | 6.25e-02 |
| Macroautophagy | 124 | 2.60e-10 | -0.329000 | 5.35e-09 |
| rRNA processing in the mitochondrion | 10 | 7.28e-02 | -0.328000 | 1.54e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 2.81e-02 | -0.327000 | 7.38e-02 |
| Phase 0 - rapid depolarisation | 28 | 2.76e-03 | 0.327000 | 1.13e-02 |
| Activation of Matrix Metalloproteinases | 21 | 9.54e-03 | 0.327000 | 3.11e-02 |
| Degradation of beta-catenin by the destruction complex | 83 | 2.83e-07 | -0.326000 | 4.02e-06 |
| Late Phase of HIV Life Cycle | 132 | 1.10e-10 | -0.325000 | 2.41e-09 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 4.20e-05 | -0.325000 | 3.15e-04 |
| SHC-mediated cascade:FGFR4 | 13 | 4.40e-02 | 0.323000 | 1.04e-01 |
| Dissolution of Fibrin Clot | 11 | 6.53e-02 | 0.321000 | 1.43e-01 |
| ABC transporter disorders | 69 | 4.06e-06 | -0.321000 | 4.47e-05 |
| ERBB2 Regulates Cell Motility | 13 | 4.52e-02 | 0.321000 | 1.07e-01 |
| Autophagy | 139 | 7.06e-11 | -0.320000 | 1.57e-09 |
| Regulation of PTEN stability and activity | 67 | 5.87e-06 | -0.320000 | 6.13e-05 |
| Smooth Muscle Contraction | 36 | 8.88e-04 | 0.320000 | 4.42e-03 |
| Regulation of RUNX2 expression and activity | 70 | 3.86e-06 | -0.319000 | 4.28e-05 |
| Mitochondrial calcium ion transport | 22 | 9.63e-03 | -0.319000 | 3.14e-02 |
| HIV Infection | 221 | 3.85e-16 | -0.318000 | 1.08e-14 |
| Downstream signaling events of B Cell Receptor (BCR) | 78 | 1.24e-06 | -0.318000 | 1.63e-05 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 9.87e-04 | -0.317000 | 4.83e-03 |
| Assembly of the pre-replicative complex | 87 | 3.23e-07 | -0.317000 | 4.55e-06 |
| Other semaphorin interactions | 19 | 1.69e-02 | 0.317000 | 4.86e-02 |
| Hh mutants are degraded by ERAD | 53 | 6.95e-05 | -0.316000 | 4.92e-04 |
| Circadian Clock | 66 | 9.56e-06 | -0.315000 | 9.33e-05 |
| Mitochondrial biogenesis | 87 | 4.26e-07 | -0.314000 | 5.88e-06 |
| Formation of Incision Complex in GG-NER | 43 | 3.75e-04 | -0.314000 | 2.11e-03 |
| Deadenylation-dependent mRNA decay | 50 | 1.27e-04 | -0.313000 | 8.60e-04 |
| Activation of NF-kappaB in B cells | 65 | 1.29e-05 | -0.313000 | 1.15e-04 |
| Translesion Synthesis by POLH | 18 | 2.16e-02 | -0.313000 | 6.04e-02 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 49 | 1.63e-04 | -0.311000 | 1.05e-03 |
| p53-Independent DNA Damage Response | 49 | 1.63e-04 | -0.311000 | 1.05e-03 |
| p53-Independent G1/S DNA damage checkpoint | 49 | 1.63e-04 | -0.311000 | 1.05e-03 |
| Molecules associated with elastic fibres | 33 | 1.98e-03 | 0.311000 | 8.40e-03 |
| Downstream TCR signaling | 80 | 1.50e-06 | -0.311000 | 1.93e-05 |
| Collagen degradation | 55 | 6.96e-05 | 0.310000 | 4.92e-04 |
| Josephin domain DUBs | 10 | 9.05e-02 | -0.309000 | 1.82e-01 |
| Complement cascade | 34 | 1.82e-03 | 0.309000 | 8.01e-03 |
| Amino acids regulate mTORC1 | 48 | 2.14e-04 | -0.309000 | 1.32e-03 |
| Sema4D induced cell migration and growth-cone collapse | 20 | 1.68e-02 | 0.309000 | 4.86e-02 |
| SARS-CoV-1 Infection | 135 | 5.94e-10 | -0.309000 | 1.18e-08 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 1.86e-04 | -0.309000 | 1.17e-03 |
| GLI3 is processed to GLI3R by the proteasome | 57 | 5.76e-05 | -0.308000 | 4.21e-04 |
| Budding and maturation of HIV virion | 27 | 5.65e-03 | -0.308000 | 2.08e-02 |
| CDK-mediated phosphorylation and removal of Cdc6 | 68 | 1.19e-05 | -0.307000 | 1.09e-04 |
| RHO GTPases activate CIT | 18 | 2.41e-02 | 0.307000 | 6.53e-02 |
| mRNA 3’-end processing | 57 | 6.31e-05 | -0.306000 | 4.57e-04 |
| RNA Polymerase II Transcription Termination | 66 | 1.68e-05 | -0.306000 | 1.43e-04 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 68 | 1.26e-05 | -0.306000 | 1.13e-04 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 68 | 1.26e-05 | -0.306000 | 1.13e-04 |
| SCF-beta-TrCP mediated degradation of Emi1 | 52 | 1.37e-04 | -0.306000 | 9.22e-04 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 3.72e-05 | -0.305000 | 2.86e-04 |
| TNFR1-induced NF-kappa-B signaling pathway | 32 | 2.89e-03 | -0.304000 | 1.17e-02 |
| Metabolism of porphyrins | 21 | 1.59e-02 | -0.304000 | 4.68e-02 |
| SARS-CoV-2 modulates autophagy | 11 | 8.10e-02 | -0.304000 | 1.69e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 19 | 2.20e-02 | -0.304000 | 6.09e-02 |
| Elastic fibre formation | 40 | 9.12e-04 | 0.303000 | 4.49e-03 |
| Deadenylation of mRNA | 22 | 1.41e-02 | -0.302000 | 4.23e-02 |
| Detoxification of Reactive Oxygen Species | 33 | 2.67e-03 | -0.302000 | 1.10e-02 |
| Heme signaling | 44 | 5.29e-04 | -0.302000 | 2.84e-03 |
| Degradation of GLI2 by the proteasome | 57 | 8.05e-05 | -0.302000 | 5.66e-04 |
| Interactions of Rev with host cellular proteins | 37 | 1.50e-03 | -0.302000 | 6.68e-03 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 44 | 5.37e-04 | -0.302000 | 2.88e-03 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 1.02e-05 | -0.301000 | 9.71e-05 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 6.81e-03 | -0.301000 | 2.41e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 6.81e-03 | -0.301000 | 2.41e-02 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 85 | 1.70e-06 | 0.300000 | 2.05e-05 |
| SARS-CoV-2-host interactions | 175 | 8.44e-12 | -0.300000 | 2.06e-10 |
| FGFR2 alternative splicing | 24 | 1.12e-02 | -0.299000 | 3.54e-02 |
| Switching of origins to a post-replicative state | 85 | 2.01e-06 | -0.298000 | 2.39e-05 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 2.89e-02 | -0.298000 | 7.51e-02 |
| Uptake and function of anthrax toxins | 11 | 8.77e-02 | -0.297000 | 1.77e-01 |
| Cellular response to chemical stress | 183 | 4.56e-12 | -0.297000 | 1.15e-10 |
| Collagen chain trimerization | 41 | 1.02e-03 | 0.297000 | 4.96e-03 |
| Cellular response to hypoxia | 72 | 1.38e-05 | -0.296000 | 1.21e-04 |
| Host Interactions of HIV factors | 125 | 1.12e-08 | -0.296000 | 1.94e-07 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 16 | 4.09e-02 | -0.295000 | 9.79e-02 |
| Endogenous sterols | 19 | 2.59e-02 | -0.295000 | 6.94e-02 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 27 | 7.95e-03 | -0.295000 | 2.74e-02 |
| LGI-ADAM interactions | 11 | 9.31e-02 | 0.292000 | 1.86e-01 |
| SUMOylation of RNA binding proteins | 47 | 5.26e-04 | -0.292000 | 2.84e-03 |
| Metabolism of non-coding RNA | 53 | 2.36e-04 | -0.292000 | 1.43e-03 |
| snRNP Assembly | 53 | 2.36e-04 | -0.292000 | 1.43e-03 |
| SUMOylation of chromatin organization proteins | 57 | 1.44e-04 | -0.291000 | 9.60e-04 |
| HSF1-dependent transactivation | 33 | 3.85e-03 | -0.291000 | 1.49e-02 |
| TP53 Regulates Metabolic Genes | 81 | 6.17e-06 | -0.291000 | 6.40e-05 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 1.19e-02 | -0.290000 | 3.70e-02 |
| FCERI mediated NF-kB activation | 79 | 8.21e-06 | -0.290000 | 8.12e-05 |
| HATs acetylate histones | 84 | 4.33e-06 | -0.290000 | 4.62e-05 |
| Selective autophagy | 72 | 2.16e-05 | -0.290000 | 1.78e-04 |
| Degradation of GLI1 by the proteasome | 57 | 1.68e-04 | -0.288000 | 1.08e-03 |
| Cyclin E associated events during G1/S transition | 80 | 8.58e-06 | -0.288000 | 8.42e-05 |
| Inactivation of CSF3 (G-CSF) signaling | 25 | 1.28e-02 | -0.288000 | 3.89e-02 |
| DNA Double Strand Break Response | 45 | 8.61e-04 | -0.287000 | 4.30e-03 |
| p130Cas linkage to MAPK signaling for integrins | 12 | 8.52e-02 | 0.287000 | 1.74e-01 |
| Cellular responses to stress | 687 | 2.12e-37 | -0.287000 | 3.88e-35 |
| HCMV Late Events | 60 | 1.26e-04 | -0.286000 | 8.56e-04 |
| Formation of TC-NER Pre-Incision Complex | 53 | 3.13e-04 | -0.286000 | 1.82e-03 |
| NCAM signaling for neurite out-growth | 52 | 3.60e-04 | 0.286000 | 2.04e-03 |
| RHOBTB1 GTPase cycle | 23 | 1.76e-02 | -0.286000 | 5.04e-02 |
| Adenylate cyclase inhibitory pathway | 13 | 7.46e-02 | 0.286000 | 1.58e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 15 | 5.56e-02 | -0.285000 | 1.27e-01 |
| Regulation of signaling by CBL | 22 | 2.06e-02 | -0.285000 | 5.80e-02 |
| CLEC7A (Dectin-1) signaling | 95 | 1.59e-06 | -0.285000 | 1.97e-05 |
| Regulation of TP53 Activity through Acetylation | 29 | 7.93e-03 | -0.285000 | 2.74e-02 |
| Pyruvate metabolism | 27 | 1.06e-02 | -0.284000 | 3.40e-02 |
| mRNA Capping | 29 | 8.10e-03 | -0.284000 | 2.78e-02 |
| Cellular responses to stimuli | 694 | 7.54e-37 | -0.283000 | 1.23e-34 |
| SUMOylation of DNA damage response and repair proteins | 77 | 1.75e-05 | -0.283000 | 1.49e-04 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 3.77e-03 | -0.283000 | 1.47e-02 |
| Post-translational protein phosphorylation | 76 | 2.01e-05 | 0.283000 | 1.69e-04 |
| Initial triggering of complement | 17 | 4.36e-02 | 0.283000 | 1.04e-01 |
| Diseases of mitotic cell cycle | 35 | 3.89e-03 | -0.282000 | 1.50e-02 |
| Physiological factors | 10 | 1.24e-01 | -0.281000 | 2.32e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 1.06e-01 | 0.281000 | 2.07e-01 |
| rRNA modification in the nucleus and cytosol | 59 | 1.95e-04 | -0.280000 | 1.22e-03 |
| Hh mutants abrogate ligand secretion | 55 | 3.28e-04 | -0.280000 | 1.88e-03 |
| Viral Infection Pathways | 656 | 3.27e-34 | -0.280000 | 4.79e-32 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 18 | 4.01e-02 | -0.279000 | 9.66e-02 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 6.10e-02 | -0.279000 | 1.35e-01 |
| Formation of the cornified envelope | 22 | 2.33e-02 | 0.279000 | 6.36e-02 |
| Keratinization | 22 | 2.33e-02 | 0.279000 | 6.36e-02 |
| Deactivation of the beta-catenin transactivating complex | 39 | 2.57e-03 | -0.279000 | 1.07e-02 |
| Regulation of TNFR1 signaling | 47 | 9.43e-04 | -0.279000 | 4.63e-03 |
| FGFR2 ligand binding and activation | 10 | 1.27e-01 | 0.279000 | 2.36e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 8.20e-02 | -0.279000 | 1.70e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 5.38e-02 | -0.278000 | 1.23e-01 |
| ER Quality Control Compartment (ERQC) | 21 | 2.74e-02 | -0.278000 | 7.21e-02 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 7.83e-06 | -0.277000 | 7.79e-05 |
| Regulation of ornithine decarboxylase (ODC) | 48 | 8.91e-04 | -0.277000 | 4.42e-03 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 46 | 1.18e-03 | -0.277000 | 5.58e-03 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 70 | 6.50e-05 | -0.276000 | 4.69e-04 |
| S Phase | 152 | 4.31e-09 | -0.276000 | 7.95e-08 |
| Synthesis of bile acids and bile salts | 25 | 1.69e-02 | -0.276000 | 4.86e-02 |
| Potassium Channels | 54 | 4.55e-04 | 0.276000 | 2.51e-03 |
| Base-Excision Repair, AP Site Formation | 23 | 2.22e-02 | -0.275000 | 6.13e-02 |
| Transport of Mature Transcript to Cytoplasm | 81 | 1.86e-05 | -0.275000 | 1.57e-04 |
| Degradation of DVL | 55 | 4.17e-04 | -0.275000 | 2.32e-03 |
| Assembly of collagen fibrils and other multimeric structures | 57 | 3.28e-04 | 0.275000 | 1.88e-03 |
| Regulation of NPAS4 gene expression | 12 | 9.90e-02 | -0.275000 | 1.96e-01 |
| Metabolism of cofactors | 18 | 4.36e-02 | -0.275000 | 1.04e-01 |
| Retrograde neurotrophin signalling | 13 | 8.65e-02 | -0.275000 | 1.76e-01 |
| Chromatin modifying enzymes | 205 | 1.44e-11 | -0.274000 | 3.33e-10 |
| Chromatin organization | 205 | 1.44e-11 | -0.274000 | 3.33e-10 |
| TBC/RABGAPs | 43 | 1.92e-03 | -0.273000 | 8.24e-03 |
| SCF(Skp2)-mediated degradation of p27/p21 | 58 | 3.22e-04 | -0.273000 | 1.86e-03 |
| Phosphorylation of the APC/C | 19 | 3.94e-02 | -0.273000 | 9.54e-02 |
| SHC-mediated cascade:FGFR1 | 13 | 8.92e-02 | 0.272000 | 1.80e-01 |
| SUMOylation of transcription factors | 16 | 5.96e-02 | -0.272000 | 1.33e-01 |
| Downregulation of TGF-beta receptor signaling | 26 | 1.66e-02 | -0.272000 | 4.80e-02 |
| Regulation of gene expression by Hypoxia-inducible Factor | 10 | 1.38e-01 | -0.271000 | 2.50e-01 |
| NRIF signals cell death from the nucleus | 16 | 6.08e-02 | -0.271000 | 1.34e-01 |
| MET activates PTK2 signaling | 30 | 1.05e-02 | 0.270000 | 3.39e-02 |
| Signaling by WNT in cancer | 29 | 1.19e-02 | -0.270000 | 3.70e-02 |
| Protein methylation | 15 | 7.06e-02 | -0.270000 | 1.51e-01 |
| RHO GTPases Activate NADPH Oxidases | 21 | 3.25e-02 | -0.270000 | 8.14e-02 |
| Regulation of RUNX3 expression and activity | 55 | 5.51e-04 | -0.269000 | 2.92e-03 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 13 | 9.37e-02 | -0.269000 | 1.87e-01 |
| DNA Replication Pre-Initiation | 101 | 3.15e-06 | -0.269000 | 3.60e-05 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 2.06e-04 | -0.268000 | 1.28e-03 |
| Defective B3GAT3 causes JDSSDHD | 16 | 6.33e-02 | 0.268000 | 1.39e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 71 | 9.43e-05 | -0.268000 | 6.57e-04 |
| Rev-mediated nuclear export of HIV RNA | 35 | 6.09e-03 | -0.268000 | 2.21e-02 |
| Sulfur amino acid metabolism | 25 | 2.04e-02 | -0.268000 | 5.77e-02 |
| Signaling by CSF3 (G-CSF) | 30 | 1.11e-02 | -0.268000 | 3.53e-02 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 1.43e-01 | -0.268000 | 2.56e-01 |
| HIV Transcription Initiation | 45 | 1.91e-03 | -0.268000 | 8.20e-03 |
| RNA Polymerase II HIV Promoter Escape | 45 | 1.91e-03 | -0.268000 | 8.20e-03 |
| RNA Polymerase II Promoter Escape | 45 | 1.91e-03 | -0.268000 | 8.20e-03 |
| RNA Polymerase II Transcription Initiation | 45 | 1.91e-03 | -0.268000 | 8.20e-03 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 1.91e-03 | -0.268000 | 8.20e-03 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 1.91e-03 | -0.268000 | 8.20e-03 |
| Orc1 removal from chromatin | 66 | 1.73e-04 | -0.267000 | 1.10e-03 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 1.09e-01 | 0.267000 | 2.10e-01 |
| Estrogen-dependent gene expression | 92 | 1.00e-05 | -0.267000 | 9.67e-05 |
| Asymmetric localization of PCP proteins | 61 | 3.22e-04 | -0.266000 | 1.86e-03 |
| Stabilization of p53 | 54 | 7.14e-04 | -0.266000 | 3.67e-03 |
| Hyaluronan metabolism | 14 | 8.46e-02 | 0.266000 | 1.73e-01 |
| Nuclear import of Rev protein | 34 | 7.26e-03 | -0.266000 | 2.55e-02 |
| Metabolism of polyamines | 56 | 5.79e-04 | -0.266000 | 3.03e-03 |
| COPII-mediated vesicle transport | 63 | 2.64e-04 | -0.266000 | 1.56e-03 |
| Signaling by Retinoic Acid | 35 | 6.65e-03 | -0.265000 | 2.36e-02 |
| Extracellular matrix organization | 253 | 4.11e-13 | 0.265000 | 1.09e-11 |
| Nuclear events mediated by NFE2L2 | 76 | 6.60e-05 | -0.265000 | 4.74e-04 |
| Chemokine receptors bind chemokines | 30 | 1.22e-02 | 0.264000 | 3.75e-02 |
| Integrin cell surface interactions | 76 | 6.82e-05 | 0.264000 | 4.87e-04 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 8.72e-02 | -0.264000 | 1.77e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 82 | 3.68e-05 | -0.264000 | 2.85e-04 |
| Transcriptional activation of mitochondrial biogenesis | 50 | 1.27e-03 | -0.264000 | 5.82e-03 |
| Calnexin/calreticulin cycle | 26 | 2.04e-02 | -0.263000 | 5.77e-02 |
| HS-GAG degradation | 21 | 3.72e-02 | 0.263000 | 9.12e-02 |
| TNFs bind their physiological receptors | 18 | 5.38e-02 | 0.263000 | 1.23e-01 |
| Interaction between L1 and Ankyrins | 26 | 2.08e-02 | 0.262000 | 5.83e-02 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 25 | 2.34e-02 | -0.262000 | 6.37e-02 |
| GPCR ligand binding | 197 | 2.47e-10 | 0.262000 | 5.17e-09 |
| SUMOylation of DNA replication proteins | 44 | 2.76e-03 | -0.261000 | 1.13e-02 |
| Regulation of HSF1-mediated heat shock response | 79 | 6.18e-05 | -0.261000 | 4.50e-04 |
| Presynaptic depolarization and calcium channel opening | 10 | 1.54e-01 | 0.260000 | 2.69e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 1.36e-01 | -0.259000 | 2.48e-01 |
| PPARA activates gene expression | 106 | 4.14e-06 | -0.259000 | 4.51e-05 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 8.97e-04 | -0.259000 | 4.43e-03 |
| TNF signaling | 56 | 8.45e-04 | -0.258000 | 4.24e-03 |
| Regulation of APC/C activators between G1/S and early anaphase | 76 | 1.15e-04 | -0.256000 | 7.93e-04 |
| SUMO E3 ligases SUMOylate target proteins | 159 | 2.84e-08 | -0.255000 | 4.57e-07 |
| G alpha (q) signalling events | 128 | 6.51e-07 | 0.255000 | 8.90e-06 |
| Acetylcholine Neurotransmitter Release Cycle | 11 | 1.46e-01 | 0.253000 | 2.60e-01 |
| tRNA processing in the nucleus | 59 | 7.72e-04 | -0.253000 | 3.92e-03 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 12 | 1.30e-01 | -0.253000 | 2.40e-01 |
| Negative regulation of MET activity | 19 | 5.73e-02 | -0.252000 | 1.30e-01 |
| Synthesis of DNA | 112 | 4.16e-06 | -0.252000 | 4.51e-05 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 1.24e-02 | -0.252000 | 3.80e-02 |
| GABA receptor activation | 39 | 6.58e-03 | 0.252000 | 2.35e-02 |
| Interactions of Vpr with host cellular proteins | 37 | 8.17e-03 | -0.251000 | 2.78e-02 |
| Vpr-mediated nuclear import of PICs | 34 | 1.13e-02 | -0.251000 | 3.54e-02 |
| Cholesterol biosynthesis | 27 | 2.39e-02 | -0.251000 | 6.49e-02 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 33 | 1.28e-02 | -0.250000 | 3.89e-02 |
| KEAP1-NFE2L2 pathway | 101 | 1.38e-05 | -0.250000 | 1.21e-04 |
| Thrombin signalling through proteinase activated receptors (PARs) | 25 | 3.03e-02 | 0.250000 | 7.79e-02 |
| Retinoid metabolism and transport | 29 | 1.98e-02 | 0.250000 | 5.64e-02 |
| Aspartate and asparagine metabolism | 10 | 1.71e-01 | 0.250000 | 2.91e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 2.48e-02 | -0.250000 | 6.69e-02 |
| ADP signalling through P2Y purinoceptor 12 | 14 | 1.06e-01 | 0.249000 | 2.07e-01 |
| Nonhomologous End-Joining (NHEJ) | 35 | 1.08e-02 | -0.249000 | 3.45e-02 |
| p75NTR recruits signalling complexes | 13 | 1.21e-01 | -0.249000 | 2.27e-01 |
| Cellular response to heat stress | 97 | 2.41e-05 | -0.248000 | 1.95e-04 |
| RHOBTB2 GTPase cycle | 23 | 4.00e-02 | -0.247000 | 9.63e-02 |
| Formation of WDR5-containing histone-modifying complexes | 42 | 5.56e-03 | -0.247000 | 2.05e-02 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 37 | 9.26e-03 | -0.247000 | 3.07e-02 |
| FLT3 Signaling | 35 | 1.17e-02 | -0.246000 | 3.63e-02 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | 14 | 1.11e-01 | -0.246000 | 2.13e-01 |
| ABC-family proteins mediated transport | 93 | 4.24e-05 | -0.246000 | 3.16e-04 |
| Transcription of E2F targets under negative control by DREAM complex | 18 | 7.11e-02 | -0.246000 | 1.52e-01 |
| Cytosolic iron-sulfur cluster assembly | 13 | 1.26e-01 | -0.245000 | 2.35e-01 |
| DNA Damage Recognition in GG-NER | 38 | 8.97e-03 | -0.245000 | 3.00e-02 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 2.51e-02 | -0.245000 | 6.75e-02 |
| Chondroitin sulfate biosynthesis | 15 | 1.01e-01 | 0.245000 | 1.99e-01 |
| Regulation of lipid metabolism by PPARalpha | 108 | 1.18e-05 | -0.244000 | 1.08e-04 |
| SUMOylation | 165 | 6.57e-08 | -0.244000 | 1.01e-06 |
| APC/C-mediated degradation of cell cycle proteins | 81 | 1.49e-04 | -0.244000 | 9.76e-04 |
| Regulation of mitotic cell cycle | 81 | 1.49e-04 | -0.244000 | 9.76e-04 |
| Inhibition of DNA recombination at telomere | 27 | 2.83e-02 | -0.244000 | 7.41e-02 |
| Prolonged ERK activation events | 14 | 1.14e-01 | -0.244000 | 2.18e-01 |
| SUMOylation of SUMOylation proteins | 35 | 1.27e-02 | -0.243000 | 3.88e-02 |
| P2Y receptors | 10 | 1.83e-01 | 0.243000 | 3.05e-01 |
| HDACs deacetylate histones | 37 | 1.05e-02 | -0.243000 | 3.38e-02 |
| C-type lectin receptors (CLRs) | 121 | 3.86e-06 | -0.243000 | 4.28e-05 |
| RHOBTB GTPase Cycle | 35 | 1.29e-02 | -0.243000 | 3.90e-02 |
| Processing and activation of SUMO | 10 | 1.85e-01 | -0.242000 | 3.06e-01 |
| Collagen formation | 84 | 1.27e-04 | 0.242000 | 8.60e-04 |
| MTOR signalling | 41 | 7.36e-03 | -0.242000 | 2.57e-02 |
| Sema4D in semaphorin signaling | 24 | 4.09e-02 | 0.241000 | 9.79e-02 |
| Disorders of Developmental Biology | 12 | 1.48e-01 | -0.241000 | 2.63e-01 |
| Disorders of Nervous System Development | 12 | 1.48e-01 | -0.241000 | 2.63e-01 |
| Loss of function of MECP2 in Rett syndrome | 12 | 1.48e-01 | -0.241000 | 2.63e-01 |
| Pervasive developmental disorders | 12 | 1.48e-01 | -0.241000 | 2.63e-01 |
| Glycogen storage diseases | 14 | 1.20e-01 | -0.240000 | 2.26e-01 |
| SUMOylation of DNA methylation proteins | 16 | 9.64e-02 | -0.240000 | 1.92e-01 |
| Viral Messenger RNA Synthesis | 44 | 5.91e-03 | -0.240000 | 2.16e-02 |
| PKMTs methylate histone lysines | 42 | 7.25e-03 | -0.240000 | 2.55e-02 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 31 | 2.10e-02 | -0.239000 | 5.89e-02 |
| DNA Replication | 124 | 4.22e-06 | -0.239000 | 4.54e-05 |
| PTEN Regulation | 138 | 1.25e-06 | -0.239000 | 1.63e-05 |
| Cleavage of the damaged pyrimidine | 21 | 5.78e-02 | -0.239000 | 1.30e-01 |
| Depyrimidination | 21 | 5.78e-02 | -0.239000 | 1.30e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 21 | 5.78e-02 | -0.239000 | 1.30e-01 |
| Nucleotide Excision Repair | 110 | 1.51e-05 | -0.239000 | 1.31e-04 |
| Signaling by BMP | 24 | 4.29e-02 | 0.239000 | 1.02e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.96e-02 | -0.238000 | 5.60e-02 |
| Effects of PIP2 hydrolysis | 23 | 4.80e-02 | 0.238000 | 1.13e-01 |
| Diseases associated with N-glycosylation of proteins | 20 | 6.57e-02 | 0.238000 | 1.43e-01 |
| Epigenetic regulation of gene expression | 133 | 2.24e-06 | -0.238000 | 2.59e-05 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 3.07e-04 | -0.237000 | 1.79e-03 |
| Glycolysis | 65 | 9.97e-04 | -0.236000 | 4.86e-03 |
| Nucleotide-like (purinergic) receptors | 14 | 1.27e-01 | 0.236000 | 2.36e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 1.77e-01 | -0.235000 | 2.97e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 2.14e-02 | -0.235000 | 6.00e-02 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 28 | 3.15e-02 | -0.235000 | 8.00e-02 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 2.02e-04 | -0.235000 | 1.25e-03 |
| Long-term potentiation | 19 | 7.67e-02 | 0.235000 | 1.62e-01 |
| Vitamin B5 (pantothenate) metabolism | 16 | 1.04e-01 | -0.235000 | 2.04e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 22 | 5.84e-02 | 0.233000 | 1.31e-01 |
| Signaling by PDGFR in disease | 20 | 7.16e-02 | -0.233000 | 1.53e-01 |
| Defective pyroptosis | 20 | 7.17e-02 | -0.233000 | 1.53e-01 |
| IRAK1 recruits IKK complex | 14 | 1.32e-01 | -0.233000 | 2.43e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 14 | 1.32e-01 | -0.233000 | 2.43e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 30 | 2.76e-02 | 0.232000 | 7.25e-02 |
| Dual incision in TC-NER | 65 | 1.20e-03 | -0.232000 | 5.65e-03 |
| Termination of translesion DNA synthesis | 31 | 2.52e-02 | -0.232000 | 6.76e-02 |
| Platelet Adhesion to exposed collagen | 11 | 1.83e-01 | 0.232000 | 3.04e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 13 | 1.47e-01 | 0.232000 | 2.62e-01 |
| Striated Muscle Contraction | 35 | 1.77e-02 | 0.232000 | 5.08e-02 |
| Hedgehog ligand biogenesis | 60 | 1.94e-03 | -0.231000 | 8.30e-03 |
| Neurexins and neuroligins | 39 | 1.25e-02 | 0.231000 | 3.81e-02 |
| Phase 2 - plateau phase | 11 | 1.84e-01 | 0.231000 | 3.06e-01 |
| Signaling by the B Cell Receptor (BCR) | 105 | 4.36e-05 | -0.231000 | 3.24e-04 |
| Synthesis of PIPs at the late endosome membrane | 11 | 1.85e-01 | -0.231000 | 3.06e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 16 | 1.10e-01 | 0.231000 | 2.12e-01 |
| Gene Silencing by RNA | 78 | 4.35e-04 | -0.230000 | 2.41e-03 |
| O-linked glycosylation | 86 | 2.29e-04 | 0.230000 | 1.40e-03 |
| Glycogen synthesis | 13 | 1.51e-01 | -0.230000 | 2.66e-01 |
| Carnitine metabolism | 14 | 1.37e-01 | -0.230000 | 2.48e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 29 | 3.25e-02 | -0.229000 | 8.14e-02 |
| Dual Incision in GG-NER | 41 | 1.13e-02 | -0.229000 | 3.54e-02 |
| Platelet Aggregation (Plug Formation) | 30 | 3.05e-02 | 0.228000 | 7.79e-02 |
| IKK complex recruitment mediated by RIP1 | 23 | 5.82e-02 | -0.228000 | 1.31e-01 |
| p53-Dependent G1 DNA Damage Response | 61 | 2.06e-03 | -0.228000 | 8.62e-03 |
| p53-Dependent G1/S DNA damage checkpoint | 61 | 2.06e-03 | -0.228000 | 8.62e-03 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 51 | 4.86e-03 | -0.228000 | 1.81e-02 |
| Non-integrin membrane-ECM interactions | 57 | 2.92e-03 | 0.228000 | 1.18e-02 |
| Negative regulation of FLT3 | 13 | 1.55e-01 | -0.228000 | 2.71e-01 |
| Meiotic synapsis | 32 | 2.65e-02 | -0.227000 | 7.01e-02 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 1.17e-01 | -0.226000 | 2.22e-01 |
| SARS-CoV-2 Infection | 262 | 3.61e-10 | -0.225000 | 7.33e-09 |
| Transcriptional regulation by small RNAs | 54 | 4.26e-03 | -0.225000 | 1.61e-02 |
| SIRT1 negatively regulates rRNA expression | 15 | 1.32e-01 | -0.225000 | 2.43e-01 |
| RNA polymerase II transcribes snRNA genes | 71 | 1.07e-03 | -0.225000 | 5.13e-03 |
| The NLRP3 inflammasome | 16 | 1.20e-01 | -0.224000 | 2.27e-01 |
| Defects in vitamin and cofactor metabolism | 20 | 8.28e-02 | -0.224000 | 1.71e-01 |
| DNA Damage Bypass | 45 | 9.34e-03 | -0.224000 | 3.09e-02 |
| Downstream signal transduction | 28 | 4.05e-02 | -0.224000 | 9.71e-02 |
| Metabolism of folate and pterines | 17 | 1.10e-01 | -0.224000 | 2.12e-01 |
| Adenylate cyclase activating pathway | 10 | 2.21e-01 | 0.223000 | 3.51e-01 |
| Regulation of RAS by GAPs | 65 | 1.88e-03 | -0.223000 | 8.20e-03 |
| UCH proteinases | 85 | 3.83e-04 | -0.223000 | 2.15e-03 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 2.01e-01 | -0.223000 | 3.26e-01 |
| Somitogenesis | 50 | 6.47e-03 | -0.223000 | 2.32e-02 |
| Unwinding of DNA | 10 | 2.23e-01 | -0.223000 | 3.52e-01 |
| Removal of the Flap Intermediate | 14 | 1.49e-01 | -0.223000 | 2.64e-01 |
| SUMOylation of ubiquitinylation proteins | 39 | 1.63e-02 | -0.222000 | 4.75e-02 |
| RMTs methylate histone arginines | 33 | 2.71e-02 | -0.222000 | 7.14e-02 |
| Ub-specific processing proteases | 157 | 1.58e-06 | -0.222000 | 1.97e-05 |
| Defects in cobalamin (B12) metabolism | 12 | 1.83e-01 | -0.222000 | 3.05e-01 |
| SHC1 events in ERBB4 signaling | 12 | 1.83e-01 | 0.222000 | 3.05e-01 |
| Cell junction organization | 92 | 2.37e-04 | 0.222000 | 1.43e-03 |
| RNA Polymerase III Abortive And Retractive Initiation | 41 | 1.41e-02 | -0.222000 | 4.23e-02 |
| RNA Polymerase III Transcription | 41 | 1.41e-02 | -0.222000 | 4.23e-02 |
| Inflammasomes | 20 | 8.68e-02 | -0.221000 | 1.77e-01 |
| Erythropoietin activates RAS | 13 | 1.68e-01 | -0.221000 | 2.88e-01 |
| RNA Polymerase III Transcription Initiation | 36 | 2.20e-02 | -0.221000 | 6.09e-02 |
| Transcriptional Regulation by E2F6 | 33 | 2.87e-02 | -0.220000 | 7.50e-02 |
| Uptake and actions of bacterial toxins | 24 | 6.21e-02 | -0.220000 | 1.37e-01 |
| mRNA decay by 3’ to 5’ exoribonuclease | 13 | 1.70e-01 | -0.220000 | 2.91e-01 |
| Golgi Associated Vesicle Biogenesis | 54 | 5.26e-03 | -0.220000 | 1.95e-02 |
| Activation of GABAB receptors | 31 | 3.49e-02 | 0.219000 | 8.62e-02 |
| GABA B receptor activation | 31 | 3.49e-02 | 0.219000 | 8.62e-02 |
| TCF dependent signaling in response to WNT | 161 | 1.67e-06 | -0.219000 | 2.04e-05 |
| Fatty acyl-CoA biosynthesis | 31 | 3.51e-02 | 0.219000 | 8.65e-02 |
| Signal transduction by L1 | 21 | 8.29e-02 | 0.219000 | 1.71e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 15 | 1.43e-01 | -0.218000 | 2.56e-01 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 8.18e-03 | -0.218000 | 2.78e-02 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | 13 | 1.74e-01 | -0.218000 | 2.94e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 30 | 3.92e-02 | -0.218000 | 9.50e-02 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 30 | 3.92e-02 | -0.218000 | 9.50e-02 |
| FOXO-mediated transcription | 56 | 4.89e-03 | -0.217000 | 1.82e-02 |
| HCMV Infection | 100 | 1.76e-04 | -0.217000 | 1.11e-03 |
| SHC1 events in EGFR signaling | 10 | 2.35e-01 | 0.217000 | 3.66e-01 |
| RAS processing | 22 | 7.84e-02 | -0.217000 | 1.64e-01 |
| TCR signaling | 100 | 1.87e-04 | -0.216000 | 1.17e-03 |
| MicroRNA (miRNA) biogenesis | 25 | 6.15e-02 | -0.216000 | 1.36e-01 |
| PCP/CE pathway | 87 | 4.97e-04 | -0.216000 | 2.71e-03 |
| Ephrin signaling | 18 | 1.13e-01 | 0.216000 | 2.15e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 20 | 9.44e-02 | -0.216000 | 1.88e-01 |
| Negative regulation of MAPK pathway | 41 | 1.68e-02 | -0.216000 | 4.86e-02 |
| MAPK6/MAPK4 signaling | 84 | 6.35e-04 | -0.216000 | 3.30e-03 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 72 | 1.58e-03 | -0.215000 | 7.01e-03 |
| Transcriptional Regulation by TP53 | 338 | 1.12e-11 | -0.215000 | 2.68e-10 |
| NOTCH1 Intracellular Domain Regulates Transcription | 47 | 1.09e-02 | -0.215000 | 3.48e-02 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 49 | 9.37e-03 | -0.215000 | 3.09e-02 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 24 | 6.92e-02 | -0.214000 | 1.49e-01 |
| G1/S DNA Damage Checkpoints | 62 | 3.62e-03 | -0.214000 | 1.42e-02 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 2.01e-01 | 0.213000 | 3.26e-01 |
| HS-GAG biosynthesis | 22 | 8.37e-02 | 0.213000 | 1.72e-01 |
| SARS-CoV Infections | 373 | 1.86e-12 | -0.213000 | 4.79e-11 |
| Collagen biosynthesis and modifying enzymes | 64 | 3.27e-03 | 0.213000 | 1.30e-02 |
| B-WICH complex positively regulates rRNA expression | 38 | 2.34e-02 | -0.213000 | 6.37e-02 |
| Activated NTRK2 signals through FRS2 and FRS3 | 11 | 2.22e-01 | -0.212000 | 3.52e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 58 | 5.20e-03 | 0.212000 | 1.93e-02 |
| EPH-ephrin mediated repulsion of cells | 44 | 1.50e-02 | 0.212000 | 4.45e-02 |
| Protein-protein interactions at synapses | 61 | 4.22e-03 | 0.212000 | 1.61e-02 |
| Transport of the SLBP independent Mature mRNA | 35 | 3.04e-02 | -0.212000 | 7.79e-02 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 1.11e-01 | -0.211000 | 2.13e-01 |
| Infectious disease | 824 | 1.42e-24 | -0.211000 | 5.78e-23 |
| RHO GTPases Activate ROCKs | 19 | 1.12e-01 | 0.211000 | 2.14e-01 |
| Telomere Extension By Telomerase | 21 | 9.51e-02 | -0.210000 | 1.89e-01 |
| SUMOylation of intracellular receptors | 27 | 5.84e-02 | -0.210000 | 1.31e-01 |
| Listeria monocytogenes entry into host cells | 17 | 1.33e-01 | -0.210000 | 2.45e-01 |
| Regulation of insulin secretion | 61 | 4.63e-03 | 0.210000 | 1.74e-02 |
| Advanced glycosylation endproduct receptor signaling | 12 | 2.09e-01 | 0.210000 | 3.36e-01 |
| ER-Phagosome pathway | 79 | 1.38e-03 | -0.208000 | 6.20e-03 |
| Glucose metabolism | 83 | 1.05e-03 | -0.208000 | 5.07e-03 |
| Activation of gene expression by SREBF (SREBP) | 42 | 2.01e-02 | -0.207000 | 5.72e-02 |
| Mitotic Prophase | 89 | 7.36e-04 | -0.207000 | 3.76e-03 |
| Biotin transport and metabolism | 11 | 2.35e-01 | -0.207000 | 3.66e-01 |
| Nuclear Envelope (NE) Reassembly | 68 | 3.23e-03 | -0.207000 | 1.29e-02 |
| RA biosynthesis pathway | 15 | 1.66e-01 | -0.207000 | 2.85e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 3.76e-02 | -0.206000 | 9.19e-02 |
| ECM proteoglycans | 66 | 3.84e-03 | 0.206000 | 1.49e-02 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 2.41e-01 | 0.204000 | 3.72e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 23 | 9.04e-02 | -0.204000 | 1.82e-01 |
| Packaging Of Telomere Ends | 13 | 2.04e-01 | -0.203000 | 3.31e-01 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | 12 | 2.23e-01 | 0.203000 | 3.52e-01 |
| Muscle contraction | 165 | 6.84e-06 | 0.203000 | 6.95e-05 |
| Antigen processing: Ubiquitination & Proteasome degradation | 291 | 2.80e-09 | -0.203000 | 5.26e-08 |
| Platelet calcium homeostasis | 23 | 9.24e-02 | 0.203000 | 1.85e-01 |
| G-protein mediated events | 50 | 1.32e-02 | 0.203000 | 3.98e-02 |
| CRMPs in Sema3A signaling | 15 | 1.74e-01 | 0.203000 | 2.95e-01 |
| Heme biosynthesis | 13 | 2.07e-01 | -0.202000 | 3.34e-01 |
| DNA strand elongation | 30 | 5.56e-02 | -0.202000 | 1.27e-01 |
| Glutathione conjugation | 27 | 6.99e-02 | -0.202000 | 1.50e-01 |
| Frs2-mediated activation | 12 | 2.27e-01 | -0.201000 | 3.57e-01 |
| Cargo concentration in the ER | 28 | 6.55e-02 | -0.201000 | 1.43e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 16 | 1.65e-01 | 0.200000 | 2.84e-01 |
| Gap junction assembly | 20 | 1.21e-01 | 0.200000 | 2.27e-01 |
| Deubiquitination | 228 | 2.08e-07 | -0.200000 | 2.99e-06 |
| Rab regulation of trafficking | 115 | 2.19e-04 | -0.200000 | 1.35e-03 |
| Rap1 signalling | 13 | 2.13e-01 | 0.199000 | 3.39e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 1.33e-01 | -0.199000 | 2.44e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 1.33e-01 | -0.199000 | 2.44e-01 |
| Metabolism of fat-soluble vitamins | 32 | 5.19e-02 | 0.199000 | 1.20e-01 |
| GPER1 signaling | 37 | 3.66e-02 | 0.199000 | 8.99e-02 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 33 | 4.84e-02 | -0.199000 | 1.13e-01 |
| Metabolism of Angiotensinogen to Angiotensins | 13 | 2.15e-01 | 0.198000 | 3.43e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 6.16e-03 | -0.198000 | 2.23e-02 |
| Cleavage of the damaged purine | 16 | 1.71e-01 | -0.198000 | 2.91e-01 |
| Depurination | 16 | 1.71e-01 | -0.198000 | 2.91e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 16 | 1.71e-01 | -0.198000 | 2.91e-01 |
| Positive epigenetic regulation of rRNA expression | 53 | 1.28e-02 | -0.198000 | 3.89e-02 |
| Antigen processing-Cross presentation | 92 | 1.09e-03 | -0.197000 | 5.20e-03 |
| PRC2 methylates histones and DNA | 20 | 1.28e-01 | -0.197000 | 2.37e-01 |
| Sensory perception of taste | 16 | 1.74e-01 | 0.196000 | 2.95e-01 |
| eNOS activation | 11 | 2.60e-01 | -0.196000 | 3.92e-01 |
| PLC beta mediated events | 46 | 2.18e-02 | 0.196000 | 6.08e-02 |
| RHO GTPases activate PAKs | 21 | 1.22e-01 | 0.195000 | 2.28e-01 |
| Fc epsilon receptor (FCERI) signaling | 128 | 1.40e-04 | -0.195000 | 9.38e-04 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 2.96e-02 | -0.194000 | 7.66e-02 |
| Signaling by Erythropoietin | 24 | 1.00e-01 | -0.194000 | 1.98e-01 |
| Sensory Perception | 153 | 3.65e-05 | 0.194000 | 2.84e-04 |
| Formation of paraxial mesoderm | 62 | 8.45e-03 | -0.193000 | 2.85e-02 |
| RIPK1-mediated regulated necrosis | 30 | 6.72e-02 | -0.193000 | 1.45e-01 |
| Regulation of necroptotic cell death | 30 | 6.72e-02 | -0.193000 | 1.45e-01 |
| Metabolic disorders of biological oxidation enzymes | 22 | 1.18e-01 | -0.193000 | 2.23e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 19 | 1.46e-01 | 0.193000 | 2.60e-01 |
| EPH-Ephrin signaling | 83 | 2.59e-03 | 0.191000 | 1.07e-02 |
| Lagging Strand Synthesis | 20 | 1.38e-01 | -0.191000 | 2.51e-01 |
| PECAM1 interactions | 11 | 2.72e-01 | 0.191000 | 4.08e-01 |
| G1/S Transition | 123 | 2.54e-04 | -0.191000 | 1.52e-03 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 8.02e-02 | -0.191000 | 1.68e-01 |
| Nuclear Envelope Breakdown | 53 | 1.63e-02 | -0.191000 | 4.75e-02 |
| CASP8 activity is inhibited | 10 | 2.96e-01 | 0.191000 | 4.36e-01 |
| Dimerization of procaspase-8 | 10 | 2.96e-01 | 0.191000 | 4.36e-01 |
| Regulation by c-FLIP | 10 | 2.96e-01 | 0.191000 | 4.36e-01 |
| RAF activation | 34 | 5.46e-02 | -0.191000 | 1.25e-01 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 4.82e-02 | -0.190000 | 1.13e-01 |
| Bile acid and bile salt metabolism | 28 | 8.13e-02 | -0.190000 | 1.69e-01 |
| Signaling by NOTCH4 | 81 | 3.11e-03 | -0.190000 | 1.25e-02 |
| Removal of the Flap Intermediate from the C-strand | 17 | 1.75e-01 | -0.190000 | 2.96e-01 |
| NGF-stimulated transcription | 35 | 5.22e-02 | 0.190000 | 1.20e-01 |
| Processive synthesis on the lagging strand | 15 | 2.04e-01 | -0.189000 | 3.31e-01 |
| ER to Golgi Anterograde Transport | 140 | 1.11e-04 | -0.189000 | 7.67e-04 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 7.86e-03 | -0.189000 | 2.73e-02 |
| Signaling by FGFR1 in disease | 32 | 6.43e-02 | -0.189000 | 1.41e-01 |
| Base Excision Repair | 51 | 1.97e-02 | -0.189000 | 5.62e-02 |
| RNA Polymerase III Transcription Termination | 23 | 1.17e-01 | -0.189000 | 2.22e-01 |
| Class I MHC mediated antigen processing & presentation | 352 | 1.27e-09 | -0.189000 | 2.44e-08 |
| Synthesis of PIPs at the early endosome membrane | 16 | 1.92e-01 | -0.189000 | 3.15e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 33 | 6.16e-02 | -0.188000 | 1.36e-01 |
| RUNX3 regulates p14-ARF | 10 | 3.04e-01 | -0.188000 | 4.42e-01 |
| Generation of second messenger molecules | 18 | 1.68e-01 | 0.188000 | 2.88e-01 |
| Processing of Capped Intronless Pre-mRNA | 29 | 8.08e-02 | -0.187000 | 1.68e-01 |
| Disorders of transmembrane transporters | 136 | 1.69e-04 | -0.187000 | 1.08e-03 |
| Nuclear Receptor transcription pathway | 43 | 3.40e-02 | -0.187000 | 8.44e-02 |
| Transcriptional Regulation by VENTX | 37 | 4.98e-02 | -0.186000 | 1.16e-01 |
| Cell surface interactions at the vascular wall | 104 | 1.04e-03 | 0.186000 | 5.05e-03 |
| Miscellaneous transport and binding events | 20 | 1.50e-01 | 0.186000 | 2.65e-01 |
| Integrin signaling | 23 | 1.23e-01 | 0.186000 | 2.31e-01 |
| Signaling by GPCR | 404 | 1.70e-10 | 0.186000 | 3.65e-09 |
| Germ layer formation at gastrulation | 10 | 3.12e-01 | -0.185000 | 4.49e-01 |
| PI3K events in ERBB2 signaling | 14 | 2.33e-01 | 0.184000 | 3.63e-01 |
| FGFR1 mutant receptor activation | 25 | 1.11e-01 | -0.184000 | 2.13e-01 |
| Resolution of Abasic Sites (AP sites) | 38 | 5.04e-02 | -0.183000 | 1.17e-01 |
| FLT3 signaling in disease | 27 | 9.95e-02 | -0.183000 | 1.96e-01 |
| Neddylation | 233 | 1.53e-06 | -0.183000 | 1.94e-05 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 1.92e-01 | -0.183000 | 3.15e-01 |
| SHC-mediated cascade:FGFR2 | 14 | 2.36e-01 | 0.183000 | 3.67e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 16 | 2.05e-01 | 0.183000 | 3.32e-01 |
| Acyl chain remodelling of PS | 15 | 2.20e-01 | 0.183000 | 3.50e-01 |
| Aquaporin-mediated transport | 36 | 5.79e-02 | 0.183000 | 1.30e-01 |
| ISG15 antiviral mechanism | 71 | 7.93e-03 | -0.182000 | 2.74e-02 |
| trans-Golgi Network Vesicle Budding | 68 | 9.47e-03 | -0.182000 | 3.10e-02 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 1.94e-01 | -0.182000 | 3.17e-01 |
| Downregulation of ERBB2:ERBB3 signaling | 13 | 2.57e-01 | -0.181000 | 3.89e-01 |
| Metabolism of proteins | 1630 | 1.73e-33 | -0.181000 | 2.11e-31 |
| Mitotic Anaphase | 209 | 7.06e-06 | -0.180000 | 7.12e-05 |
| Signaling by CSF1 (M-CSF) in myeloid cells | 31 | 8.21e-02 | -0.180000 | 1.70e-01 |
| Regulation of MECP2 expression and activity | 28 | 9.86e-02 | -0.180000 | 1.96e-01 |
| Aggrephagy | 34 | 6.94e-02 | -0.180000 | 1.49e-01 |
| Signaling by Activin | 14 | 2.44e-01 | 0.180000 | 3.75e-01 |
| GPCR downstream signalling | 363 | 4.35e-09 | 0.180000 | 7.95e-08 |
| Glutamate Neurotransmitter Release Cycle | 20 | 1.65e-01 | 0.179000 | 2.84e-01 |
| Diseases of glycosylation | 125 | 5.43e-04 | 0.179000 | 2.89e-03 |
| Regulation of localization of FOXO transcription factors | 11 | 3.05e-01 | -0.179000 | 4.42e-01 |
| Cellular hexose transport | 14 | 2.48e-01 | 0.179000 | 3.78e-01 |
| Signaling by WNT | 240 | 2.09e-06 | -0.178000 | 2.45e-05 |
| Signaling by FGFR in disease | 54 | 2.37e-02 | -0.178000 | 6.44e-02 |
| Metabolism | 1742 | 3.78e-34 | -0.178000 | 5.02e-32 |
| Telomere Maintenance | 70 | 1.02e-02 | -0.178000 | 3.30e-02 |
| RNA Polymerase III Chain Elongation | 18 | 1.92e-01 | -0.178000 | 3.15e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 23 | 1.41e-01 | -0.178000 | 2.53e-01 |
| CTLA4 inhibitory signaling | 18 | 1.93e-01 | -0.177000 | 3.15e-01 |
| Activation of AMPK downstream of NMDARs | 22 | 1.50e-01 | 0.177000 | 2.65e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 29 | 9.90e-02 | -0.177000 | 1.96e-01 |
| Negative epigenetic regulation of rRNA expression | 56 | 2.20e-02 | -0.177000 | 6.09e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 1.26e-01 | -0.177000 | 2.35e-01 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 4.50e-02 | -0.177000 | 1.07e-01 |
| Neuronal System | 266 | 7.35e-07 | 0.177000 | 9.86e-06 |
| RNA Polymerase I Promoter Escape | 38 | 5.96e-02 | -0.177000 | 1.33e-01 |
| WNT5A-dependent internalization of FZD4 | 14 | 2.54e-01 | -0.176000 | 3.85e-01 |
| Glycogen metabolism | 24 | 1.36e-01 | -0.176000 | 2.48e-01 |
| Semaphorin interactions | 63 | 1.57e-02 | 0.176000 | 4.65e-02 |
| AKT phosphorylates targets in the nucleus | 10 | 3.35e-01 | -0.176000 | 4.68e-01 |
| Transport of vitamins, nucleosides, and related molecules | 29 | 1.01e-01 | 0.176000 | 1.99e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 7.64e-02 | 0.176000 | 1.61e-01 |
| DAG and IP3 signaling | 38 | 6.16e-02 | 0.175000 | 1.36e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 11 | 3.14e-01 | 0.175000 | 4.51e-01 |
| Mitotic Metaphase and Anaphase | 210 | 1.26e-05 | -0.175000 | 1.13e-04 |
| GRB2 events in ERBB2 signaling | 14 | 2.58e-01 | 0.175000 | 3.90e-01 |
| Regulation of IFNA/IFNB signaling | 12 | 2.95e-01 | 0.175000 | 4.36e-01 |
| RHO GTPases activate KTN1 | 10 | 3.41e-01 | -0.174000 | 4.74e-01 |
| M Phase | 336 | 4.84e-08 | -0.174000 | 7.53e-07 |
| Ovarian tumor domain proteases | 36 | 7.17e-02 | -0.174000 | 1.53e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 144 | 3.42e-04 | 0.173000 | 1.95e-03 |
| NS1 Mediated Effects on Host Pathways | 40 | 5.91e-02 | -0.172000 | 1.32e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 70 | 1.29e-02 | -0.172000 | 3.90e-02 |
| Adherens junctions interactions | 48 | 3.95e-02 | 0.172000 | 9.54e-02 |
| tRNA processing | 109 | 1.98e-03 | -0.172000 | 8.40e-03 |
| SHC1 events in ERBB2 signaling | 20 | 1.86e-01 | 0.171000 | 3.07e-01 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 41 | 5.83e-02 | 0.171000 | 1.31e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 54 | 3.01e-02 | -0.171000 | 7.77e-02 |
| WNT ligand biogenesis and trafficking | 15 | 2.53e-01 | -0.171000 | 3.83e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 12 | 3.06e-01 | 0.171000 | 4.44e-01 |
| Activation of G protein gated Potassium channels | 18 | 2.10e-01 | 0.171000 | 3.37e-01 |
| G protein gated Potassium channels | 18 | 2.10e-01 | 0.171000 | 3.37e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 18 | 2.10e-01 | 0.171000 | 3.37e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 17 | 2.24e-01 | 0.170000 | 3.53e-01 |
| Post NMDA receptor activation events | 67 | 1.62e-02 | 0.170000 | 4.74e-02 |
| Scavenging by Class A Receptors | 16 | 2.39e-01 | 0.170000 | 3.71e-01 |
| FCGR3A-mediated IL10 synthesis | 37 | 7.46e-02 | 0.169000 | 1.58e-01 |
| Plasma lipoprotein assembly | 11 | 3.32e-01 | 0.169000 | 4.66e-01 |
| Activation of NMDA receptors and postsynaptic events | 78 | 9.91e-03 | 0.169000 | 3.22e-02 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 101 | 3.37e-03 | -0.169000 | 1.33e-02 |
| Chaperonin-mediated protein folding | 75 | 1.15e-02 | -0.169000 | 3.60e-02 |
| Cell-Cell communication | 121 | 1.35e-03 | 0.169000 | 6.12e-03 |
| Hedgehog ‘on’ state | 82 | 8.32e-03 | -0.169000 | 2.81e-02 |
| Inwardly rectifying K+ channels | 23 | 1.62e-01 | 0.169000 | 2.81e-01 |
| Leading Strand Synthesis | 14 | 2.76e-01 | -0.168000 | 4.12e-01 |
| Polymerase switching | 14 | 2.76e-01 | -0.168000 | 4.12e-01 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 15 | 2.60e-01 | -0.168000 | 3.92e-01 |
| Ca-dependent events | 34 | 9.06e-02 | 0.168000 | 1.82e-01 |
| Regulation of TP53 Expression and Degradation | 36 | 8.19e-02 | -0.168000 | 1.70e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 12 | 3.16e-01 | -0.167000 | 4.52e-01 |
| Tight junction interactions | 17 | 2.33e-01 | 0.167000 | 3.63e-01 |
| Transcriptional Regulation by NPAS4 | 31 | 1.07e-01 | -0.167000 | 2.08e-01 |
| Assembly of the ORC complex at the origin of replication | 15 | 2.63e-01 | -0.167000 | 3.95e-01 |
| HCMV Early Events | 77 | 1.13e-02 | -0.167000 | 3.54e-02 |
| Apoptotic cleavage of cellular proteins | 35 | 8.73e-02 | 0.167000 | 1.77e-01 |
| Signaling by ALK fusions and activated point mutants | 53 | 3.60e-02 | -0.167000 | 8.86e-02 |
| Signaling by ALK in cancer | 53 | 3.60e-02 | -0.167000 | 8.86e-02 |
| TNFR2 non-canonical NF-kB pathway | 85 | 8.14e-03 | -0.166000 | 2.78e-02 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 8.46e-02 | -0.166000 | 1.73e-01 |
| Interferon gamma signaling | 72 | 1.50e-02 | 0.166000 | 4.45e-02 |
| Cytochrome P450 - arranged by substrate type | 33 | 9.93e-02 | -0.166000 | 1.96e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 3.20e-01 | -0.166000 | 4.57e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 1.44e-01 | -0.166000 | 2.57e-01 |
| IL-6-type cytokine receptor ligand interactions | 13 | 3.03e-01 | 0.165000 | 4.41e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 84 | 8.98e-03 | -0.165000 | 3.00e-02 |
| RNA Polymerase I Transcription Initiation | 47 | 5.06e-02 | -0.165000 | 1.17e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 2.40e-01 | -0.165000 | 3.71e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 45 | 5.66e-02 | -0.164000 | 1.29e-01 |
| Cell-cell junction organization | 67 | 2.04e-02 | 0.164000 | 5.77e-02 |
| Platelet sensitization by LDL | 17 | 2.43e-01 | -0.164000 | 3.74e-01 |
| RNA Polymerase I Promoter Clearance | 57 | 3.26e-02 | -0.164000 | 8.14e-02 |
| RNA Polymerase I Transcription | 57 | 3.26e-02 | -0.164000 | 8.14e-02 |
| Aspirin ADME | 15 | 2.74e-01 | -0.163000 | 4.11e-01 |
| G1/S-Specific Transcription | 23 | 1.77e-01 | -0.163000 | 2.97e-01 |
| Gene expression (Transcription) | 1352 | 2.93e-23 | -0.163000 | 1.16e-21 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 2.77e-01 | -0.162000 | 4.13e-01 |
| Phase I - Functionalization of compounds | 67 | 2.20e-02 | -0.162000 | 6.09e-02 |
| Bacterial Infection Pathways | 63 | 2.63e-02 | -0.162000 | 6.98e-02 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 1.61e-01 | -0.162000 | 2.81e-01 |
| Synthesis of PIPs at the plasma membrane | 51 | 4.59e-02 | -0.162000 | 1.08e-01 |
| Regulation of TP53 Activity | 149 | 6.76e-04 | -0.161000 | 3.49e-03 |
| Meiosis | 50 | 4.84e-02 | -0.161000 | 1.13e-01 |
| RHOV GTPase cycle | 34 | 1.04e-01 | -0.161000 | 2.03e-01 |
| TNFR1-induced proapoptotic signaling | 24 | 1.72e-01 | -0.161000 | 2.92e-01 |
| Activation of HOX genes during differentiation | 67 | 2.27e-02 | -0.161000 | 6.24e-02 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 67 | 2.27e-02 | -0.161000 | 6.24e-02 |
| Transport to the Golgi and subsequent modification | 165 | 3.69e-04 | -0.161000 | 2.09e-03 |
| Early SARS-CoV-2 Infection Events | 32 | 1.15e-01 | -0.161000 | 2.20e-01 |
| Transcriptional regulation by RUNX1 | 165 | 4.09e-04 | -0.160000 | 2.28e-03 |
| Regulation of TP53 Degradation | 35 | 1.03e-01 | -0.159000 | 2.02e-01 |
| Synthesis of PC | 23 | 1.87e-01 | -0.159000 | 3.09e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 66 | 2.62e-02 | 0.158000 | 6.97e-02 |
| Leishmania parasite growth and survival | 66 | 2.62e-02 | 0.158000 | 6.97e-02 |
| RHOH GTPase cycle | 31 | 1.28e-01 | -0.158000 | 2.38e-01 |
| G beta:gamma signalling through BTK | 12 | 3.47e-01 | 0.157000 | 4.78e-01 |
| Separation of Sister Chromatids | 166 | 5.07e-04 | -0.157000 | 2.75e-03 |
| Transcriptional regulation by RUNX2 | 113 | 4.09e-03 | -0.156000 | 1.57e-02 |
| ADORA2B mediated anti-inflammatory cytokines production | 34 | 1.16e-01 | 0.156000 | 2.20e-01 |
| ROS and RNS production in phagocytes | 29 | 1.47e-01 | -0.156000 | 2.61e-01 |
| Protein folding | 81 | 1.56e-02 | -0.156000 | 4.60e-02 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 36 | 1.07e-01 | -0.155000 | 2.08e-01 |
| G beta:gamma signalling through PLC beta | 14 | 3.15e-01 | 0.155000 | 4.51e-01 |
| Attachment and Entry 9694614 | 15 | 3.01e-01 | 0.154000 | 4.39e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 21 | 2.22e-01 | 0.154000 | 3.51e-01 |
| MET promotes cell motility | 40 | 9.23e-02 | 0.154000 | 1.85e-01 |
| Nuclear events stimulated by ALK signaling in cancer | 17 | 2.72e-01 | -0.154000 | 4.08e-01 |
| Glucagon signaling in metabolic regulation | 26 | 1.76e-01 | 0.153000 | 2.97e-01 |
| DNA Repair | 278 | 1.14e-05 | -0.153000 | 1.06e-04 |
| DNA methylation | 11 | 3.80e-01 | -0.153000 | 5.13e-01 |
| RNA Polymerase I Promoter Opening | 10 | 4.02e-01 | -0.153000 | 5.35e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 20 | 2.37e-01 | 0.153000 | 3.68e-01 |
| Telomere C-strand synthesis initiation | 13 | 3.41e-01 | -0.153000 | 4.74e-01 |
| Dopamine Neurotransmitter Release Cycle | 19 | 2.50e-01 | 0.152000 | 3.80e-01 |
| Cytosolic sensors of pathogen-associated DNA | 62 | 3.80e-02 | -0.152000 | 9.24e-02 |
| CaM pathway | 32 | 1.36e-01 | 0.152000 | 2.48e-01 |
| Calmodulin induced events | 32 | 1.36e-01 | 0.152000 | 2.48e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 11 | 3.82e-01 | -0.152000 | 5.14e-01 |
| G alpha (i) signalling events | 174 | 5.42e-04 | 0.152000 | 2.89e-03 |
| NoRC negatively regulates rRNA expression | 53 | 5.60e-02 | -0.152000 | 1.28e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 43 | 8.54e-02 | -0.152000 | 1.74e-01 |
| CD209 (DC-SIGN) signaling | 20 | 2.41e-01 | -0.152000 | 3.72e-01 |
| Signaling by TGF-beta Receptor Complex | 92 | 1.21e-02 | -0.151000 | 3.74e-02 |
| Signaling by Leptin | 11 | 3.85e-01 | -0.151000 | 5.16e-01 |
| RUNX2 regulates osteoblast differentiation | 21 | 2.30e-01 | 0.151000 | 3.61e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 23 | 2.12e-01 | 0.150000 | 3.38e-01 |
| SUMOylation of immune response proteins | 11 | 3.88e-01 | -0.150000 | 5.20e-01 |
| Sensory processing of sound by outer hair cells of the cochlea | 38 | 1.09e-01 | 0.150000 | 2.10e-01 |
| Diseases of carbohydrate metabolism | 29 | 1.62e-01 | -0.150000 | 2.81e-01 |
| Transcriptional regulation by RUNX3 | 95 | 1.16e-02 | -0.150000 | 3.63e-02 |
| Lysosome Vesicle Biogenesis | 31 | 1.49e-01 | -0.150000 | 2.63e-01 |
| Membrane Trafficking | 565 | 1.38e-09 | -0.150000 | 2.62e-08 |
| LDL clearance | 17 | 2.86e-01 | -0.150000 | 4.24e-01 |
| G alpha (s) signalling events | 89 | 1.48e-02 | 0.150000 | 4.41e-02 |
| RAF-independent MAPK1/3 activation | 20 | 2.49e-01 | 0.149000 | 3.80e-01 |
| EPHB-mediated forward signaling | 39 | 1.09e-01 | 0.148000 | 2.10e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 34 | 1.35e-01 | 0.148000 | 2.47e-01 |
| Regulation of FZD by ubiquitination | 16 | 3.05e-01 | -0.148000 | 4.42e-01 |
| RNA Polymerase II Transcription | 1195 | 1.28e-17 | -0.148000 | 3.74e-16 |
| Transmission across Chemical Synapses | 190 | 4.72e-04 | 0.147000 | 2.60e-03 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 183 | 6.01e-04 | -0.147000 | 3.14e-03 |
| Cellular Senescence | 127 | 4.23e-03 | -0.147000 | 1.61e-02 |
| Impaired BRCA2 binding to PALB2 | 21 | 2.44e-01 | 0.147000 | 3.75e-01 |
| Neurotransmitter release cycle | 36 | 1.29e-01 | 0.146000 | 2.39e-01 |
| Infection with Mycobacterium tuberculosis | 27 | 1.88e-01 | -0.146000 | 3.11e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 15 | 3.28e-01 | -0.146000 | 4.63e-01 |
| Iron uptake and transport | 52 | 6.93e-02 | -0.146000 | 1.49e-01 |
| Extension of Telomeres | 49 | 7.80e-02 | -0.146000 | 1.64e-01 |
| Cell Cycle, Mitotic | 466 | 8.01e-08 | -0.146000 | 1.21e-06 |
| Response of Mtb to phagocytosis | 23 | 2.28e-01 | -0.145000 | 3.58e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 29 | 1.76e-01 | 0.145000 | 2.97e-01 |
| Fatty acid metabolism | 142 | 2.86e-03 | -0.145000 | 1.16e-02 |
| Acyl chain remodelling of PG | 11 | 4.06e-01 | 0.145000 | 5.37e-01 |
| Mitotic G1 phase and G1/S transition | 139 | 3.29e-03 | -0.145000 | 1.30e-02 |
| Surfactant metabolism | 18 | 2.89e-01 | 0.145000 | 4.27e-01 |
| Activation of BAD and translocation to mitochondria | 14 | 3.51e-01 | -0.144000 | 4.82e-01 |
| Platelet degranulation | 111 | 8.96e-03 | 0.144000 | 3.00e-02 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 22 | 2.45e-01 | -0.143000 | 3.76e-01 |
| Lysine catabolism | 11 | 4.11e-01 | -0.143000 | 5.40e-01 |
| PERK regulates gene expression | 30 | 1.75e-01 | -0.143000 | 2.96e-01 |
| Ion homeostasis | 48 | 8.79e-02 | 0.142000 | 1.78e-01 |
| Signaling by FGFR4 in disease | 11 | 4.14e-01 | -0.142000 | 5.42e-01 |
| Gluconeogenesis | 29 | 1.85e-01 | -0.142000 | 3.06e-01 |
| G-protein activation | 17 | 3.12e-01 | 0.142000 | 4.49e-01 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 4.16e-01 | -0.142000 | 5.43e-01 |
| Hemostasis | 481 | 1.14e-07 | 0.142000 | 1.68e-06 |
| Synaptic adhesion-like molecules | 17 | 3.13e-01 | 0.141000 | 4.51e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 2.87e-01 | -0.141000 | 4.25e-01 |
| Antiviral mechanism by IFN-stimulated genes | 79 | 3.09e-02 | -0.141000 | 7.88e-02 |
| Depolymerization of the Nuclear Lamina | 15 | 3.46e-01 | -0.141000 | 4.78e-01 |
| DARPP-32 events | 23 | 2.43e-01 | -0.141000 | 3.75e-01 |
| Prostacyclin signalling through prostacyclin receptor | 13 | 3.80e-01 | 0.140000 | 5.14e-01 |
| Biological oxidations | 137 | 4.73e-03 | -0.140000 | 1.77e-02 |
| Integration of energy metabolism | 89 | 2.30e-02 | 0.140000 | 6.30e-02 |
| Cardiac conduction | 100 | 1.61e-02 | 0.139000 | 4.72e-02 |
| Cell Cycle | 573 | 1.37e-08 | -0.139000 | 2.33e-07 |
| Signaling by ERBB2 ECD mutants | 16 | 3.35e-01 | -0.139000 | 4.68e-01 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 13 | 3.85e-01 | 0.139000 | 5.16e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 55 | 7.43e-02 | -0.139000 | 1.58e-01 |
| Transcriptional regulation of white adipocyte differentiation | 81 | 3.15e-02 | -0.138000 | 8.00e-02 |
| Regulation of PTEN gene transcription | 60 | 6.60e-02 | -0.137000 | 1.44e-01 |
| Assembly and cell surface presentation of NMDA receptors | 33 | 1.73e-01 | 0.137000 | 2.94e-01 |
| Spry regulation of FGF signaling | 16 | 3.43e-01 | -0.137000 | 4.76e-01 |
| Polymerase switching on the C-strand of the telomere | 26 | 2.29e-01 | -0.136000 | 3.58e-01 |
| Interleukin-12 family signaling | 45 | 1.13e-01 | -0.136000 | 2.17e-01 |
| RND2 GTPase cycle | 35 | 1.63e-01 | -0.136000 | 2.82e-01 |
| Interleukin-6 signaling | 10 | 4.55e-01 | -0.136000 | 5.79e-01 |
| G alpha (z) signalling events | 37 | 1.52e-01 | 0.136000 | 2.66e-01 |
| Metabolism of steroid hormones | 21 | 2.80e-01 | 0.136000 | 4.16e-01 |
| Interleukin-1 signaling | 108 | 1.49e-02 | -0.136000 | 4.44e-02 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 3.80e-01 | 0.136000 | 5.13e-01 |
| Resolution of D-Loop Structures | 30 | 1.99e-01 | 0.135000 | 3.25e-01 |
| Intra-Golgi traffic | 41 | 1.34e-01 | -0.135000 | 2.45e-01 |
| Nuclear signaling by ERBB4 | 29 | 2.09e-01 | 0.135000 | 3.36e-01 |
| Processing of Intronless Pre-mRNAs | 20 | 2.98e-01 | -0.135000 | 4.37e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 3.10e-01 | -0.134000 | 4.48e-01 |
| Regulation of CDH11 gene transcription | 10 | 4.62e-01 | 0.134000 | 5.86e-01 |
| Other interleukin signaling | 20 | 2.99e-01 | 0.134000 | 4.38e-01 |
| G alpha (12/13) signalling events | 68 | 5.61e-02 | 0.134000 | 1.28e-01 |
| RNA Polymerase I Transcription Termination | 30 | 2.05e-01 | -0.134000 | 3.31e-01 |
| Vesicle-mediated transport | 596 | 2.92e-08 | -0.134000 | 4.65e-07 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 15 | 3.71e-01 | -0.133000 | 5.06e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 15 | 3.71e-01 | -0.133000 | 5.06e-01 |
| Synthesis of PIPs at the Golgi membrane | 15 | 3.72e-01 | -0.133000 | 5.06e-01 |
| Platelet activation, signaling and aggregation | 223 | 6.29e-04 | 0.133000 | 3.27e-03 |
| Metabolism of steroids | 120 | 1.19e-02 | -0.133000 | 3.70e-02 |
| Disease | 1460 | 6.87e-17 | -0.132000 | 1.97e-15 |
| FRS-mediated FGFR4 signaling | 15 | 3.76e-01 | 0.132000 | 5.09e-01 |
| Costimulation by the CD28 family | 50 | 1.07e-01 | -0.132000 | 2.08e-01 |
| RHOB GTPase cycle | 64 | 6.86e-02 | 0.132000 | 1.48e-01 |
| Potential therapeutics for SARS | 93 | 2.88e-02 | -0.131000 | 7.51e-02 |
| Signaling by EGFR in Cancer | 21 | 2.99e-01 | -0.131000 | 4.38e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 21 | 3.00e-01 | -0.131000 | 4.39e-01 |
| Maturation of nucleoprotein 9683610 | 11 | 4.55e-01 | -0.130000 | 5.79e-01 |
| Class I peroxisomal membrane protein import | 20 | 3.14e-01 | -0.130000 | 4.51e-01 |
| Generic Transcription Pathway | 1077 | 9.55e-13 | -0.130000 | 2.49e-11 |
| Response to elevated platelet cytosolic Ca2+ | 115 | 1.63e-02 | 0.130000 | 4.75e-02 |
| Polo-like kinase mediated events | 12 | 4.37e-01 | -0.130000 | 5.59e-01 |
| PIP3 activates AKT signaling | 244 | 4.99e-04 | -0.130000 | 2.71e-03 |
| Serotonin Neurotransmitter Release Cycle | 14 | 4.02e-01 | 0.129000 | 5.35e-01 |
| Gap junction trafficking | 31 | 2.14e-01 | 0.129000 | 3.41e-01 |
| Plasma lipoprotein clearance | 32 | 2.07e-01 | -0.129000 | 3.34e-01 |
| SHC-mediated cascade:FGFR3 | 12 | 4.42e-01 | 0.128000 | 5.64e-01 |
| Beta-catenin independent WNT signaling | 132 | 1.12e-02 | -0.128000 | 3.54e-02 |
| Signaling by FGFR2 | 61 | 8.41e-02 | -0.128000 | 1.73e-01 |
| Ion transport by P-type ATPases | 44 | 1.43e-01 | 0.128000 | 2.56e-01 |
| G2/M Transition | 182 | 3.03e-03 | -0.128000 | 1.22e-02 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 24 | 2.81e-01 | 0.127000 | 4.17e-01 |
| Cytosolic sulfonation of small molecules | 18 | 3.51e-01 | 0.127000 | 4.82e-01 |
| Mitotic G2-G2/M phases | 184 | 3.03e-03 | -0.127000 | 1.22e-02 |
| Cardiogenesis | 20 | 3.26e-01 | 0.127000 | 4.62e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 41 | 1.60e-01 | 0.127000 | 2.80e-01 |
| G2/M Checkpoints | 122 | 1.59e-02 | -0.126000 | 4.68e-02 |
| PKA activation in glucagon signalling | 16 | 3.81e-01 | 0.126000 | 5.14e-01 |
| Kinesins | 45 | 1.43e-01 | 0.126000 | 2.57e-01 |
| COPI-mediated anterograde transport | 91 | 3.79e-02 | -0.126000 | 9.23e-02 |
| ABC transporters in lipid homeostasis | 13 | 4.32e-01 | 0.126000 | 5.56e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 84 | 4.65e-02 | 0.126000 | 1.09e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 20 | 3.31e-01 | 0.126000 | 4.66e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 19 | 3.44e-01 | -0.125000 | 4.77e-01 |
| Oxidative Stress Induced Senescence | 69 | 7.22e-02 | -0.125000 | 1.53e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 24 | 2.90e-01 | 0.125000 | 4.28e-01 |
| Regulated Necrosis | 52 | 1.20e-01 | -0.125000 | 2.26e-01 |
| Translation of Structural Proteins 9683701 | 29 | 2.46e-01 | -0.124000 | 3.77e-01 |
| GAB1 signalosome | 13 | 4.40e-01 | 0.124000 | 5.63e-01 |
| Cyclin D associated events in G1 | 45 | 1.52e-01 | -0.124000 | 2.66e-01 |
| G1 Phase | 45 | 1.52e-01 | -0.124000 | 2.66e-01 |
| Glycosaminoglycan metabolism | 103 | 3.05e-02 | 0.124000 | 7.79e-02 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 18 | 3.65e-01 | -0.123000 | 4.99e-01 |
| Neurodegenerative Diseases | 18 | 3.65e-01 | -0.123000 | 4.99e-01 |
| activated TAK1 mediates p38 MAPK activation | 23 | 3.07e-01 | -0.123000 | 4.45e-01 |
| Fanconi Anemia Pathway | 34 | 2.17e-01 | -0.122000 | 3.45e-01 |
| Programmed Cell Death | 188 | 3.93e-03 | -0.122000 | 1.51e-02 |
| Regulation of IFNG signaling | 13 | 4.47e-01 | -0.122000 | 5.69e-01 |
| Organelle biogenesis and maintenance | 272 | 5.59e-04 | -0.122000 | 2.95e-03 |
| Platelet homeostasis | 71 | 7.74e-02 | 0.121000 | 1.63e-01 |
| Homologous DNA Pairing and Strand Exchange | 39 | 1.92e-01 | 0.121000 | 3.15e-01 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 3.90e-01 | -0.120000 | 5.22e-01 |
| Metabolism of water-soluble vitamins and cofactors | 110 | 3.02e-02 | -0.120000 | 7.78e-02 |
| Signaling by NOTCH | 175 | 6.43e-03 | -0.120000 | 2.31e-02 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 16 | 4.08e-01 | -0.119000 | 5.38e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 22 | 3.32e-01 | 0.119000 | 4.66e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 22 | 3.32e-01 | 0.119000 | 4.66e-01 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 22 | 3.32e-01 | 0.119000 | 4.66e-01 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | 22 | 3.32e-01 | 0.119000 | 4.66e-01 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 3.45e-01 | -0.119000 | 4.77e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 15 | 4.26e-01 | 0.119000 | 5.51e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 24 | 3.14e-01 | -0.119000 | 4.51e-01 |
| TGF-beta receptor signaling activates SMADs | 46 | 1.65e-01 | -0.118000 | 2.84e-01 |
| p38MAPK events | 13 | 4.60e-01 | 0.118000 | 5.84e-01 |
| Class B/2 (Secretin family receptors) | 52 | 1.41e-01 | 0.118000 | 2.54e-01 |
| Gastrulation | 85 | 6.01e-02 | -0.118000 | 1.33e-01 |
| Regulation of TP53 Activity through Phosphorylation | 85 | 6.05e-02 | -0.118000 | 1.34e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 2.35e-01 | -0.118000 | 3.66e-01 |
| Signaling by FGFR2 in disease | 34 | 2.35e-01 | -0.118000 | 3.66e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 32 | 2.50e-01 | -0.118000 | 3.80e-01 |
| Apoptosis | 161 | 1.02e-02 | -0.117000 | 3.30e-02 |
| G0 and Early G1 | 23 | 3.32e-01 | -0.117000 | 4.66e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 76 | 7.92e-02 | 0.117000 | 1.66e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 15 | 4.35e-01 | -0.116000 | 5.58e-01 |
| Diseases of programmed cell death | 48 | 1.64e-01 | -0.116000 | 2.83e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 16 | 4.21e-01 | 0.116000 | 5.48e-01 |
| Regulation of CDH11 function | 10 | 5.25e-01 | 0.116000 | 6.45e-01 |
| RHOU GTPase cycle | 39 | 2.11e-01 | -0.116000 | 3.37e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 5.26e-01 | -0.116000 | 6.45e-01 |
| Meiotic recombination | 26 | 3.08e-01 | -0.116000 | 4.46e-01 |
| Translation of Structural Proteins 9694635 | 57 | 1.32e-01 | -0.115000 | 2.43e-01 |
| Extra-nuclear estrogen signaling | 63 | 1.18e-01 | 0.114000 | 2.23e-01 |
| NR1H2 and NR1H3-mediated signaling | 40 | 2.13e-01 | -0.114000 | 3.39e-01 |
| Maturation of nucleoprotein 9694631 | 15 | 4.45e-01 | -0.114000 | 5.68e-01 |
| Gap junction trafficking and regulation | 33 | 2.58e-01 | 0.114000 | 3.90e-01 |
| Nuclear Events (kinase and transcription factor activation) | 57 | 1.39e-01 | 0.113000 | 2.51e-01 |
| Interconversion of nucleotide di- and triphosphates | 27 | 3.09e-01 | -0.113000 | 4.47e-01 |
| Signaling by KIT in disease | 19 | 3.95e-01 | -0.113000 | 5.27e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 19 | 3.95e-01 | -0.113000 | 5.27e-01 |
| The phototransduction cascade | 20 | 3.83e-01 | -0.113000 | 5.15e-01 |
| DCC mediated attractive signaling | 13 | 4.86e-01 | 0.112000 | 6.09e-01 |
| Thromboxane signalling through TP receptor | 18 | 4.14e-01 | 0.111000 | 5.42e-01 |
| Opioid Signalling | 79 | 8.75e-02 | 0.111000 | 1.77e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 393 | 1.61e-04 | -0.111000 | 1.05e-03 |
| Processive synthesis on the C-strand of the telomere | 19 | 4.04e-01 | -0.110000 | 5.36e-01 |
| Azathioprine ADME | 18 | 4.18e-01 | -0.110000 | 5.44e-01 |
| Interleukin-20 family signaling | 14 | 4.76e-01 | 0.110000 | 6.01e-01 |
| PI Metabolism | 79 | 9.14e-02 | -0.110000 | 1.83e-01 |
| Signal amplification | 25 | 3.44e-01 | 0.109000 | 4.77e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 37 | 2.50e-01 | -0.109000 | 3.80e-01 |
| Phase II - Conjugation of compounds | 66 | 1.25e-01 | -0.109000 | 2.33e-01 |
| Signaling by Nuclear Receptors | 213 | 6.10e-03 | -0.109000 | 2.21e-02 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 10 | 5.51e-01 | -0.109000 | 6.70e-01 |
| Chromosome Maintenance | 92 | 7.18e-02 | -0.109000 | 1.53e-01 |
| BBSome-mediated cargo-targeting to cilium | 21 | 3.89e-01 | -0.109000 | 5.20e-01 |
| Golgi-to-ER retrograde transport | 117 | 4.31e-02 | -0.108000 | 1.03e-01 |
| PI-3K cascade:FGFR4 | 13 | 5.00e-01 | 0.108000 | 6.21e-01 |
| MAP kinase activation | 63 | 1.40e-01 | -0.107000 | 2.53e-01 |
| Zinc transporters | 10 | 5.57e-01 | -0.107000 | 6.75e-01 |
| FCERI mediated MAPK activation | 33 | 2.88e-01 | 0.107000 | 4.26e-01 |
| Metal ion SLC transporters | 18 | 4.33e-01 | -0.107000 | 5.56e-01 |
| ERKs are inactivated | 13 | 5.07e-01 | 0.106000 | 6.26e-01 |
| Late SARS-CoV-2 Infection Events | 65 | 1.40e-01 | -0.106000 | 2.53e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 4.93e-01 | 0.106000 | 6.15e-01 |
| ESR-mediated signaling | 152 | 2.49e-02 | -0.106000 | 6.70e-02 |
| Notch-HLH transcription pathway | 28 | 3.35e-01 | -0.105000 | 4.68e-01 |
| SARS-CoV-1 activates/modulates innate immune responses | 39 | 2.56e-01 | -0.105000 | 3.87e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 40 | 2.52e-01 | -0.105000 | 3.82e-01 |
| Signaling by FLT3 ITD and TKD mutants | 15 | 4.84e-01 | -0.104000 | 6.07e-01 |
| PI-3K cascade:FGFR3 | 12 | 5.32e-01 | -0.104000 | 6.50e-01 |
| Signaling by FGFR2 IIIa TM | 19 | 4.34e-01 | -0.104000 | 5.57e-01 |
| Downstream signaling of activated FGFR4 | 20 | 4.23e-01 | 0.104000 | 5.49e-01 |
| STING mediated induction of host immune responses | 15 | 4.89e-01 | 0.103000 | 6.12e-01 |
| CD28 dependent PI3K/Akt signaling | 20 | 4.25e-01 | -0.103000 | 5.51e-01 |
| RAB geranylgeranylation | 54 | 1.91e-01 | -0.103000 | 3.14e-01 |
| Asparagine N-linked glycosylation | 276 | 3.32e-03 | -0.103000 | 1.31e-02 |
| Activation of kainate receptors upon glutamate binding | 22 | 4.04e-01 | 0.103000 | 5.36e-01 |
| Presynaptic function of Kainate receptors | 15 | 4.91e-01 | 0.103000 | 6.14e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 3.56e-01 | -0.103000 | 4.89e-01 |
| Defective Intrinsic Pathway for Apoptosis | 21 | 4.17e-01 | -0.102000 | 5.44e-01 |
| Sensory processing of sound | 52 | 2.02e-01 | 0.102000 | 3.28e-01 |
| Activation of BH3-only proteins | 27 | 3.58e-01 | -0.102000 | 4.91e-01 |
| Leishmania infection | 147 | 3.27e-02 | 0.102000 | 8.14e-02 |
| Parasitic Infection Pathways | 147 | 3.27e-02 | 0.102000 | 8.14e-02 |
| Adaptive Immune System | 650 | 9.72e-06 | -0.102000 | 9.42e-05 |
| Nicotinamide salvaging | 16 | 4.80e-01 | -0.102000 | 6.05e-01 |
| TRAF6 mediated IRF7 activation | 15 | 4.95e-01 | -0.102000 | 6.16e-01 |
| Unfolded Protein Response (UPR) | 89 | 9.70e-02 | -0.102000 | 1.93e-01 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 5.78e-01 | -0.102000 | 6.91e-01 |
| FOXO-mediated transcription of cell cycle genes | 16 | 4.84e-01 | -0.101000 | 6.07e-01 |
| Sensory processing of sound by inner hair cells of the cochlea | 47 | 2.31e-01 | 0.101000 | 3.62e-01 |
| Metabolism of lipids | 610 | 2.52e-05 | -0.100000 | 2.02e-04 |
| L1CAM interactions | 102 | 8.13e-02 | 0.100000 | 1.69e-01 |
| FCGR3A-mediated phagocytosis | 60 | 1.81e-01 | 0.099800 | 3.03e-01 |
| Leishmania phagocytosis | 60 | 1.81e-01 | 0.099800 | 3.03e-01 |
| Parasite infection | 60 | 1.81e-01 | 0.099800 | 3.03e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 57 | 1.93e-01 | 0.099800 | 3.15e-01 |
| E2F mediated regulation of DNA replication | 21 | 4.29e-01 | -0.099700 | 5.54e-01 |
| Reproduction | 65 | 1.66e-01 | -0.099500 | 2.85e-01 |
| RUNX2 regulates bone development | 27 | 3.73e-01 | 0.099200 | 5.06e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 30 | 3.48e-01 | 0.099100 | 4.79e-01 |
| The activation of arylsulfatases | 10 | 5.88e-01 | 0.098900 | 7.00e-01 |
| NPAS4 regulates expression of target genes | 19 | 4.56e-01 | -0.098800 | 5.79e-01 |
| Post-translational protein modification | 1190 | 1.29e-08 | -0.098800 | 2.22e-07 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 32 | 3.34e-01 | -0.098700 | 4.68e-01 |
| PKA activation | 17 | 4.82e-01 | 0.098400 | 6.06e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 25 | 3.95e-01 | -0.098200 | 5.27e-01 |
| Transport of connexons to the plasma membrane | 14 | 5.25e-01 | 0.098100 | 6.45e-01 |
| TRP channels | 20 | 4.50e-01 | 0.097500 | 5.73e-01 |
| Tie2 Signaling | 16 | 5.00e-01 | -0.097300 | 6.21e-01 |
| VEGFR2 mediated vascular permeability | 27 | 3.82e-01 | -0.097200 | 5.14e-01 |
| AKT phosphorylates targets in the cytosol | 14 | 5.29e-01 | -0.097100 | 6.48e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 71 | 1.59e-01 | 0.096800 | 2.77e-01 |
| Hedgehog ‘off’ state | 106 | 8.58e-02 | -0.096700 | 1.75e-01 |
| Cell Cycle Checkpoints | 228 | 1.22e-02 | -0.096500 | 3.75e-02 |
| RHOG GTPase cycle | 70 | 1.63e-01 | -0.096500 | 2.82e-01 |
| RAC1 GTPase cycle | 174 | 2.90e-02 | 0.096100 | 7.54e-02 |
| Interleukin-12 signaling | 39 | 3.03e-01 | -0.095400 | 4.41e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 23 | 4.29e-01 | 0.095200 | 5.54e-01 |
| Pre-NOTCH Transcription and Translation | 40 | 2.98e-01 | -0.095100 | 4.37e-01 |
| RHOA GTPase cycle | 141 | 5.18e-02 | 0.095000 | 1.20e-01 |
| Interleukin-17 signaling | 67 | 1.81e-01 | -0.094600 | 3.03e-01 |
| Amino acid transport across the plasma membrane | 25 | 4.15e-01 | 0.094200 | 5.42e-01 |
| Creation of C4 and C2 activators | 10 | 6.06e-01 | 0.094100 | 7.16e-01 |
| Pre-NOTCH Expression and Processing | 56 | 2.26e-01 | -0.093600 | 3.55e-01 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 37 | 3.24e-01 | 0.093600 | 4.61e-01 |
| Diseases of DNA Double-Strand Break Repair | 37 | 3.24e-01 | 0.093600 | 4.61e-01 |
| Signaling by RAF1 mutants | 37 | 3.25e-01 | 0.093600 | 4.61e-01 |
| Carboxyterminal post-translational modifications of tubulin | 32 | 3.61e-01 | 0.093300 | 4.94e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 31 | 3.76e-01 | -0.092000 | 5.09e-01 |
| Regulation of NF-kappa B signaling | 18 | 5.01e-01 | -0.091700 | 6.21e-01 |
| Keratan sulfate degradation | 13 | 5.68e-01 | -0.091600 | 6.83e-01 |
| PKA-mediated phosphorylation of CREB | 19 | 4.90e-01 | 0.091500 | 6.13e-01 |
| Netrin-1 signaling | 41 | 3.12e-01 | 0.091400 | 4.49e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 11 | 6.00e-01 | -0.091300 | 7.11e-01 |
| ADP signalling through P2Y purinoceptor 1 | 19 | 4.93e-01 | 0.090800 | 6.15e-01 |
| Glucagon-type ligand receptors | 18 | 5.05e-01 | 0.090700 | 6.25e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 10 | 6.20e-01 | -0.090700 | 7.27e-01 |
| Sphingolipid de novo biosynthesis | 38 | 3.38e-01 | 0.089900 | 4.71e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 13 | 5.76e-01 | -0.089600 | 6.91e-01 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 41 | 3.22e-01 | -0.089500 | 4.58e-01 |
| IRS-mediated signalling | 37 | 3.50e-01 | -0.088800 | 4.81e-01 |
| IRE1alpha activates chaperones | 50 | 2.78e-01 | -0.088700 | 4.14e-01 |
| DAP12 signaling | 26 | 4.35e-01 | 0.088500 | 5.58e-01 |
| FRS-mediated FGFR1 signaling | 15 | 5.54e-01 | 0.088400 | 6.72e-01 |
| Intracellular signaling by second messengers | 281 | 1.11e-02 | -0.088200 | 3.53e-02 |
| RND1 GTPase cycle | 36 | 3.61e-01 | -0.088000 | 4.94e-01 |
| O-linked glycosylation of mucins | 41 | 3.30e-01 | 0.087900 | 4.66e-01 |
| Interleukin-1 family signaling | 136 | 8.05e-02 | -0.086900 | 1.68e-01 |
| Interleukin-4 and Interleukin-13 signaling | 85 | 1.66e-01 | 0.086900 | 2.85e-01 |
| NOD1/2 Signaling Pathway | 36 | 3.67e-01 | -0.086900 | 5.01e-01 |
| Cargo trafficking to the periciliary membrane | 45 | 3.18e-01 | -0.086000 | 4.54e-01 |
| SLC-mediated transmembrane transport | 163 | 5.86e-02 | 0.085900 | 1.31e-01 |
| PI3K Cascade | 33 | 4.01e-01 | -0.084600 | 5.33e-01 |
| Killing mechanisms | 10 | 6.44e-01 | -0.084400 | 7.44e-01 |
| WNT5:FZD7-mediated leishmania damping | 10 | 6.44e-01 | -0.084400 | 7.44e-01 |
| XBP1(S) activates chaperone genes | 48 | 3.16e-01 | -0.083700 | 4.52e-01 |
| GABA synthesis, release, reuptake and degradation | 11 | 6.31e-01 | 0.083600 | 7.36e-01 |
| Stimuli-sensing channels | 76 | 2.11e-01 | 0.083000 | 3.37e-01 |
| HDR through Single Strand Annealing (SSA) | 33 | 4.09e-01 | 0.083000 | 5.38e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 16 | 5.66e-01 | 0.082900 | 6.82e-01 |
| Syndecan interactions | 26 | 4.68e-01 | 0.082300 | 5.92e-01 |
| GPVI-mediated activation cascade | 31 | 4.29e-01 | -0.082100 | 5.54e-01 |
| Glutamate and glutamine metabolism | 11 | 6.39e-01 | -0.081800 | 7.41e-01 |
| FCERI mediated Ca+2 mobilization | 31 | 4.31e-01 | 0.081700 | 5.56e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 19 | 5.38e-01 | 0.081600 | 6.56e-01 |
| CD28 co-stimulation | 31 | 4.32e-01 | -0.081600 | 5.56e-01 |
| Processing of DNA double-strand break ends | 60 | 2.77e-01 | -0.081100 | 4.13e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 85 | 1.98e-01 | -0.080800 | 3.23e-01 |
| NRAGE signals death through JNK | 56 | 2.96e-01 | 0.080800 | 4.36e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 89 | 1.90e-01 | -0.080400 | 3.13e-01 |
| Role of phospholipids in phagocytosis | 24 | 4.98e-01 | 0.080000 | 6.19e-01 |
| RHO GTPases Activate WASPs and WAVEs | 36 | 4.08e-01 | 0.079800 | 5.38e-01 |
| Phospholipid metabolism | 181 | 6.63e-02 | -0.079200 | 1.44e-01 |
| Trafficking of GluR2-containing AMPA receptors | 14 | 6.11e-01 | -0.078400 | 7.20e-01 |
| Mucopolysaccharidoses | 11 | 6.53e-01 | 0.078300 | 7.52e-01 |
| Activation of the pre-replicative complex | 28 | 4.74e-01 | -0.078200 | 5.99e-01 |
| Visual phototransduction | 59 | 3.00e-01 | 0.078100 | 4.38e-01 |
| Acyl chain remodelling of PI | 10 | 6.70e-01 | 0.077900 | 7.69e-01 |
| Post-chaperonin tubulin folding pathway | 18 | 5.68e-01 | 0.077700 | 6.84e-01 |
| TRAF6 mediated NF-kB activation | 23 | 5.26e-01 | -0.076500 | 6.45e-01 |
| Signaling by FLT3 fusion proteins | 19 | 5.64e-01 | -0.076400 | 6.81e-01 |
| Regulation of Expression and Function of Type II Classical Cadherins | 29 | 4.79e-01 | 0.076000 | 6.03e-01 |
| Regulation of Homotypic Cell-Cell Adhesion | 29 | 4.79e-01 | 0.076000 | 6.03e-01 |
| Incretin synthesis, secretion, and inactivation | 13 | 6.35e-01 | 0.075900 | 7.39e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 13 | 6.35e-01 | 0.075900 | 7.39e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 36 | 4.32e-01 | 0.075800 | 5.56e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 56 | 3.27e-01 | -0.075800 | 4.63e-01 |
| Axon guidance | 489 | 4.28e-03 | -0.075700 | 1.62e-02 |
| Constitutive Signaling by EGFRvIII | 15 | 6.14e-01 | -0.075300 | 7.21e-01 |
| Signaling by EGFRvIII in Cancer | 15 | 6.14e-01 | -0.075300 | 7.21e-01 |
| Mitotic Spindle Checkpoint | 96 | 2.05e-01 | -0.074900 | 3.31e-01 |
| Ca2+ pathway | 53 | 3.49e-01 | 0.074400 | 4.81e-01 |
| Metabolism of vitamins and cofactors | 158 | 1.07e-01 | -0.074300 | 2.08e-01 |
| Interleukin receptor SHC signaling | 20 | 5.69e-01 | 0.073600 | 6.84e-01 |
| Cytochrome c-mediated apoptotic response | 13 | 6.51e-01 | 0.072500 | 7.50e-01 |
| DAP12 interactions | 32 | 4.79e-01 | 0.072300 | 6.03e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 6.28e-01 | 0.072300 | 7.33e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 6.28e-01 | 0.072300 | 7.33e-01 |
| DNA Double-Strand Break Repair | 128 | 1.59e-01 | -0.072200 | 2.77e-01 |
| Signalling to RAS | 20 | 5.77e-01 | 0.072100 | 6.91e-01 |
| RUNX3 regulates NOTCH signaling | 14 | 6.44e-01 | -0.071400 | 7.44e-01 |
| CDC42 GTPase cycle | 145 | 1.38e-01 | 0.071400 | 2.51e-01 |
| Signaling by NOTCH1 | 72 | 3.00e-01 | -0.070600 | 4.39e-01 |
| Death Receptor Signaling | 146 | 1.42e-01 | -0.070600 | 2.55e-01 |
| Insulin receptor recycling | 24 | 5.54e-01 | -0.069800 | 6.72e-01 |
| Ion channel transport | 137 | 1.62e-01 | 0.069200 | 2.82e-01 |
| Nervous system development | 509 | 7.92e-03 | -0.069000 | 2.74e-02 |
| CD28 dependent Vav1 pathway | 10 | 7.06e-01 | -0.068900 | 7.97e-01 |
| Downregulation of ERBB2 signaling | 27 | 5.37e-01 | -0.068700 | 6.56e-01 |
| Diseases of DNA repair | 46 | 4.23e-01 | 0.068200 | 5.50e-01 |
| RHOD GTPase cycle | 49 | 4.16e-01 | -0.067200 | 5.43e-01 |
| MET activates RAS signaling | 11 | 7.00e-01 | 0.067000 | 7.94e-01 |
| Interleukin-35 Signalling | 10 | 7.15e-01 | -0.066700 | 8.01e-01 |
| Signaling by Hedgehog | 140 | 1.80e-01 | -0.065700 | 3.02e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 105 | 2.46e-01 | -0.065500 | 3.77e-01 |
| Factors involved in megakaryocyte development and platelet production | 115 | 2.27e-01 | 0.065300 | 3.57e-01 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 7.21e-01 | 0.065200 | 8.04e-01 |
| MyD88-independent TLR4 cascade | 107 | 2.47e-01 | -0.064900 | 3.77e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling | 107 | 2.47e-01 | -0.064900 | 3.77e-01 |
| Signaling by FGFR | 71 | 3.45e-01 | -0.064800 | 4.77e-01 |
| Centrosome maturation | 79 | 3.23e-01 | -0.064400 | 4.60e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 79 | 3.23e-01 | -0.064400 | 4.60e-01 |
| Regulated proteolysis of p75NTR | 11 | 7.13e-01 | -0.064000 | 8.00e-01 |
| Mitotic Prometaphase | 180 | 1.43e-01 | -0.063400 | 2.56e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 57 | 4.10e-01 | -0.063100 | 5.38e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 57 | 4.10e-01 | -0.063100 | 5.38e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 57 | 4.10e-01 | -0.063100 | 5.38e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 57 | 4.10e-01 | -0.063100 | 5.38e-01 |
| Signaling by NOTCH1 in Cancer | 57 | 4.10e-01 | -0.063100 | 5.38e-01 |
| MECP2 regulates neuronal receptors and channels | 14 | 6.83e-01 | 0.063100 | 7.78e-01 |
| FGFR2 mutant receptor activation | 24 | 5.93e-01 | -0.063100 | 7.04e-01 |
| Assembly of active LPL and LIPC lipase complexes | 12 | 7.06e-01 | -0.062800 | 7.97e-01 |
| Negative regulation of FGFR1 signaling | 25 | 5.88e-01 | 0.062700 | 7.00e-01 |
| Growth hormone receptor signaling | 19 | 6.38e-01 | -0.062300 | 7.41e-01 |
| Synthesis of substrates in N-glycan biosythesis | 57 | 4.17e-01 | 0.062100 | 5.44e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 103 | 2.77e-01 | -0.062000 | 4.13e-01 |
| Downstream signaling of activated FGFR1 | 21 | 6.24e-01 | 0.061800 | 7.32e-01 |
| EGFR downregulation | 25 | 5.93e-01 | -0.061800 | 7.04e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 83 | 3.32e-01 | 0.061600 | 4.66e-01 |
| CS/DS degradation | 10 | 7.37e-01 | 0.061400 | 8.16e-01 |
| VEGFR2 mediated cell proliferation | 19 | 6.46e-01 | 0.061000 | 7.45e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 40 | 5.06e-01 | 0.060800 | 6.25e-01 |
| Signaling by ERBB2 in Cancer | 24 | 6.07e-01 | 0.060700 | 7.16e-01 |
| Lewis blood group biosynthesis | 10 | 7.40e-01 | -0.060600 | 8.18e-01 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 7.05e-01 | 0.060600 | 7.97e-01 |
| Keratan sulfate biosynthesis | 26 | 5.94e-01 | -0.060400 | 7.05e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 6.96e-01 | 0.060400 | 7.91e-01 |
| Triglyceride metabolism | 24 | 6.09e-01 | 0.060300 | 7.18e-01 |
| Neutrophil degranulation | 406 | 4.03e-02 | -0.059500 | 9.69e-02 |
| Transcriptional Regulation by MECP2 | 48 | 4.82e-01 | -0.058600 | 6.06e-01 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 14 | 7.07e-01 | 0.058000 | 7.97e-01 |
| Insulin processing | 20 | 6.55e-01 | -0.057700 | 7.53e-01 |
| PI-3K cascade:FGFR1 | 13 | 7.19e-01 | 0.057600 | 8.04e-01 |
| Signaling by ERBB2 KD Mutants | 23 | 6.34e-01 | 0.057400 | 7.38e-01 |
| Negative regulation of FGFR4 signaling | 24 | 6.27e-01 | 0.057400 | 7.33e-01 |
| Apoptotic execution phase | 43 | 5.19e-01 | 0.056900 | 6.40e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 100 | 3.27e-01 | -0.056800 | 4.62e-01 |
| Mismatch Repair | 14 | 7.13e-01 | -0.056700 | 8.00e-01 |
| TAK1-dependent IKK and NF-kappa-B activation | 43 | 5.21e-01 | -0.056500 | 6.43e-01 |
| Clathrin-mediated endocytosis | 128 | 2.76e-01 | -0.055800 | 4.12e-01 |
| Negative regulation of FGFR3 signaling | 23 | 6.44e-01 | -0.055600 | 7.44e-01 |
| ALK mutants bind TKIs | 11 | 7.50e-01 | -0.055600 | 8.24e-01 |
| Signaling by Insulin receptor | 65 | 4.40e-01 | -0.055400 | 5.62e-01 |
| Signaling by FGFR3 in disease | 16 | 7.01e-01 | -0.055400 | 7.94e-01 |
| Free fatty acids regulate insulin secretion | 10 | 7.62e-01 | -0.055300 | 8.35e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 102 | 3.36e-01 | -0.055200 | 4.68e-01 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 85 | 3.83e-01 | 0.054700 | 5.15e-01 |
| Signaling by FGFR3 | 33 | 5.87e-01 | -0.054700 | 7.00e-01 |
| Sialic acid metabolism | 27 | 6.25e-01 | 0.054400 | 7.32e-01 |
| MyD88 dependent cascade initiated on endosome | 101 | 3.45e-01 | -0.054400 | 4.77e-01 |
| Pre-NOTCH Processing in Golgi | 18 | 6.89e-01 | 0.054400 | 7.85e-01 |
| Signaling by high-kinase activity BRAF mutants | 32 | 6.00e-01 | 0.053600 | 7.11e-01 |
| Innate Immune System | 841 | 9.19e-03 | -0.053200 | 3.06e-02 |
| Activation of SMO | 16 | 7.13e-01 | -0.053200 | 8.00e-01 |
| MyD88 cascade initiated on plasma membrane | 94 | 3.73e-01 | -0.053200 | 5.06e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 94 | 3.73e-01 | -0.053200 | 5.06e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 94 | 3.73e-01 | -0.053200 | 5.06e-01 |
| Oncogene Induced Senescence | 32 | 6.04e-01 | -0.053000 | 7.14e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 6.99e-01 | 0.052700 | 7.92e-01 |
| RAC2 GTPase cycle | 84 | 4.04e-01 | -0.052700 | 5.36e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 17 | 7.07e-01 | -0.052700 | 7.97e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 5.60e-01 | 0.052700 | 6.76e-01 |
| Signaling by RAS mutants | 41 | 5.60e-01 | 0.052700 | 6.76e-01 |
| Signaling by moderate kinase activity BRAF mutants | 41 | 5.60e-01 | 0.052700 | 6.76e-01 |
| Signaling downstream of RAS mutants | 41 | 5.60e-01 | 0.052700 | 6.76e-01 |
| G beta:gamma signalling through CDC42 | 14 | 7.37e-01 | 0.051800 | 8.17e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 13 | 7.48e-01 | 0.051400 | 8.24e-01 |
| Repression of WNT target genes | 14 | 7.40e-01 | -0.051200 | 8.18e-01 |
| Interferon alpha/beta signaling | 57 | 5.05e-01 | 0.051100 | 6.25e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 12 | 7.64e-01 | -0.050100 | 8.35e-01 |
| Signaling by NTRK3 (TRKC) | 16 | 7.30e-01 | 0.049800 | 8.11e-01 |
| Diseases associated with glycosaminoglycan metabolism | 37 | 6.02e-01 | 0.049600 | 7.12e-01 |
| Signaling by ERBB2 | 47 | 5.60e-01 | -0.049200 | 6.76e-01 |
| Signaling by Hippo | 19 | 7.12e-01 | -0.048900 | 8.00e-01 |
| Negative regulation of the PI3K/AKT network | 90 | 4.24e-01 | 0.048800 | 5.50e-01 |
| MHC class II antigen presentation | 95 | 4.12e-01 | -0.048700 | 5.40e-01 |
| Intrinsic Pathway for Apoptosis | 51 | 5.48e-01 | -0.048700 | 6.66e-01 |
| Glycerophospholipid biosynthesis | 103 | 3.95e-01 | -0.048600 | 5.27e-01 |
| Maturation of spike protein 9694548 | 37 | 6.11e-01 | -0.048300 | 7.20e-01 |
| MET activates RAP1 and RAC1 | 11 | 7.82e-01 | -0.048200 | 8.50e-01 |
| FRS-mediated FGFR3 signaling | 14 | 7.55e-01 | -0.048200 | 8.28e-01 |
| FCGR activation | 13 | 7.64e-01 | 0.048200 | 8.35e-01 |
| Nucleotide biosynthesis | 12 | 7.74e-01 | 0.047900 | 8.43e-01 |
| Regulation of TLR by endogenous ligand | 15 | 7.48e-01 | -0.047900 | 8.24e-01 |
| SLC transporter disorders | 67 | 5.01e-01 | -0.047500 | 6.21e-01 |
| Diseases of metabolism | 204 | 2.43e-01 | 0.047500 | 3.74e-01 |
| Diseases associated with the TLR signaling cascade | 27 | 6.76e-01 | -0.046400 | 7.73e-01 |
| Diseases of Immune System | 27 | 6.76e-01 | -0.046400 | 7.73e-01 |
| COPI-dependent Golgi-to-ER retrograde traffic | 84 | 4.62e-01 | -0.046400 | 5.86e-01 |
| Plasma lipoprotein remodeling | 20 | 7.20e-01 | 0.046300 | 8.04e-01 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 7.64e-01 | -0.046300 | 8.35e-01 |
| Apoptotic factor-mediated response | 20 | 7.22e-01 | 0.045900 | 8.05e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 21 | 7.16e-01 | 0.045900 | 8.01e-01 |
| Developmental Biology | 795 | 2.92e-02 | -0.045800 | 7.58e-02 |
| Impaired BRCA2 binding to RAD51 | 31 | 6.65e-01 | 0.045000 | 7.63e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 25 | 6.98e-01 | 0.044800 | 7.92e-01 |
| Trafficking of AMPA receptors | 25 | 6.98e-01 | 0.044800 | 7.92e-01 |
| Regulation of beta-cell development | 21 | 7.25e-01 | -0.044400 | 8.07e-01 |
| RHOJ GTPase cycle | 52 | 5.82e-01 | -0.044100 | 6.95e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 30 | 6.77e-01 | 0.044000 | 7.73e-01 |
| Nucleosome assembly | 30 | 6.77e-01 | 0.044000 | 7.73e-01 |
| Signaling by Receptor Tyrosine Kinases | 470 | 1.04e-01 | 0.043900 | 2.04e-01 |
| RHO GTPases activate IQGAPs | 24 | 7.10e-01 | 0.043800 | 7.99e-01 |
| Formation of annular gap junctions | 11 | 8.01e-01 | 0.043800 | 8.65e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 64 | 5.45e-01 | -0.043700 | 6.65e-01 |
| Insulin receptor signalling cascade | 42 | 6.26e-01 | -0.043400 | 7.33e-01 |
| Peptide hormone metabolism | 54 | 5.85e-01 | 0.042900 | 6.99e-01 |
| IRS-related events triggered by IGF1R | 40 | 6.44e-01 | -0.042200 | 7.44e-01 |
| Cell recruitment (pro-inflammatory response) | 24 | 7.21e-01 | 0.042100 | 8.04e-01 |
| Purinergic signaling in leishmaniasis infection | 24 | 7.21e-01 | 0.042100 | 8.04e-01 |
| AURKA Activation by TPX2 | 69 | 5.47e-01 | -0.042000 | 6.66e-01 |
| Signaling by TGFB family members | 116 | 4.37e-01 | -0.041800 | 5.59e-01 |
| Signaling by ERBB4 | 51 | 6.07e-01 | 0.041600 | 7.17e-01 |
| Acyl chain remodelling of PE | 20 | 7.48e-01 | -0.041400 | 8.24e-01 |
| Metabolism of carbohydrates | 251 | 2.60e-01 | -0.041300 | 3.92e-01 |
| N-Glycan antennae elongation | 13 | 7.99e-01 | -0.040900 | 8.64e-01 |
| Immune System | 1591 | 7.29e-03 | -0.040900 | 2.56e-02 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 47 | 6.38e-01 | -0.039600 | 7.41e-01 |
| RAC3 GTPase cycle | 86 | 5.27e-01 | 0.039500 | 6.45e-01 |
| Loss of Nlp from mitotic centrosomes | 67 | 5.78e-01 | -0.039400 | 6.91e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 67 | 5.78e-01 | -0.039400 | 6.91e-01 |
| Gap junction degradation | 12 | 8.17e-01 | 0.038600 | 8.76e-01 |
| Toll-like Receptor Cascades | 156 | 4.07e-01 | -0.038600 | 5.38e-01 |
| Acyl chain remodelling of PC | 19 | 7.72e-01 | 0.038400 | 8.42e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 17 | 7.85e-01 | 0.038200 | 8.53e-01 |
| Signaling by FGFR1 | 40 | 6.76e-01 | 0.038200 | 7.73e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 42 | 6.74e-01 | -0.037600 | 7.72e-01 |
| Glycogen breakdown (glycogenolysis) | 14 | 8.08e-01 | -0.037500 | 8.69e-01 |
| Myogenesis | 26 | 7.44e-01 | -0.037100 | 8.21e-01 |
| Inositol phosphate metabolism | 42 | 6.78e-01 | 0.037000 | 7.73e-01 |
| Metabolism of nucleotides | 85 | 5.56e-01 | -0.037000 | 6.74e-01 |
| Condensation of Prophase Chromosomes | 20 | 7.77e-01 | -0.036600 | 8.45e-01 |
| RND3 GTPase cycle | 36 | 7.11e-01 | -0.035700 | 7.99e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 108 | 5.26e-01 | -0.035300 | 6.45e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 108 | 5.26e-01 | -0.035300 | 6.45e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 108 | 5.26e-01 | -0.035300 | 6.45e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 108 | 5.26e-01 | -0.035300 | 6.45e-01 |
| Recruitment of NuMA to mitotic centrosomes | 87 | 5.77e-01 | -0.034600 | 6.91e-01 |
| Activation of IRF3, IRF7 mediated by TBK1, IKBKE | 17 | 8.08e-01 | -0.034100 | 8.69e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 136 | 4.95e-01 | -0.033900 | 6.16e-01 |
| Pentose phosphate pathway | 13 | 8.32e-01 | 0.033900 | 8.90e-01 |
| Sphingolipid metabolism | 74 | 6.15e-01 | 0.033800 | 7.22e-01 |
| Anchoring of the basal body to the plasma membrane | 94 | 5.73e-01 | 0.033600 | 6.89e-01 |
| Amyloid fiber formation | 43 | 7.07e-01 | 0.033100 | 7.97e-01 |
| MyD88 deficiency (TLR2/4) | 14 | 8.34e-01 | -0.032300 | 8.91e-01 |
| RHO GTPases activate PKNs | 37 | 7.34e-01 | 0.032200 | 8.15e-01 |
| Paracetamol ADME | 19 | 8.08e-01 | -0.032200 | 8.69e-01 |
| MAP2K and MAPK activation | 36 | 7.41e-01 | 0.031900 | 8.18e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 20 | 8.07e-01 | -0.031600 | 8.69e-01 |
| Pyroptosis | 22 | 8.00e-01 | -0.031300 | 8.64e-01 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 8.40e-01 | -0.031200 | 8.96e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 7.65e-01 | -0.031000 | 8.36e-01 |
| Downstream signaling of activated FGFR3 | 19 | 8.16e-01 | -0.030800 | 8.76e-01 |
| tRNA modification in the nucleus and cytosol | 43 | 7.31e-01 | -0.030300 | 8.11e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 8.52e-01 | 0.029900 | 9.05e-01 |
| Cilium Assembly | 185 | 4.87e-01 | -0.029700 | 6.10e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 12 | 8.60e-01 | 0.029500 | 9.11e-01 |
| G-protein beta:gamma signalling | 26 | 7.95e-01 | -0.029400 | 8.61e-01 |
| HDR through Homologous Recombination (HRR) | 62 | 6.94e-01 | 0.028900 | 7.89e-01 |
| Intraflagellar transport | 49 | 7.30e-01 | -0.028500 | 8.11e-01 |
| Signal regulatory protein family interactions | 11 | 8.70e-01 | 0.028400 | 9.20e-01 |
| Nucleotide salvage | 22 | 8.21e-01 | 0.027900 | 8.79e-01 |
| Recycling pathway of L1 | 40 | 7.60e-01 | 0.027900 | 8.33e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 13 | 8.65e-01 | -0.027200 | 9.17e-01 |
| Transcriptional regulation of pluripotent stem cells | 17 | 8.49e-01 | 0.026700 | 9.02e-01 |
| Arachidonic acid metabolism | 37 | 7.79e-01 | 0.026600 | 8.48e-01 |
| Keratan sulfate/keratin metabolism | 32 | 7.96e-01 | -0.026500 | 8.61e-01 |
| Interleukin-2 family signaling | 33 | 7.94e-01 | 0.026300 | 8.61e-01 |
| Resolution of Sister Chromatid Cohesion | 104 | 6.49e-01 | -0.025900 | 7.48e-01 |
| G beta:gamma signalling through PI3Kgamma | 19 | 8.46e-01 | 0.025800 | 9.01e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 8.83e-01 | 0.025600 | 9.28e-01 |
| Nephrin family interactions | 19 | 8.47e-01 | 0.025500 | 9.01e-01 |
| Glycosphingolipid metabolism | 36 | 7.91e-01 | -0.025500 | 8.59e-01 |
| VxPx cargo-targeting to cilium | 17 | 8.56e-01 | -0.025500 | 9.08e-01 |
| Signaling by FGFR4 | 34 | 8.00e-01 | 0.025100 | 8.64e-01 |
| Signaling by NTRKs | 125 | 6.33e-01 | 0.024700 | 7.38e-01 |
| Synthesis of PA | 30 | 8.16e-01 | 0.024600 | 8.76e-01 |
| Signal Transduction | 2029 | 7.82e-02 | 0.024100 | 1.64e-01 |
| Signaling by BRAF and RAF1 fusions | 60 | 7.50e-01 | 0.023800 | 8.24e-01 |
| Signaling by NTRK1 (TRKA) | 108 | 6.74e-01 | 0.023400 | 7.72e-01 |
| RET signaling | 32 | 8.19e-01 | -0.023400 | 8.77e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 62 | 7.53e-01 | 0.023200 | 8.26e-01 |
| Regulation of RUNX1 Expression and Activity | 18 | 8.71e-01 | 0.022100 | 9.20e-01 |
| Homology Directed Repair | 98 | 7.08e-01 | -0.021900 | 7.98e-01 |
| FRS-mediated FGFR2 signaling | 16 | 8.81e-01 | 0.021600 | 9.27e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 9.00e-01 | 0.021000 | 9.41e-01 |
| Synthesis of PE | 12 | 9.00e-01 | 0.020900 | 9.41e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 92 | 7.30e-01 | -0.020800 | 8.11e-01 |
| Downstream signaling of activated FGFR2 | 21 | 8.69e-01 | 0.020800 | 9.19e-01 |
| Activation of ATR in response to replication stress | 31 | 8.43e-01 | 0.020500 | 8.98e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 11 | 9.07e-01 | -0.020400 | 9.46e-01 |
| Interferon Signaling | 164 | 6.55e-01 | 0.020200 | 7.53e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 11 | 9.12e-01 | 0.019300 | 9.50e-01 |
| IGF1R signaling cascade | 41 | 8.35e-01 | -0.018800 | 8.91e-01 |
| RHOC GTPase cycle | 69 | 7.94e-01 | 0.018100 | 8.61e-01 |
| Reduction of cytosolic Ca++ levels | 10 | 9.22e-01 | 0.017900 | 9.58e-01 |
| RHO GTPases Activate Formins | 118 | 7.39e-01 | 0.017800 | 8.18e-01 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 11 | 9.21e-01 | 0.017400 | 9.58e-01 |
| Antimicrobial peptides | 20 | 8.93e-01 | 0.017300 | 9.37e-01 |
| Regulation of CDH11 Expression and Function | 27 | 8.79e-01 | 0.016900 | 9.26e-01 |
| PI-3K cascade:FGFR2 | 14 | 9.15e-01 | -0.016400 | 9.53e-01 |
| Pregnenolone biosynthesis | 10 | 9.28e-01 | -0.016400 | 9.61e-01 |
| Trafficking and processing of endosomal TLR | 12 | 9.22e-01 | -0.016300 | 9.58e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 28 | 8.81e-01 | 0.016300 | 9.27e-01 |
| MAPK family signaling cascades | 274 | 6.46e-01 | -0.016200 | 7.45e-01 |
| Signaling by Interleukins | 375 | 5.92e-01 | -0.016100 | 7.04e-01 |
| Drug ADME | 59 | 8.33e-01 | 0.015900 | 8.90e-01 |
| Signaling by NTRK2 (TRKB) | 23 | 8.97e-01 | 0.015600 | 9.39e-01 |
| Interleukin-15 signaling | 13 | 9.25e-01 | -0.015000 | 9.60e-01 |
| MET receptor recycling | 10 | 9.35e-01 | -0.015000 | 9.63e-01 |
| RHOF GTPase cycle | 38 | 8.74e-01 | 0.014900 | 9.21e-01 |
| Signaling by SCF-KIT | 40 | 8.72e-01 | -0.014700 | 9.20e-01 |
| Pyrimidine salvage | 10 | 9.39e-01 | -0.013900 | 9.67e-01 |
| Activation of the AP-1 family of transcription factors | 10 | 9.40e-01 | 0.013800 | 9.67e-01 |
| Signaling by NODAL | 15 | 9.27e-01 | 0.013800 | 9.60e-01 |
| PI3K/AKT Signaling in Cancer | 84 | 8.30e-01 | 0.013500 | 8.89e-01 |
| Signaling by NOTCH2 | 29 | 9.03e-01 | 0.013100 | 9.43e-01 |
| G2/M DNA damage checkpoint | 56 | 8.67e-01 | -0.013000 | 9.17e-01 |
| Signaling by MET | 75 | 8.50e-01 | -0.012700 | 9.03e-01 |
| Nicotinate metabolism | 28 | 9.10e-01 | -0.012400 | 9.49e-01 |
| Transcriptional regulation of granulopoiesis | 34 | 9.01e-01 | -0.012400 | 9.41e-01 |
| Sema3A PAK dependent Axon repulsion | 16 | 9.33e-01 | -0.012100 | 9.63e-01 |
| Signaling by NOTCH3 | 44 | 8.91e-01 | -0.011900 | 9.35e-01 |
| ERK/MAPK targets | 22 | 9.23e-01 | 0.011900 | 9.59e-01 |
| Interleukin-7 signaling | 19 | 9.34e-01 | -0.011000 | 9.63e-01 |
| Blood group systems biosynthesis | 13 | 9.45e-01 | -0.011000 | 9.71e-01 |
| Negative regulation of FGFR2 signaling | 25 | 9.29e-01 | -0.010300 | 9.61e-01 |
| VEGFA-VEGFR2 Pathway | 95 | 8.71e-01 | 0.009690 | 9.20e-01 |
| Triglyceride catabolism | 16 | 9.47e-01 | -0.009600 | 9.72e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 20 | 9.44e-01 | 0.009110 | 9.70e-01 |
| Aflatoxin activation and detoxification | 11 | 9.59e-01 | 0.008980 | 9.79e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 73 | 8.95e-01 | 0.008950 | 9.38e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 12 | 9.59e-01 | 0.008540 | 9.79e-01 |
| Purine catabolism | 15 | 9.57e-01 | -0.008120 | 9.79e-01 |
| Transport of small molecules | 544 | 7.50e-01 | 0.008010 | 8.24e-01 |
| Nucleotide catabolism | 27 | 9.48e-01 | 0.007300 | 9.72e-01 |
| Cytokine Signaling in Immune system | 576 | 7.67e-01 | -0.007250 | 8.37e-01 |
| Condensation of Prometaphase Chromosomes | 11 | 9.67e-01 | -0.007210 | 9.84e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 50 | 9.31e-01 | -0.007120 | 9.61e-01 |
| Signaling by PTK6 | 50 | 9.31e-01 | -0.007120 | 9.61e-01 |
| Interleukin-6 family signaling | 19 | 9.58e-01 | -0.006970 | 9.79e-01 |
| RHO GTPase cycle | 415 | 8.12e-01 | -0.006820 | 8.73e-01 |
| IRAK4 deficiency (TLR2/4) | 15 | 9.64e-01 | 0.006810 | 9.82e-01 |
| Purine salvage | 13 | 9.68e-01 | 0.006520 | 9.84e-01 |
| Signaling by EGFR | 44 | 9.47e-01 | 0.005750 | 9.72e-01 |
| Interleukin-37 signaling | 20 | 9.66e-01 | -0.005550 | 9.84e-01 |
| Formation of apoptosome | 11 | 9.76e-01 | 0.005300 | 9.88e-01 |
| Regulation of the apoptosome activity | 11 | 9.76e-01 | 0.005300 | 9.88e-01 |
| MAPK1/MAPK3 signaling | 238 | 8.91e-01 | -0.005170 | 9.35e-01 |
| EML4 and NUDC in mitotic spindle formation | 96 | 9.31e-01 | 0.005150 | 9.61e-01 |
| Transferrin endocytosis and recycling | 26 | 9.67e-01 | -0.004620 | 9.84e-01 |
| Signaling by PDGF | 56 | 9.53e-01 | -0.004560 | 9.76e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 9.73e-01 | -0.004370 | 9.88e-01 |
| Regulation of KIT signaling | 15 | 9.78e-01 | -0.004110 | 9.90e-01 |
| Signaling by ALK | 26 | 9.71e-01 | -0.004070 | 9.87e-01 |
| IRF3-mediated induction of type I IFN | 12 | 9.81e-01 | -0.004040 | 9.90e-01 |
| Dectin-2 family | 13 | 9.81e-01 | -0.003810 | 9.90e-01 |
| Termination of O-glycan biosynthesis | 13 | 9.81e-01 | 0.003780 | 9.90e-01 |
| Activation of RAC1 | 11 | 9.83e-01 | 0.003630 | 9.90e-01 |
| RAF/MAP kinase cascade | 233 | 9.26e-01 | -0.003550 | 9.60e-01 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 10 | 9.86e-01 | 0.003280 | 9.90e-01 |
| HDR through MMEJ (alt-NHEJ) | 12 | 9.84e-01 | -0.003250 | 9.90e-01 |
| Signaling by VEGF | 104 | 9.61e-01 | 0.002800 | 9.80e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 20 | 9.85e-01 | 0.002380 | 9.90e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 9.84e-01 | 0.002290 | 9.90e-01 |
| RHO GTPase Effectors | 236 | 9.53e-01 | 0.002240 | 9.76e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 80 | 9.75e-01 | -0.002050 | 9.88e-01 |
| Amplification of signal from the kinetochores | 80 | 9.75e-01 | -0.002050 | 9.88e-01 |
| RHOQ GTPase cycle | 56 | 9.82e-01 | 0.001790 | 9.90e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 9.92e-01 | -0.001570 | 9.94e-01 |
| Biosynthesis of DHA-derived SPMs | 12 | 9.93e-01 | 0.001450 | 9.94e-01 |
| Oncogenic MAPK signaling | 76 | 9.85e-01 | -0.001230 | 9.90e-01 |
| p75 NTR receptor-mediated signalling | 91 | 9.88e-01 | -0.000931 | 9.91e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 11 | 9.96e-01 | 0.000898 | 9.96e-01 |
| Signalling to ERKs | 33 | 9.94e-01 | -0.000723 | 9.95e-01 |
| Signaling by Rho GTPases | 589 | 9.81e-01 | 0.000579 | 9.90e-01 |
| Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 603 | 9.93e-01 | 0.000220 | 9.94e-01 |
Cohesin Loading onto Chromatin
| 206 | |
|---|---|
| set | Cohesin Loading onto Chromatin |
| setSize | 10 |
| pANOVA | 1.15e-05 |
| s.dist | -0.801 |
| p.adjustANOVA | 0.000107 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAG2 | -9107 |
| SMC1A | -8937 |
| NIPBL | -8930 |
| RAD21 | -8569 |
| WAPL | -8298 |
| SMC3 | -8069 |
| PDS5A | -7642 |
| STAG1 | -5786 |
| PDS5B | -5495 |
| MAU2 | -5163 |
| GeneID | Gene Rank |
|---|---|
| STAG2 | -9107 |
| SMC1A | -8937 |
| NIPBL | -8930 |
| RAD21 | -8569 |
| WAPL | -8298 |
| SMC3 | -8069 |
| PDS5A | -7642 |
| STAG1 | -5786 |
| PDS5B | -5495 |
| MAU2 | -5163 |
Formation of the ternary complex, and subsequently, the 43S complex
| 424 | |
|---|---|
| set | Formation of the ternary complex, and subsequently, the 43S complex |
| setSize | 51 |
| pANOVA | 7.71e-22 |
| s.dist | -0.777 |
| p.adjustANOVA | 2.82e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| EIF3F | -8392 |
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| EIF3F | -8392 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPS20 | -7922 |
| EIF3G | -7905 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPS12 | -7764 |
| RPS9 | -7651 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPS27L | -3238 |
| EIF3L | -1209 |
| RPS26 | 577 |
Formation of a pool of free 40S subunits
| 416 | |
|---|---|
| set | Formation of a pool of free 40S subunits |
| setSize | 100 |
| pANOVA | 1.03e-37 |
| s.dist | -0.742 |
| p.adjustANOVA | 2.16e-35 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| EIF3C | -8561 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| EIF3F | -8392 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| EIF3G | -7905 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| EIF3L | -1209 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
SARS-CoV-1 modulates host translation machinery
| 1093 | |
|---|---|
| set | SARS-CoV-1 modulates host translation machinery |
| setSize | 36 |
| pANOVA | 2.55e-14 |
| s.dist | -0.733 |
| p.adjustANOVA | 6.92e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| RPS11 | -8273 |
| RPS20 | -7922 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPS12 | -7764 |
| RPS9 | -7651 |
| RPS4Y1 | -7535 |
| GeneID | Gene Rank |
|---|---|
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| RPS11 | -8273 |
| RPS20 | -7922 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPS12 | -7764 |
| RPS9 | -7651 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| HNRNPA1 | -4642 |
| RPS27L | -3238 |
| RPS26 | 577 |
| EEF1A1 | 2882 |
Ribosomal scanning and start codon recognition
| 1086 | |
|---|---|
| set | Ribosomal scanning and start codon recognition |
| setSize | 58 |
| pANOVA | 8.19e-22 |
| s.dist | -0.728 |
| p.adjustANOVA | 2.92e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| EIF3F | -8392 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPS20 | -7922 |
| EIF3G | -7905 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPS12 | -7764 |
| RPS9 | -7651 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| EIF4A2 | -7132 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| EIF5 | -6083 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| EIF4H | -4542 |
| EIF4E | -4481 |
| RPS27L | -3238 |
| EIF4G1 | -1413 |
| EIF3L | -1209 |
| RPS26 | 577 |
| EIF4A1 | 4037 |
Viral mRNA Translation
| 1416 | |
|---|---|
| set | Viral mRNA Translation |
| setSize | 88 |
| pANOVA | 5.17e-32 |
| s.dist | -0.725 |
| p.adjustANOVA | 4.45e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| GRSF1 | -3549 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| DNAJC3 | -2943 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
Peptide chain elongation
| 848 | |
|---|---|
| set | Peptide chain elongation |
| setSize | 88 |
| pANOVA | 1.09e-31 |
| s.dist | -0.721 |
| p.adjustANOVA | 8e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| EEF2 | -6569 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| EEF1A1 | 2882 |
| RPL3 | 3020 |
GTP hydrolysis and joining of the 60S ribosomal subunit
| 461 | |
|---|---|
| set | GTP hydrolysis and joining of the 60S ribosomal subunit |
| setSize | 111 |
| pANOVA | 2.3e-39 |
| s.dist | -0.72 |
| p.adjustANOVA | 1.12e-36 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| EIF3C | -8561 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| EIF3F | -8392 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| EIF3G | -7905 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| EIF5B | -7134 |
| EIF4A2 | -7132 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| EIF5 | -6083 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| EIF4H | -4542 |
| EIF4E | -4481 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| EIF4G1 | -1413 |
| EIF3L | -1209 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| EIF4A1 | 4037 |
Translation initiation complex formation
| 1369 | |
|---|---|
| set | Translation initiation complex formation |
| setSize | 58 |
| pANOVA | 3.7e-21 |
| s.dist | -0.716 |
| p.adjustANOVA | 1.26e-19 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| EIF3F | -8392 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPS20 | -7922 |
| EIF3G | -7905 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPS12 | -7764 |
| RPS9 | -7651 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| EIF4A2 | -7132 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| EIF4H | -4542 |
| EIF4E | -4481 |
| RPS27L | -3238 |
| EIF4G1 | -1413 |
| EIF3L | -1209 |
| PABPC1 | -423 |
| RPS26 | 577 |
| EIF4A1 | 4037 |
Selenocysteine synthesis
| 1138 | |
|---|---|
| set | Selenocysteine synthesis |
| setSize | 92 |
| pANOVA | 2.02e-32 |
| s.dist | -0.714 |
| p.adjustANOVA | 1.97e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| SEPHS2 | -7380 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| SECISBP2 | -7297 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| SARS1 | -3598 |
| EEFSEC | -3449 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| PSTK | -2403 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| SEPSECS | -1617 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
L13a-mediated translational silencing of Ceruloplasmin expression
| 621 | |
|---|---|
| set | L13a-mediated translational silencing of Ceruloplasmin expression |
| setSize | 110 |
| pANOVA | 2.41e-38 |
| s.dist | -0.713 |
| p.adjustANOVA | 5.89e-36 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| EIF3C | -8561 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| EIF3F | -8392 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| EIF3G | -7905 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| EIF4A2 | -7132 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| EIF4H | -4542 |
| EIF4E | -4481 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| EIF4G1 | -1413 |
| EIF3L | -1209 |
| PABPC1 | -423 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| EIF4A1 | 4037 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
| 52 | |
|---|---|
| set | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
| setSize | 59 |
| pANOVA | 3.17e-21 |
| s.dist | -0.711 |
| p.adjustANOVA | 1.1e-19 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| GeneID | Gene Rank |
|---|---|
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| EIF3C | -8561 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| EIF3F | -8392 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPS20 | -7922 |
| EIF3G | -7905 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPS12 | -7764 |
| RPS9 | -7651 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| EIF4A2 | -7132 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| EIF4H | -4542 |
| EIF4EBP1 | -4509 |
| EIF4E | -4481 |
| RPS27L | -3238 |
| EIF4G1 | -1413 |
| EIF3L | -1209 |
| PABPC1 | -423 |
| RPS26 | 577 |
| EIF4A1 | 4037 |
Eukaryotic Translation Termination
| 373 | |
|---|---|
| set | Eukaryotic Translation Termination |
| setSize | 92 |
| pANOVA | 4.28e-32 |
| s.dist | -0.71 |
| p.adjustANOVA | 3.92e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| GSPT1 | -5112 |
| RPS3 | -4984 |
| APEH | -4956 |
| RPS18 | -4906 |
| TRMT112 | -4666 |
| RPL23A | -4282 |
| ETF1 | -3370 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| N6AMT1 | -2920 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| GSPT2 | -1860 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
Eukaryotic Translation Elongation
| 371 | |
|---|---|
| set | Eukaryotic Translation Elongation |
| setSize | 93 |
| pANOVA | 8.51e-32 |
| s.dist | -0.703 |
| p.adjustANOVA | 6.56e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EEF1D | -8834 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EEF1D | -8834 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| EEF1B2 | -8057 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| EEF2 | -6569 |
| EEF1G | -6397 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| EEF1A2 | -1314 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| EEF1A1 | 2882 |
| RPL3 | 3020 |
| EEF1A1P5 | 4167 |
Establishment of Sister Chromatid Cohesion
| 368 | |
|---|---|
| set | Establishment of Sister Chromatid Cohesion |
| setSize | 10 |
| pANOVA | 0.000123 |
| s.dist | -0.701 |
| p.adjustANOVA | 0.000841 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAG2 | -9107 |
| SMC1A | -8937 |
| RAD21 | -8569 |
| WAPL | -8298 |
| SMC3 | -8069 |
| PDS5A | -7642 |
| STAG1 | -5786 |
| PDS5B | -5495 |
| ESCO2 | -3037 |
| ESCO1 | -2808 |
| GeneID | Gene Rank |
|---|---|
| STAG2 | -9107 |
| SMC1A | -8937 |
| RAD21 | -8569 |
| WAPL | -8298 |
| SMC3 | -8069 |
| PDS5A | -7642 |
| STAG1 | -5786 |
| PDS5B | -5495 |
| ESCO2 | -3037 |
| ESCO1 | -2808 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
| 780 | |
|---|---|
| set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
| setSize | 94 |
| pANOVA | 2.21e-31 |
| s.dist | -0.695 |
| p.adjustANOVA | 1.54e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| UPF1 | -9170 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| UPF1 | -9170 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| NCBP1 | -5334 |
| GSPT1 | -5112 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| ETF1 | -3370 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| GSPT2 | -1860 |
| EIF4G1 | -1413 |
| PABPC1 | -423 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| NCBP2 | 2415 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
Cap-dependent Translation Initiation
| 154 | |
|---|---|
| set | Cap-dependent Translation Initiation |
| setSize | 118 |
| pANOVA | 2.18e-38 |
| s.dist | -0.689 |
| p.adjustANOVA | 5.89e-36 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| EIF3C | -8561 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| EIF3F | -8392 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| EIF3G | -7905 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| EIF5B | -7134 |
| EIF4A2 | -7132 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| EIF2B5 | -6139 |
| EIF5 | -6083 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| EIF2B3 | -5301 |
| EIF2B4 | -5281 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| EIF4H | -4542 |
| EIF4EBP1 | -4509 |
| EIF4E | -4481 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| EIF4G1 | -1413 |
| EIF3L | -1209 |
| PABPC1 | -423 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| EIF2B2 | 1401 |
| EIF2B1 | 1899 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| EIF4A1 | 4037 |
Eukaryotic Translation Initiation
| 372 | |
|---|---|
| set | Eukaryotic Translation Initiation |
| setSize | 118 |
| pANOVA | 2.18e-38 |
| s.dist | -0.689 |
| p.adjustANOVA | 5.89e-36 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| EIF4B | -8662 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| EIF3C | -8561 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| EIF3F | -8392 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| EIF3D | -8215 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| EIF3G | -7905 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| EIF5B | -7134 |
| EIF4A2 | -7132 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| EIF3B | -6339 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| EIF2B5 | -6139 |
| EIF5 | -6083 |
| EIF2S2 | -5971 |
| EIF3K | -5872 |
| EIF3J | -5790 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| EIF2B3 | -5301 |
| EIF2B4 | -5281 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| EIF4H | -4542 |
| EIF4EBP1 | -4509 |
| EIF4E | -4481 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| EIF4G1 | -1413 |
| EIF3L | -1209 |
| PABPC1 | -423 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| EIF2B2 | 1401 |
| EIF2B1 | 1899 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| EIF4A1 | 4037 |
PINK1-PRKN Mediated Mitophagy
| 828 | |
|---|---|
| set | PINK1-PRKN Mediated Mitophagy |
| setSize | 21 |
| pANOVA | 7.32e-08 |
| s.dist | -0.678 |
| p.adjustANOVA | 1.12e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATG12 | -9158 |
| TOMM6 | -8911 |
| MAP1LC3A | -8317 |
| TOMM7 | -8063 |
| UBA52 | -8015 |
| TOMM5 | -7985 |
| MFN1 | -7734 |
| TOMM22 | -7514 |
| ATG5 | -7494 |
| TOMM40 | -7344 |
| RPS27A | -7158 |
| TOMM20 | -7042 |
| TOMM70 | -6875 |
| SQSTM1 | -6468 |
| UBB | -5814 |
| UBC | -4857 |
| PINK1 | -4645 |
| MTERF3 | -4593 |
| MFN2 | -4404 |
| VDAC1 | -3459 |
| GeneID | Gene Rank |
|---|---|
| ATG12 | -9158 |
| TOMM6 | -8911 |
| MAP1LC3A | -8317 |
| TOMM7 | -8063 |
| UBA52 | -8015 |
| TOMM5 | -7985 |
| MFN1 | -7734 |
| TOMM22 | -7514 |
| ATG5 | -7494 |
| TOMM40 | -7344 |
| RPS27A | -7158 |
| TOMM20 | -7042 |
| TOMM70 | -6875 |
| SQSTM1 | -6468 |
| UBB | -5814 |
| UBC | -4857 |
| PINK1 | -4645 |
| MTERF3 | -4593 |
| MFN2 | -4404 |
| VDAC1 | -3459 |
| MAP1LC3B | -2392 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
| 1079 | |
|---|---|
| set | Response of EIF2AK4 (GCN2) to amino acid deficiency |
| setSize | 100 |
| pANOVA | 5.41e-31 |
| s.dist | -0.669 |
| p.adjustANOVA | 3.44e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| DDIT3 | -8037 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| EIF2AK4 | -7745 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| ATF4 | -6991 |
| ATF2 | -6807 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| EIF2S2 | -5971 |
| GCN1 | -5884 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| CEBPB | -1995 |
| CEBPG | -856 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| IMPACT | 2367 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| TRIB3 | 3220 |
| ATF3 | 5044 |
| ASNS | 6691 |
Expression and translocation of olfactory receptors
| 375 | |
|---|---|
| set | Expression and translocation of olfactory receptors |
| setSize | 25 |
| pANOVA | 1.03e-08 |
| s.dist | 0.661 |
| p.adjustANOVA | 1.81e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| OR10G3 | 7119 |
| OR1D2 | 6907 |
| OR52K1 | 6891 |
| OR4D9 | 6523 |
| OR5AN1 | 6519 |
| OR6Y1 | 6248 |
| OR2AT4 | 6247 |
| OR6C75 | 6168 |
| OR5A2 | 6089 |
| OR2M3 | 5964 |
| OR51E1 | 5679 |
| OR7C1 | 5354 |
| OR56A1 | 5226 |
| OR14J1 | 5107 |
| OR5AU1 | 4763 |
| OR5AS1 | 4493 |
| OR5A1 | 4272 |
| REEP1 | 4206 |
| EBF1 | 4030 |
| OR8A1 | 3804 |
| GeneID | Gene Rank |
|---|---|
| OR10G3 | 7119 |
| OR1D2 | 6907 |
| OR52K1 | 6891 |
| OR4D9 | 6523 |
| OR5AN1 | 6519 |
| OR6Y1 | 6248 |
| OR2AT4 | 6247 |
| OR6C75 | 6168 |
| OR5A2 | 6089 |
| OR2M3 | 5964 |
| OR51E1 | 5679 |
| OR7C1 | 5354 |
| OR56A1 | 5226 |
| OR14J1 | 5107 |
| OR5AU1 | 4763 |
| OR5AS1 | 4493 |
| OR5A1 | 4272 |
| REEP1 | 4206 |
| EBF1 | 4030 |
| OR8A1 | 3804 |
| OR2V2 | 3667 |
| OR1I1 | 3257 |
| LDB1 | -1450 |
| OR7D2 | -1737 |
| OR10H5 | -3722 |
SARS-CoV-2 modulates host translation machinery
| 1099 | |
|---|---|
| set | SARS-CoV-2 modulates host translation machinery |
| setSize | 49 |
| pANOVA | 3.3e-15 |
| s.dist | -0.65 |
| p.adjustANOVA | 9.1e-14 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SMN1 | -9207 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| SNRPG | -8415 |
| RPS11 | -8273 |
| SNRPF | -8202 |
| SNRPB | -8171 |
| RPS20 | -7922 |
| RPS25 | -7825 |
| GeneID | Gene Rank |
|---|---|
| SMN1 | -9207 |
| RPSA | -9069 |
| RPS27 | -9023 |
| RPS21 | -8956 |
| RPS29 | -8889 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPS10 | -8476 |
| SNRPG | -8415 |
| RPS11 | -8273 |
| SNRPF | -8202 |
| SNRPB | -8171 |
| RPS20 | -7922 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| GEMIN5 | -7765 |
| RPS12 | -7764 |
| RPS9 | -7651 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| SNRPD3 | -5542 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| SNRPD2 | -4517 |
| GEMIN7 | -3951 |
| RPS27L | -3238 |
| GEMIN4 | -2768 |
| GEMIN6 | -2759 |
| SNRPE | -2750 |
| SNRPD1 | -2680 |
| RPS26 | 577 |
| GEMIN2 | 750 |
| DDX20 | 3136 |
| GEMIN8 | 3434 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
| 779 | |
|---|---|
| set | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
| setSize | 114 |
| pANOVA | 1.22e-32 |
| s.dist | -0.644 |
| p.adjustANOVA | 1.28e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| UPF1 | -9170 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| MAGOH | -8779 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| UPF1 | -9170 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| MAGOH | -8779 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| SMG7 | -8611 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| UPF3B | -8403 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| SMG1 | -8267 |
| UPF2 | -8225 |
| PNRC2 | -8209 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| CASC3 | -7613 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| PPP2CA | -6239 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| DCP1A | -6158 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| NCBP1 | -5334 |
| GSPT1 | -5112 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| SMG5 | -4419 |
| RPL23A | -4282 |
| RBM8A | -3948 |
| SMG6 | -3927 |
| ETF1 | -3370 |
| RNPS1 | -3368 |
| RPS27L | -3238 |
| UPF3A | -3033 |
| RPL12 | -3022 |
| PPP2R2A | -2700 |
| EIF4A3 | -2560 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| GSPT2 | -1860 |
| PPP2R1A | -1738 |
| EIF4G1 | -1413 |
| PABPC1 | -423 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| SMG9 | 848 |
| NCBP2 | 2415 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| SMG8 | 4077 |
| MAGOHB | 5294 |
Nonsense-Mediated Decay (NMD)
| 781 | |
|---|---|
| set | Nonsense-Mediated Decay (NMD) |
| setSize | 114 |
| pANOVA | 1.22e-32 |
| s.dist | -0.644 |
| p.adjustANOVA | 1.28e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| UPF1 | -9170 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| MAGOH | -8779 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| UPF1 | -9170 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| MAGOH | -8779 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| SMG7 | -8611 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| UPF3B | -8403 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| SMG1 | -8267 |
| UPF2 | -8225 |
| PNRC2 | -8209 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| CASC3 | -7613 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| PPP2CA | -6239 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| DCP1A | -6158 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| NCBP1 | -5334 |
| GSPT1 | -5112 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| SMG5 | -4419 |
| RPL23A | -4282 |
| RBM8A | -3948 |
| SMG6 | -3927 |
| ETF1 | -3370 |
| RNPS1 | -3368 |
| RPS27L | -3238 |
| UPF3A | -3033 |
| RPL12 | -3022 |
| PPP2R2A | -2700 |
| EIF4A3 | -2560 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| GSPT2 | -1860 |
| PPP2R1A | -1738 |
| EIF4G1 | -1413 |
| PABPC1 | -423 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| SMG9 | 848 |
| NCBP2 | 2415 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| SMG8 | 4077 |
| MAGOHB | 5294 |
Selenoamino acid metabolism
| 1137 | |
|---|---|
| set | Selenoamino acid metabolism |
| setSize | 114 |
| pANOVA | 8.23e-32 |
| s.dist | -0.636 |
| p.adjustANOVA | 6.56e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| AIMP1 | -9145 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| DARS1 | -8824 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| AIMP1 | -9145 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| DARS1 | -8824 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| LARS1 | -8512 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| RARS1 | -8023 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| EPRS1 | -7904 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| SEPHS2 | -7380 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| SECISBP2 | -7297 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| MARS1 | -7121 |
| RPS13 | -7092 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| CTH | -6517 |
| NNMT | -6386 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| IARS1 | -5019 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| AIMP2 | -4881 |
| RPL23A | -4282 |
| QARS1 | -3846 |
| SARS1 | -3598 |
| EEFSEC | -3449 |
| KARS1 | -3401 |
| AHCY | -3361 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| PSTK | -2403 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| GSR | -1959 |
| PAPSS2 | -1734 |
| SCLY | -1647 |
| SEPSECS | -1617 |
| HNMT | -1539 |
| TXNRD1 | -331 |
| RPLP0 | -196 |
| RPL39L | -143 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| RPL26L1 | 2574 |
| INMT | 2667 |
| RPL3 | 3020 |
| EEF1E1 | 3162 |
| PAPSS1 | 3657 |
| CBS | 4235 |
SRP-dependent cotranslational protein targeting to membrane
| 1118 | |
|---|---|
| set | SRP-dependent cotranslational protein targeting to membrane |
| setSize | 111 |
| pANOVA | 2.59e-30 |
| s.dist | -0.628 |
| p.adjustANOVA | 1.58e-28 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| SRP14 | -8598 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| SSR3 | -8474 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| SRPRA | -7569 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| SEC11A | -7378 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| SRP68 | -7027 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| SRP9 | -6031 |
| SEC61A2 | -5807 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| SEC61G | -5225 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| SPCS3 | -4843 |
| SSR2 | -4317 |
| DDOST | -4291 |
| RPL23A | -4282 |
| SRP72 | -3622 |
| SPCS2 | -3566 |
| RPS27L | -3238 |
| SEC61B | -3133 |
| RPL12 | -3022 |
| RPN1 | -2564 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| SEC11C | -1673 |
| SRPRB | -1181 |
| SEC61A1 | -1010 |
| TRAM1 | -864 |
| RPN2 | -646 |
| SSR1 | -282 |
| RPLP0 | -196 |
| RPL39L | -143 |
| SRP54 | -5 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| SPCS1 | 2080 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| SSR4 | 3336 |
| SRP19 | 5993 |
Mitophagy
| 708 | |
|---|---|
| set | Mitophagy |
| setSize | 28 |
| pANOVA | 1.5e-08 |
| s.dist | -0.618 |
| p.adjustANOVA | 2.53e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATG12 | -9158 |
| TOMM6 | -8911 |
| CSNK2A2 | -8671 |
| MAP1LC3A | -8317 |
| TOMM7 | -8063 |
| UBA52 | -8015 |
| TOMM5 | -7985 |
| ULK1 | -7767 |
| MFN1 | -7734 |
| TOMM22 | -7514 |
| ATG5 | -7494 |
| TOMM40 | -7344 |
| RPS27A | -7158 |
| CSNK2B | -7151 |
| TOMM20 | -7042 |
| TOMM70 | -6875 |
| CSNK2A1 | -6826 |
| SQSTM1 | -6468 |
| UBB | -5814 |
| UBC | -4857 |
| GeneID | Gene Rank |
|---|---|
| ATG12 | -9158 |
| TOMM6 | -8911 |
| CSNK2A2 | -8671 |
| MAP1LC3A | -8317 |
| TOMM7 | -8063 |
| UBA52 | -8015 |
| TOMM5 | -7985 |
| ULK1 | -7767 |
| MFN1 | -7734 |
| TOMM22 | -7514 |
| ATG5 | -7494 |
| TOMM40 | -7344 |
| RPS27A | -7158 |
| CSNK2B | -7151 |
| TOMM20 | -7042 |
| TOMM70 | -6875 |
| CSNK2A1 | -6826 |
| SQSTM1 | -6468 |
| UBB | -5814 |
| UBC | -4857 |
| FUNDC1 | -4734 |
| PINK1 | -4645 |
| MTERF3 | -4593 |
| MFN2 | -4404 |
| VDAC1 | -3459 |
| MAP1LC3B | -2392 |
| PGAM5 | 514 |
| SRC | 2567 |
Common Pathway of Fibrin Clot Formation
| 211 | |
|---|---|
| set | Common Pathway of Fibrin Clot Formation |
| setSize | 11 |
| pANOVA | 0.000486 |
| s.dist | 0.607 |
| p.adjustANOVA | 0.00266 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F13A1 | 6621 |
| SERPINE2 | 6504 |
| PF4 | 6150 |
| F2R | 5807 |
| F5 | 5478 |
| F10 | 5355 |
| THBD | 4047 |
| PROS1 | 3322 |
| PROCR | 3157 |
| SERPINA5 | 2655 |
| F8 | -4842 |
| GeneID | Gene Rank |
|---|---|
| F13A1 | 6621 |
| SERPINE2 | 6504 |
| PF4 | 6150 |
| F2R | 5807 |
| F5 | 5478 |
| F10 | 5355 |
| THBD | 4047 |
| PROS1 | 3322 |
| PROCR | 3157 |
| SERPINA5 | 2655 |
| F8 | -4842 |
Formation of ATP by chemiosmotic coupling
| 407 | |
|---|---|
| set | Formation of ATP by chemiosmotic coupling |
| setSize | 16 |
| pANOVA | 3.99e-05 |
| s.dist | -0.593 |
| p.adjustANOVA | 0.000301 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP5F1E | -8877 |
| ATP5ME | -8728 |
| ATP5MG | -8231 |
| ATP5MF | -7330 |
| ATP5PD | -7238 |
| ATP5PB | -6099 |
| ATP5PO | -5955 |
| ATP5MC3 | -5706 |
| ATP5MC1 | -5616 |
| ATP5PF | -5598 |
| ATP5F1D | -5435 |
| ATP5MC2 | -4894 |
| ATP5F1A | -4610 |
| ATP5F1B | -3894 |
| ATP5F1C | -3741 |
| DMAC2L | -2145 |
| GeneID | Gene Rank |
|---|---|
| ATP5F1E | -8877 |
| ATP5ME | -8728 |
| ATP5MG | -8231 |
| ATP5MF | -7330 |
| ATP5PD | -7238 |
| ATP5PB | -6099 |
| ATP5PO | -5955 |
| ATP5MC3 | -5706 |
| ATP5MC1 | -5616 |
| ATP5PF | -5598 |
| ATP5F1D | -5435 |
| ATP5MC2 | -4894 |
| ATP5F1A | -4610 |
| ATP5F1B | -3894 |
| ATP5F1C | -3741 |
| DMAC2L | -2145 |
Regulation of FOXO transcriptional activity by acetylation
| 1018 | |
|---|---|
| set | Regulation of FOXO transcriptional activity by acetylation |
| setSize | 10 |
| pANOVA | 0.00117 |
| s.dist | -0.593 |
| p.adjustANOVA | 0.00558 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EP300 | -9148 |
| SIRT1 | -9093 |
| FOXO3 | -8776 |
| KAT2B | -7840 |
| FOXO1 | -7526 |
| CREBBP | -5698 |
| TXNIP | -4759 |
| SIRT3 | -4550 |
| FOXO4 | -4161 |
| TXN | 2767 |
| GeneID | Gene Rank |
|---|---|
| EP300 | -9148 |
| SIRT1 | -9093 |
| FOXO3 | -8776 |
| KAT2B | -7840 |
| FOXO1 | -7526 |
| CREBBP | -5698 |
| TXNIP | -4759 |
| SIRT3 | -4550 |
| FOXO4 | -4161 |
| TXN | 2767 |
Olfactory Signaling Pathway
| 803 | |
|---|---|
| set | Olfactory Signaling Pathway |
| setSize | 29 |
| pANOVA | 3.34e-08 |
| s.dist | 0.592 |
| p.adjustANOVA | 5.26e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| OR10G3 | 7119 |
| ADCY3 | 6928 |
| OR1D2 | 6907 |
| OR52K1 | 6891 |
| OR4D9 | 6523 |
| OR5AN1 | 6519 |
| OR6Y1 | 6248 |
| OR2AT4 | 6247 |
| OR6C75 | 6168 |
| OR5A2 | 6089 |
| OR2M3 | 5964 |
| OR51E1 | 5679 |
| OR7C1 | 5354 |
| OR56A1 | 5226 |
| OR14J1 | 5107 |
| OR5AU1 | 4763 |
| OR5AS1 | 4493 |
| OR5A1 | 4272 |
| REEP1 | 4206 |
| EBF1 | 4030 |
| GeneID | Gene Rank |
|---|---|
| OR10G3 | 7119 |
| ADCY3 | 6928 |
| OR1D2 | 6907 |
| OR52K1 | 6891 |
| OR4D9 | 6523 |
| OR5AN1 | 6519 |
| OR6Y1 | 6248 |
| OR2AT4 | 6247 |
| OR6C75 | 6168 |
| OR5A2 | 6089 |
| OR2M3 | 5964 |
| OR51E1 | 5679 |
| OR7C1 | 5354 |
| OR56A1 | 5226 |
| OR14J1 | 5107 |
| OR5AU1 | 4763 |
| OR5AS1 | 4493 |
| OR5A1 | 4272 |
| REEP1 | 4206 |
| EBF1 | 4030 |
| OR8A1 | 3804 |
| OR2V2 | 3667 |
| OR1I1 | 3257 |
| GNB1 | 1364 |
| LDB1 | -1450 |
| OR7D2 | -1737 |
| ANO2 | -3154 |
| OR10H5 | -3722 |
| GNAL | -3836 |
Influenza Viral RNA Transcription and Replication
| 559 | |
|---|---|
| set | Influenza Viral RNA Transcription and Replication |
| setSize | 135 |
| pANOVA | 4.32e-30 |
| s.dist | -0.568 |
| p.adjustANOVA | 2.53e-28 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| HSP90AA1 | -8943 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| HSP90AA1 | -8943 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RANBP2 | -8628 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| GTF2F1 | -8540 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| POLR2F | -8470 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| POLR2L | -8103 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| NUP98 | -7680 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| GTF2F2 | -7325 |
| RPL10A | -7319 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| NUP54 | -7060 |
| NUP58 | -6798 |
| NUP160 | -6761 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| SEC13 | -6317 |
| NUP37 | -6292 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| NUP133 | -5771 |
| NUP153 | -5691 |
| NUP50 | -5632 |
| RPL36A | -5540 |
| NUP210 | -5396 |
| POLR2I | -5309 |
| POLR2B | -5288 |
| IPO5 | -5262 |
| NUP188 | -5218 |
| NUP42 | -5201 |
| PARP1 | -5170 |
| NUP205 | -5042 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| POLR2A | -4758 |
| RPL23A | -4282 |
| NUP93 | -4260 |
| RAE1 | -3893 |
| POLR2C | -3742 |
| GRSF1 | -3549 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| NUP62 | -2956 |
| DNAJC3 | -2943 |
| POLR2J | -2719 |
| TPR | -2493 |
| RPL14 | -2377 |
| POM121C | -2353 |
| RPL3L | -2329 |
| POM121 | -863 |
| NUP155 | -830 |
| POLR2K | -326 |
| POLR2E | -285 |
| NUP107 | -257 |
| NUP35 | -211 |
| RPLP0 | -196 |
| RPL39L | -143 |
| POLR2G | 121 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| NUP88 | 790 |
| NUP214 | 985 |
| SEH1L | 1613 |
| RPL26L1 | 2574 |
| AAAS | 2639 |
| POLR2D | 2746 |
| RPL3 | 3020 |
| NUP43 | 4730 |
| POLR2H | 5035 |
| NUP85 | 5357 |
| NDC1 | 6027 |
Cellular response to starvation
| 181 | |
|---|---|
| set | Cellular response to starvation |
| setSize | 148 |
| pANOVA | 2.33e-31 |
| s.dist | -0.554 |
| p.adjustANOVA | 1.55e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| RPSA | -9069 |
| RRAGB | -9059 |
| KPTN | -9057 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| LAMTOR1 | -8803 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| EIF2S3 | -9153 |
| RPSA | -9069 |
| RRAGB | -9059 |
| KPTN | -9057 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| LAMTOR1 | -8803 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| RRAGA | -8372 |
| RPL35A | -8364 |
| FNIP1 | -8332 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| DDIT3 | -8037 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| EIF2AK4 | -7745 |
| RPL23 | -7726 |
| WDR24 | -7682 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| BMT2 | -7650 |
| ATP6V0E1 | -7592 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| LAMTOR3 | -7300 |
| ATP6V1G1 | -7278 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| EIF2S1 | -7203 |
| LAMTOR4 | -7197 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| SESN1 | -7144 |
| RPS13 | -7092 |
| ATF4 | -6991 |
| ATF2 | -6807 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| ATP6V0C | -6499 |
| MIOS | -6437 |
| SEC13 | -6317 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| EIF2S2 | -5971 |
| GCN1 | -5884 |
| MTOR | -5874 |
| RPL27A | -5778 |
| LAMTOR5 | -5664 |
| MLST8 | -5640 |
| RHEB | -5629 |
| RPL36A | -5540 |
| ITFG2 | -5516 |
| ATP6V1C1 | -5445 |
| LAMTOR2 | -5357 |
| ATP6V1B2 | -5157 |
| ATP6V0E2 | -5021 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| RPL23A | -4282 |
| NPRL3 | -4016 |
| FLCN | -3406 |
| ATP6V0D1 | -3311 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| NPRL2 | -2954 |
| RRAGD | -2891 |
| ATP6V1E2 | -2563 |
| ATP6V1D | -2542 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| CEBPB | -1995 |
| RRAGC | -1559 |
| ATP6V0B | -1434 |
| WDR59 | -1293 |
| CEBPG | -856 |
| ATP6V1H | -643 |
| ATP6V1A | -601 |
| ATP6V1E1 | -442 |
| RPLP0 | -196 |
| RPL39L | -143 |
| SESN2 | -19 |
| ATP6V1F | 568 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| FNIP2 | 717 |
| SLC38A9 | 727 |
| SEH1L | 1613 |
| SH3BP4 | 2277 |
| IMPACT | 2367 |
| DEPDC5 | 2471 |
| RPTOR | 2481 |
| ATP6V1C2 | 2495 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| SZT2 | 3073 |
| TRIB3 | 3220 |
| ATF3 | 5044 |
| TCIRG1 | 5752 |
| ASNS | 6691 |
Translation
| 1368 | |
|---|---|
| set | Translation |
| setSize | 292 |
| pANOVA | 1.17e-59 |
| s.dist | -0.553 |
| p.adjustANOVA | 8.54e-57 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| MRPL54 | -9175 |
| EIF2S3 | -9153 |
| AIMP1 | -9145 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| MRPL48 | -8950 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| MRPL22 | -8839 |
| RPL19 | -8835 |
| EEF1D | -8834 |
| DARS1 | -8824 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| MRPL54 | -9175 |
| EIF2S3 | -9153 |
| AIMP1 | -9145 |
| EIF3E | -9125 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| MRPL48 | -8950 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| EIF3A | -8865 |
| RPL5 | -8844 |
| MRPL22 | -8839 |
| RPL19 | -8835 |
| EEF1D | -8834 |
| DARS1 | -8824 |
| EIF3I | -8804 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| EIF3H | -8715 |
| MRPS30 | -8683 |
| EIF4B | -8662 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| YARS2 | -8617 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| SRP14 | -8598 |
| RPL38 | -8575 |
| EIF3C | -8561 |
| RPL30 | -8551 |
| PPA2 | -8547 |
| RPS15 | -8544 |
| MRPS5 | -8542 |
| RPS6 | -8538 |
| LARS1 | -8512 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| SSR3 | -8474 |
| MRPL34 | -8468 |
| RPL36 | -8458 |
| MRPS2 | -8420 |
| EIF3F | -8392 |
| RPL35A | -8364 |
| PPA1 | -8339 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| MRPL13 | -8240 |
| EIF3D | -8215 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| CARS2 | -8147 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| RPL11 | -8081 |
| IARS2 | -8066 |
| MRPS36 | -8062 |
| EEF1B2 | -8057 |
| HARS2 | -8046 |
| RPL24 | -8040 |
| RARS1 | -8023 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| EIF3G | -7905 |
| EPRS1 | -7904 |
| MTRF1L | -7895 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| MRPL28 | -7802 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| CHCHD1 | -7733 |
| RPL23 | -7726 |
| WARS2 | -7683 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| SRPRA | -7569 |
| TUFM | -7564 |
| MRPS34 | -7562 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| EIF3M | -7495 |
| EIF1AX | -7473 |
| NARS1 | -7454 |
| RPS8 | -7427 |
| SEC11A | -7378 |
| MRPL19 | -7376 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| RPL10A | -7319 |
| MRPL27 | -7283 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| EIF2S1 | -7203 |
| RPS28 | -7167 |
| MRPL12 | -7164 |
| RPS27A | -7158 |
| GARS1 | -7155 |
| RPS2 | -7146 |
| EIF5B | -7134 |
| EIF4A2 | -7132 |
| MARS1 | -7121 |
| RPS13 | -7092 |
| MRPS27 | -7037 |
| GADD45GIP1 | -7031 |
| SRP68 | -7027 |
| MRPL16 | -6987 |
| MRPL18 | -6934 |
| MRPL58 | -6870 |
| MRPL4 | -6846 |
| MRPL52 | -6792 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| MRPL57 | -6665 |
| MRPL46 | -6656 |
| AARS1 | -6599 |
| RPS14 | -6574 |
| EEF2 | -6569 |
| MRPS21 | -6507 |
| MRPL42 | -6451 |
| MRPL1 | -6405 |
| EEF1G | -6397 |
| TARS1 | -6379 |
| EIF3B | -6339 |
| MRPS25 | -6310 |
| MRPL11 | -6283 |
| DARS2 | -6210 |
| MRPS14 | -6190 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| MRPS15 | -6153 |
| EIF2B5 | -6139 |
| DAP3 | -6131 |
| MRRF | -6096 |
| EIF5 | -6083 |
| SRP9 | -6031 |
| EIF2S2 | -5971 |
| MRPS9 | -5883 |
| EIF3K | -5872 |
| MRPL41 | -5867 |
| SEC61A2 | -5807 |
| EIF3J | -5790 |
| RPL27A | -5778 |
| MRPL21 | -5747 |
| MRPL24 | -5724 |
| MTIF3 | -5720 |
| MRPL45 | -5609 |
| MTIF2 | -5550 |
| PTCD3 | -5547 |
| RPL36A | -5540 |
| MRPS16 | -5488 |
| MRPL33 | -5487 |
| MRPL38 | -5462 |
| MRPL37 | -5453 |
| MRPL15 | -5432 |
| MRPL44 | -5420 |
| EIF2B3 | -5301 |
| MRPS26 | -5293 |
| EIF2B4 | -5281 |
| SEC61G | -5225 |
| GSPT1 | -5112 |
| RARS2 | -5110 |
| MRPS18B | -5089 |
| GFM1 | -5050 |
| IARS1 | -5019 |
| FARSA | -5005 |
| RPS3 | -4984 |
| MTFMT | -4965 |
| APEH | -4956 |
| RPS18 | -4906 |
| AIMP2 | -4881 |
| MRPL17 | -4871 |
| SPCS3 | -4843 |
| MRPL2 | -4827 |
| LARS2 | -4826 |
| MRPL39 | -4731 |
| OXA1L | -4723 |
| TRMT112 | -4666 |
| MRPS22 | -4603 |
| MRPS11 | -4578 |
| EIF4H | -4542 |
| EIF4EBP1 | -4509 |
| EIF4E | -4481 |
| YARS1 | -4345 |
| MRPL53 | -4339 |
| MRPS18A | -4326 |
| SSR2 | -4317 |
| DDOST | -4291 |
| RPL23A | -4282 |
| MRPS35 | -4276 |
| AURKAIP1 | -4245 |
| MARS2 | -4181 |
| TARS2 | -4097 |
| MRPL35 | -4049 |
| MRPS33 | -4027 |
| MRPL20 | -3969 |
| MRPS10 | -3918 |
| GFM2 | -3914 |
| QARS1 | -3846 |
| MRPL55 | -3816 |
| TSFM | -3735 |
| MRPS12 | -3716 |
| SRP72 | -3622 |
| SARS1 | -3598 |
| SPCS2 | -3566 |
| KARS1 | -3401 |
| ETF1 | -3370 |
| RPS27L | -3238 |
| CARS1 | -3231 |
| MRPS7 | -3161 |
| MRPS24 | -3150 |
| SEC61B | -3133 |
| MRPL49 | -3106 |
| MRPL10 | -3084 |
| RPL12 | -3022 |
| N6AMT1 | -2920 |
| MRPL36 | -2733 |
| SARS2 | -2692 |
| FARSB | -2570 |
| RPN1 | -2564 |
| MRPS23 | -2539 |
| ERAL1 | -2519 |
| MRPS28 | -2436 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| MRPL40 | -2188 |
| MRPL43 | -2122 |
| MRPL50 | -2063 |
| NARS2 | -1917 |
| GSPT2 | -1860 |
| SEC11C | -1673 |
| EIF4G1 | -1413 |
| MRPL14 | -1341 |
| EEF1A2 | -1314 |
| EIF3L | -1209 |
| SRPRB | -1181 |
| MRPS18C | -1155 |
| FARS2 | -1137 |
| SEC61A1 | -1010 |
| TRAM1 | -864 |
| RPN2 | -646 |
| EARS2 | -568 |
| MRPL23 | -454 |
| PABPC1 | -423 |
| SSR1 | -282 |
| RPLP0 | -196 |
| RPL39L | -143 |
| WARS1 | -105 |
| SRP54 | -5 |
| AARS2 | -2 |
| MRPL3 | 494 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| PARS2 | 655 |
| VARS1 | 831 |
| EIF2B2 | 1401 |
| MRPS31 | 1430 |
| EIF2B1 | 1899 |
| SPCS1 | 2080 |
| HARS1 | 2405 |
| RPL26L1 | 2574 |
| EEF1A1 | 2882 |
| RPL3 | 3020 |
| EEF1E1 | 3162 |
| SSR4 | 3336 |
| EIF4A1 | 4037 |
| EEF1A1P5 | 4167 |
| MRPS6 | 4951 |
| VARS2 | 5425 |
| SRP19 | 5993 |
Cristae formation
| 230 | |
|---|---|
| set | Cristae formation |
| setSize | 29 |
| pANOVA | 4.03e-07 |
| s.dist | -0.544 |
| p.adjustANOVA | 5.61e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP5F1E | -8877 |
| ATP5ME | -8728 |
| ATP5MG | -8231 |
| ATP5MF | -7330 |
| ATP5PD | -7238 |
| DNAJC11 | -7230 |
| HSPA9 | -6518 |
| MICOS10 | -6516 |
| MICOS13 | -6415 |
| APOOL | -6358 |
| ATP5PB | -6099 |
| SAMM50 | -6028 |
| ATP5PO | -5955 |
| ATP5MC3 | -5706 |
| ATP5MC1 | -5616 |
| ATP5PF | -5598 |
| ATP5F1D | -5435 |
| MTX1 | -5425 |
| CHCHD6 | -5326 |
| ATP5MC2 | -4894 |
| GeneID | Gene Rank |
|---|---|
| ATP5F1E | -8877 |
| ATP5ME | -8728 |
| ATP5MG | -8231 |
| ATP5MF | -7330 |
| ATP5PD | -7238 |
| DNAJC11 | -7230 |
| HSPA9 | -6518 |
| MICOS10 | -6516 |
| MICOS13 | -6415 |
| APOOL | -6358 |
| ATP5PB | -6099 |
| SAMM50 | -6028 |
| ATP5PO | -5955 |
| ATP5MC3 | -5706 |
| ATP5MC1 | -5616 |
| ATP5PF | -5598 |
| ATP5F1D | -5435 |
| MTX1 | -5425 |
| CHCHD6 | -5326 |
| ATP5MC2 | -4894 |
| CHCHD3 | -4867 |
| ATP5F1A | -4610 |
| ATP5F1B | -3894 |
| MTX2 | -3782 |
| ATP5F1C | -3741 |
| APOO | -3321 |
| IMMT | -2166 |
| DMAC2L | -2145 |
| TMEM11 | -562 |
Complex I biogenesis
| 214 | |
|---|---|
| set | Complex I biogenesis |
| setSize | 51 |
| pANOVA | 2.08e-11 |
| s.dist | -0.542 |
| p.adjustANOVA | 4.68e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NDUFA3 | -8846 |
| NDUFA13 | -8067 |
| NDUFB1 | -8003 |
| NDUFS5 | -7980 |
| ACAD9 | -7909 |
| NDUFA1 | -7698 |
| NDUFA5 | -7269 |
| NDUFB6 | -7222 |
| ECSIT | -7191 |
| NDUFAF3 | -7123 |
| NDUFB7 | -7112 |
| NDUFS6 | -7098 |
| NDUFAF7 | -7081 |
| NDUFB3 | -7055 |
| NDUFA2 | -6890 |
| NUBPL | -6772 |
| NDUFAF2 | -6732 |
| NDUFB11 | -6297 |
| NDUFS4 | -6030 |
| TMEM126B | -6018 |
| GeneID | Gene Rank |
|---|---|
| NDUFA3 | -8846 |
| NDUFA13 | -8067 |
| NDUFB1 | -8003 |
| NDUFS5 | -7980 |
| ACAD9 | -7909 |
| NDUFA1 | -7698 |
| NDUFA5 | -7269 |
| NDUFB6 | -7222 |
| ECSIT | -7191 |
| NDUFAF3 | -7123 |
| NDUFB7 | -7112 |
| NDUFS6 | -7098 |
| NDUFAF7 | -7081 |
| NDUFB3 | -7055 |
| NDUFA2 | -6890 |
| NUBPL | -6772 |
| NDUFAF2 | -6732 |
| NDUFB11 | -6297 |
| NDUFS4 | -6030 |
| TMEM126B | -6018 |
| NDUFV1 | -5939 |
| NDUFAF4 | -5911 |
| NDUFB4 | -5862 |
| NDUFAB1 | -5813 |
| NDUFA9 | -5531 |
| NDUFS8 | -5514 |
| NDUFB2 | -5440 |
| NDUFB8 | -5236 |
| NDUFS3 | -5200 |
| NDUFA6 | -5145 |
| TIMMDC1 | -5100 |
| NDUFA8 | -5082 |
| NDUFA12 | -5058 |
| NDUFC2 | -5013 |
| NDUFB5 | -4794 |
| NDUFA11 | -4742 |
| NDUFS7 | -4717 |
| NDUFA10 | -4614 |
| NDUFB10 | -4599 |
| NDUFV2 | -4583 |
| NDUFV3 | -4416 |
| NDUFAF5 | -3963 |
| NDUFC1 | -3785 |
| TMEM186 | -3467 |
| COA1 | -3444 |
| NDUFS1 | -3379 |
| NDUFS2 | -3012 |
| NDUFB9 | -2423 |
| NDUFAF6 | -1592 |
| NDUFA7 | -1474 |
| NDUFAF1 | 1210 |
Respiratory electron transport
| 1076 | |
|---|---|
| set | Respiratory electron transport |
| setSize | 93 |
| pANOVA | 3.66e-19 |
| s.dist | -0.537 |
| p.adjustANOVA | 1.22e-17 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| COX7A2L | -8906 |
| NDUFA3 | -8846 |
| ETFDH | -8196 |
| NDUFA13 | -8067 |
| UQCRB | -8044 |
| NDUFB1 | -8003 |
| NDUFS5 | -7980 |
| ACAD9 | -7909 |
| NDUFA1 | -7698 |
| COX19 | -7513 |
| NDUFA5 | -7269 |
| NDUFB6 | -7222 |
| UQCRH | -7220 |
| ECSIT | -7191 |
| SDHD | -7137 |
| NDUFAF3 | -7123 |
| NDUFB7 | -7112 |
| NDUFS6 | -7098 |
| NDUFAF7 | -7081 |
| NDUFB3 | -7055 |
| GeneID | Gene Rank |
|---|---|
| COX7A2L | -8906 |
| NDUFA3 | -8846 |
| ETFDH | -8196 |
| NDUFA13 | -8067 |
| UQCRB | -8044 |
| NDUFB1 | -8003 |
| NDUFS5 | -7980 |
| ACAD9 | -7909 |
| NDUFA1 | -7698 |
| COX19 | -7513 |
| NDUFA5 | -7269 |
| NDUFB6 | -7222 |
| UQCRH | -7220 |
| ECSIT | -7191 |
| SDHD | -7137 |
| NDUFAF3 | -7123 |
| NDUFB7 | -7112 |
| NDUFS6 | -7098 |
| NDUFAF7 | -7081 |
| NDUFB3 | -7055 |
| COX16 | -7034 |
| NDUFA2 | -6890 |
| COX4I1 | -6885 |
| SCO1 | -6863 |
| COX11 | -6850 |
| NUBPL | -6772 |
| COX7C | -6734 |
| NDUFAF2 | -6732 |
| COX6B1 | -6548 |
| SURF1 | -6412 |
| SDHC | -6395 |
| CYCS | -6361 |
| UQCR11 | -6321 |
| NDUFB11 | -6297 |
| LRPPRC | -6094 |
| COX18 | -6055 |
| NDUFS4 | -6030 |
| TMEM126B | -6018 |
| TACO1 | -6011 |
| NDUFV1 | -5939 |
| ETFB | -5922 |
| NDUFAF4 | -5911 |
| NDUFB4 | -5862 |
| UQCR10 | -5858 |
| NDUFAB1 | -5813 |
| SDHB | -5717 |
| COX5A | -5712 |
| COX5B | -5661 |
| NDUFA9 | -5531 |
| NDUFS8 | -5514 |
| COX7B | -5472 |
| NDUFB2 | -5440 |
| UQCRQ | -5274 |
| NDUFB8 | -5236 |
| UQCRFS1 | -5204 |
| NDUFS3 | -5200 |
| NDUFA6 | -5145 |
| CYC1 | -5107 |
| TIMMDC1 | -5100 |
| NDUFA8 | -5082 |
| NDUFA12 | -5058 |
| UQCRC2 | -5018 |
| NDUFC2 | -5013 |
| SDHA | -4816 |
| NDUFB5 | -4794 |
| NDUFA11 | -4742 |
| NDUFS7 | -4717 |
| NDUFA10 | -4614 |
| NDUFB10 | -4599 |
| NDUFV2 | -4583 |
| COX8A | -4434 |
| NDUFV3 | -4416 |
| COX6C | -4251 |
| ETFA | -4099 |
| NDUFA4 | -4050 |
| NDUFAF5 | -3963 |
| NDUFC1 | -3785 |
| TRAP1 | -3690 |
| UQCRC1 | -3562 |
| COX14 | -3557 |
| TMEM186 | -3467 |
| COA1 | -3444 |
| NDUFS1 | -3379 |
| NDUFS2 | -3012 |
| COQ10A | -2975 |
| SCO2 | -2688 |
| NDUFB9 | -2423 |
| NDUFAF6 | -1592 |
| NDUFA7 | -1474 |
| COX6A1 | -390 |
| COQ10B | 303 |
| COX20 | 1152 |
| NDUFAF1 | 1210 |
Receptor Mediated Mitophagy
| 997 | |
|---|---|
| set | Receptor Mediated Mitophagy |
| setSize | 11 |
| pANOVA | 0.00212 |
| s.dist | -0.535 |
| p.adjustANOVA | 0.00888 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATG12 | -9158 |
| CSNK2A2 | -8671 |
| MAP1LC3A | -8317 |
| ULK1 | -7767 |
| ATG5 | -7494 |
| CSNK2B | -7151 |
| CSNK2A1 | -6826 |
| FUNDC1 | -4734 |
| MAP1LC3B | -2392 |
| PGAM5 | 514 |
| SRC | 2567 |
| GeneID | Gene Rank |
|---|---|
| ATG12 | -9158 |
| CSNK2A2 | -8671 |
| MAP1LC3A | -8317 |
| ULK1 | -7767 |
| ATG5 | -7494 |
| CSNK2B | -7151 |
| CSNK2A1 | -6826 |
| FUNDC1 | -4734 |
| MAP1LC3B | -2392 |
| PGAM5 | 514 |
| SRC | 2567 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
| 1077 | |
|---|---|
| set | Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. |
| setSize | 113 |
| pANOVA | 1.39e-22 |
| s.dist | -0.532 |
| p.adjustANOVA | 5.37e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| COX7A2L | -8906 |
| ATP5F1E | -8877 |
| NDUFA3 | -8846 |
| ATP5ME | -8728 |
| ATP5MG | -8231 |
| ETFDH | -8196 |
| NDUFA13 | -8067 |
| UQCRB | -8044 |
| NDUFB1 | -8003 |
| NDUFS5 | -7980 |
| ACAD9 | -7909 |
| NDUFA1 | -7698 |
| COX19 | -7513 |
| ATP5MF | -7330 |
| NDUFA5 | -7269 |
| ATP5PD | -7238 |
| NDUFB6 | -7222 |
| UQCRH | -7220 |
| ECSIT | -7191 |
| SDHD | -7137 |
| GeneID | Gene Rank |
|---|---|
| COX7A2L | -8906 |
| ATP5F1E | -8877 |
| NDUFA3 | -8846 |
| ATP5ME | -8728 |
| ATP5MG | -8231 |
| ETFDH | -8196 |
| NDUFA13 | -8067 |
| UQCRB | -8044 |
| NDUFB1 | -8003 |
| NDUFS5 | -7980 |
| ACAD9 | -7909 |
| NDUFA1 | -7698 |
| COX19 | -7513 |
| ATP5MF | -7330 |
| NDUFA5 | -7269 |
| ATP5PD | -7238 |
| NDUFB6 | -7222 |
| UQCRH | -7220 |
| ECSIT | -7191 |
| SDHD | -7137 |
| NDUFAF3 | -7123 |
| NDUFB7 | -7112 |
| NDUFS6 | -7098 |
| NDUFAF7 | -7081 |
| NDUFB3 | -7055 |
| COX16 | -7034 |
| NDUFA2 | -6890 |
| COX4I1 | -6885 |
| SCO1 | -6863 |
| COX11 | -6850 |
| NUBPL | -6772 |
| COX7C | -6734 |
| NDUFAF2 | -6732 |
| SLC25A27 | -6590 |
| COX6B1 | -6548 |
| SURF1 | -6412 |
| SDHC | -6395 |
| CYCS | -6361 |
| UQCR11 | -6321 |
| NDUFB11 | -6297 |
| ATP5PB | -6099 |
| LRPPRC | -6094 |
| COX18 | -6055 |
| NDUFS4 | -6030 |
| TMEM126B | -6018 |
| TACO1 | -6011 |
| ATP5PO | -5955 |
| NDUFV1 | -5939 |
| ETFB | -5922 |
| NDUFAF4 | -5911 |
| NDUFB4 | -5862 |
| UQCR10 | -5858 |
| NDUFAB1 | -5813 |
| SDHB | -5717 |
| COX5A | -5712 |
| ATP5MC3 | -5706 |
| COX5B | -5661 |
| ATP5MC1 | -5616 |
| ATP5PF | -5598 |
| NDUFA9 | -5531 |
| NDUFS8 | -5514 |
| COX7B | -5472 |
| NDUFB2 | -5440 |
| ATP5F1D | -5435 |
| UQCRQ | -5274 |
| NDUFB8 | -5236 |
| UQCRFS1 | -5204 |
| NDUFS3 | -5200 |
| NDUFA6 | -5145 |
| CYC1 | -5107 |
| TIMMDC1 | -5100 |
| NDUFA8 | -5082 |
| NDUFA12 | -5058 |
| UQCRC2 | -5018 |
| NDUFC2 | -5013 |
| ATP5MC2 | -4894 |
| SDHA | -4816 |
| NDUFB5 | -4794 |
| NDUFA11 | -4742 |
| NDUFS7 | -4717 |
| NDUFA10 | -4614 |
| ATP5F1A | -4610 |
| NDUFB10 | -4599 |
| NDUFV2 | -4583 |
| COX8A | -4434 |
| NDUFV3 | -4416 |
| COX6C | -4251 |
| ETFA | -4099 |
| NDUFA4 | -4050 |
| NDUFAF5 | -3963 |
| ATP5F1B | -3894 |
| NDUFC1 | -3785 |
| ATP5F1C | -3741 |
| TRAP1 | -3690 |
| UQCRC1 | -3562 |
| COX14 | -3557 |
| TMEM186 | -3467 |
| COA1 | -3444 |
| NDUFS1 | -3379 |
| SLC25A14 | -3176 |
| NDUFS2 | -3012 |
| COQ10A | -2975 |
| SCO2 | -2688 |
| NDUFB9 | -2423 |
| DMAC2L | -2145 |
| NDUFAF6 | -1592 |
| NDUFA7 | -1474 |
| UCP2 | -701 |
| COX6A1 | -390 |
| COQ10B | 303 |
| COX20 | 1152 |
| NDUFAF1 | 1210 |
| UCP3 | 1325 |
Mitochondrial translation
| 704 | |
|---|---|
| set | Mitochondrial translation |
| setSize | 94 |
| pANOVA | 5.59e-19 |
| s.dist | -0.531 |
| p.adjustANOVA | 1.82e-17 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MTRF1L | -7895 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| TUFM | -7564 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MTRF1L | -7895 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| TUFM | -7564 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| MRPL27 | -7283 |
| MRPL12 | -7164 |
| MRPS27 | -7037 |
| GADD45GIP1 | -7031 |
| MRPL16 | -6987 |
| MRPL18 | -6934 |
| MRPL58 | -6870 |
| MRPL4 | -6846 |
| MRPL52 | -6792 |
| MRPL57 | -6665 |
| MRPL46 | -6656 |
| MRPS21 | -6507 |
| MRPL42 | -6451 |
| MRPL1 | -6405 |
| MRPS25 | -6310 |
| MRPL11 | -6283 |
| MRPS14 | -6190 |
| MRPS15 | -6153 |
| DAP3 | -6131 |
| MRRF | -6096 |
| MRPS9 | -5883 |
| MRPL41 | -5867 |
| MRPL21 | -5747 |
| MRPL24 | -5724 |
| MTIF3 | -5720 |
| MRPL45 | -5609 |
| MTIF2 | -5550 |
| PTCD3 | -5547 |
| MRPS16 | -5488 |
| MRPL33 | -5487 |
| MRPL38 | -5462 |
| MRPL37 | -5453 |
| MRPL15 | -5432 |
| MRPL44 | -5420 |
| MRPS26 | -5293 |
| MRPS18B | -5089 |
| GFM1 | -5050 |
| MTFMT | -4965 |
| MRPL17 | -4871 |
| MRPL2 | -4827 |
| MRPL39 | -4731 |
| OXA1L | -4723 |
| MRPS22 | -4603 |
| MRPS11 | -4578 |
| MRPL53 | -4339 |
| MRPS18A | -4326 |
| MRPS35 | -4276 |
| AURKAIP1 | -4245 |
| MRPL35 | -4049 |
| MRPS33 | -4027 |
| MRPL20 | -3969 |
| MRPS10 | -3918 |
| GFM2 | -3914 |
| MRPL55 | -3816 |
| TSFM | -3735 |
| MRPS12 | -3716 |
| MRPS7 | -3161 |
| MRPS24 | -3150 |
| MRPL49 | -3106 |
| MRPL10 | -3084 |
| MRPL36 | -2733 |
| MRPS23 | -2539 |
| ERAL1 | -2519 |
| MRPS28 | -2436 |
| MRPL40 | -2188 |
| MRPL43 | -2122 |
| MRPL50 | -2063 |
| MRPL14 | -1341 |
| MRPS18C | -1155 |
| MRPL23 | -454 |
| MRPL3 | 494 |
| MRPS31 | 1430 |
| MRPS6 | 4951 |
Mitochondrial translation termination
| 707 | |
|---|---|
| set | Mitochondrial translation termination |
| setSize | 88 |
| pANOVA | 8.14e-18 |
| s.dist | -0.53 |
| p.adjustANOVA | 2.53e-16 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MTRF1L | -7895 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MTRF1L | -7895 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| MRPL27 | -7283 |
| MRPL12 | -7164 |
| MRPS27 | -7037 |
| GADD45GIP1 | -7031 |
| MRPL16 | -6987 |
| MRPL18 | -6934 |
| MRPL58 | -6870 |
| MRPL4 | -6846 |
| MRPL52 | -6792 |
| MRPL57 | -6665 |
| MRPL46 | -6656 |
| MRPS21 | -6507 |
| MRPL42 | -6451 |
| MRPL1 | -6405 |
| MRPS25 | -6310 |
| MRPL11 | -6283 |
| MRPS14 | -6190 |
| MRPS15 | -6153 |
| DAP3 | -6131 |
| MRRF | -6096 |
| MRPS9 | -5883 |
| MRPL41 | -5867 |
| MRPL21 | -5747 |
| MRPL24 | -5724 |
| MRPL45 | -5609 |
| PTCD3 | -5547 |
| MRPS16 | -5488 |
| MRPL33 | -5487 |
| MRPL38 | -5462 |
| MRPL37 | -5453 |
| MRPL15 | -5432 |
| MRPL44 | -5420 |
| MRPS26 | -5293 |
| MRPS18B | -5089 |
| MRPL17 | -4871 |
| MRPL2 | -4827 |
| MRPL39 | -4731 |
| OXA1L | -4723 |
| MRPS22 | -4603 |
| MRPS11 | -4578 |
| MRPL53 | -4339 |
| MRPS18A | -4326 |
| MRPS35 | -4276 |
| AURKAIP1 | -4245 |
| MRPL35 | -4049 |
| MRPS33 | -4027 |
| MRPL20 | -3969 |
| MRPS10 | -3918 |
| GFM2 | -3914 |
| MRPL55 | -3816 |
| MRPS12 | -3716 |
| MRPS7 | -3161 |
| MRPS24 | -3150 |
| MRPL49 | -3106 |
| MRPL10 | -3084 |
| MRPL36 | -2733 |
| MRPS23 | -2539 |
| ERAL1 | -2519 |
| MRPS28 | -2436 |
| MRPL40 | -2188 |
| MRPL43 | -2122 |
| MRPL50 | -2063 |
| MRPL14 | -1341 |
| MRPS18C | -1155 |
| MRPL23 | -454 |
| MRPL3 | 494 |
| MRPS31 | 1430 |
| MRPS6 | 4951 |
Mitochondrial translation elongation
| 705 | |
|---|---|
| set | Mitochondrial translation elongation |
| setSize | 88 |
| pANOVA | 1.1e-17 |
| s.dist | -0.528 |
| p.adjustANOVA | 3.36e-16 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| TUFM | -7564 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| TUFM | -7564 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| MRPL27 | -7283 |
| MRPL12 | -7164 |
| MRPS27 | -7037 |
| GADD45GIP1 | -7031 |
| MRPL16 | -6987 |
| MRPL18 | -6934 |
| MRPL58 | -6870 |
| MRPL4 | -6846 |
| MRPL52 | -6792 |
| MRPL57 | -6665 |
| MRPL46 | -6656 |
| MRPS21 | -6507 |
| MRPL42 | -6451 |
| MRPL1 | -6405 |
| MRPS25 | -6310 |
| MRPL11 | -6283 |
| MRPS14 | -6190 |
| MRPS15 | -6153 |
| DAP3 | -6131 |
| MRPS9 | -5883 |
| MRPL41 | -5867 |
| MRPL21 | -5747 |
| MRPL24 | -5724 |
| MRPL45 | -5609 |
| PTCD3 | -5547 |
| MRPS16 | -5488 |
| MRPL33 | -5487 |
| MRPL38 | -5462 |
| MRPL37 | -5453 |
| MRPL15 | -5432 |
| MRPL44 | -5420 |
| MRPS26 | -5293 |
| MRPS18B | -5089 |
| GFM1 | -5050 |
| MRPL17 | -4871 |
| MRPL2 | -4827 |
| MRPL39 | -4731 |
| OXA1L | -4723 |
| MRPS22 | -4603 |
| MRPS11 | -4578 |
| MRPL53 | -4339 |
| MRPS18A | -4326 |
| MRPS35 | -4276 |
| AURKAIP1 | -4245 |
| MRPL35 | -4049 |
| MRPS33 | -4027 |
| MRPL20 | -3969 |
| MRPS10 | -3918 |
| MRPL55 | -3816 |
| TSFM | -3735 |
| MRPS12 | -3716 |
| MRPS7 | -3161 |
| MRPS24 | -3150 |
| MRPL49 | -3106 |
| MRPL10 | -3084 |
| MRPL36 | -2733 |
| MRPS23 | -2539 |
| ERAL1 | -2519 |
| MRPS28 | -2436 |
| MRPL40 | -2188 |
| MRPL43 | -2122 |
| MRPL50 | -2063 |
| MRPL14 | -1341 |
| MRPS18C | -1155 |
| MRPL23 | -454 |
| MRPL3 | 494 |
| MRPS31 | 1430 |
| MRPS6 | 4951 |
Mitochondrial translation initiation
| 706 | |
|---|---|
| set | Mitochondrial translation initiation |
| setSize | 88 |
| pANOVA | 1.13e-17 |
| s.dist | -0.528 |
| p.adjustANOVA | 3.37e-16 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| MRPL27 | -7283 |
| GeneID | Gene Rank |
|---|---|
| MRPL54 | -9175 |
| MRPL48 | -8950 |
| MRPL22 | -8839 |
| MRPS30 | -8683 |
| MRPS5 | -8542 |
| MRPL34 | -8468 |
| MRPS2 | -8420 |
| MRPL13 | -8240 |
| MRPL9 | -8107 |
| MRPS17 | -8104 |
| MRPS36 | -8062 |
| MRPL28 | -7802 |
| CHCHD1 | -7733 |
| MRPS34 | -7562 |
| MRPL30 | -7505 |
| MRPL51 | -7503 |
| MRPL19 | -7376 |
| MRPL32 | -7346 |
| MRPL47 | -7343 |
| MRPL27 | -7283 |
| MRPL12 | -7164 |
| MRPS27 | -7037 |
| GADD45GIP1 | -7031 |
| MRPL16 | -6987 |
| MRPL18 | -6934 |
| MRPL58 | -6870 |
| MRPL4 | -6846 |
| MRPL52 | -6792 |
| MRPL57 | -6665 |
| MRPL46 | -6656 |
| MRPS21 | -6507 |
| MRPL42 | -6451 |
| MRPL1 | -6405 |
| MRPS25 | -6310 |
| MRPL11 | -6283 |
| MRPS14 | -6190 |
| MRPS15 | -6153 |
| DAP3 | -6131 |
| MRPS9 | -5883 |
| MRPL41 | -5867 |
| MRPL21 | -5747 |
| MRPL24 | -5724 |
| MTIF3 | -5720 |
| MRPL45 | -5609 |
| MTIF2 | -5550 |
| PTCD3 | -5547 |
| MRPS16 | -5488 |
| MRPL33 | -5487 |
| MRPL38 | -5462 |
| MRPL37 | -5453 |
| MRPL15 | -5432 |
| MRPL44 | -5420 |
| MRPS26 | -5293 |
| MRPS18B | -5089 |
| MTFMT | -4965 |
| MRPL17 | -4871 |
| MRPL2 | -4827 |
| MRPL39 | -4731 |
| OXA1L | -4723 |
| MRPS22 | -4603 |
| MRPS11 | -4578 |
| MRPL53 | -4339 |
| MRPS18A | -4326 |
| MRPS35 | -4276 |
| AURKAIP1 | -4245 |
| MRPL35 | -4049 |
| MRPS33 | -4027 |
| MRPL20 | -3969 |
| MRPS10 | -3918 |
| MRPL55 | -3816 |
| MRPS12 | -3716 |
| MRPS7 | -3161 |
| MRPS24 | -3150 |
| MRPL49 | -3106 |
| MRPL10 | -3084 |
| MRPL36 | -2733 |
| MRPS23 | -2539 |
| ERAL1 | -2519 |
| MRPS28 | -2436 |
| MRPL40 | -2188 |
| MRPL43 | -2122 |
| MRPL50 | -2063 |
| MRPL14 | -1341 |
| MRPS18C | -1155 |
| MRPL23 | -454 |
| MRPL3 | 494 |
| MRPS31 | 1430 |
| MRPS6 | 4951 |
Influenza Infection
| 558 | |
|---|---|
| set | Influenza Infection |
| setSize | 154 |
| pANOVA | 3.36e-29 |
| s.dist | -0.523 |
| p.adjustANOVA | 1.76e-27 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| HSP90AA1 | -8943 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| HSP90AA1 | -8943 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RANBP2 | -8628 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| GTF2F1 | -8540 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| POLR2F | -8470 |
| RPL36 | -8458 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| KPNB1 | -8234 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| POLR2L | -8103 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| NUP98 | -7680 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| SLC25A6 | -7550 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| GTF2F2 | -7325 |
| RPL10A | -7319 |
| XPO1 | -7296 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| RPS13 | -7092 |
| NUP54 | -7060 |
| NUP58 | -6798 |
| NUP160 | -6761 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| HSPA1A | -6509 |
| SEC13 | -6317 |
| NUP37 | -6292 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| RPL27A | -5778 |
| NUP133 | -5771 |
| NUP153 | -5691 |
| NUP50 | -5632 |
| RPL36A | -5540 |
| NUP210 | -5396 |
| POLR2I | -5309 |
| POLR2B | -5288 |
| IPO5 | -5262 |
| ISG15 | -5246 |
| NUP188 | -5218 |
| NUP42 | -5201 |
| PARP1 | -5170 |
| NUP205 | -5042 |
| RPS3 | -4984 |
| RPS18 | -4906 |
| POLR2A | -4758 |
| CLTA | -4620 |
| RPL23A | -4282 |
| NUP93 | -4260 |
| CALR | -3922 |
| RAE1 | -3893 |
| RAN | -3759 |
| POLR2C | -3742 |
| GRSF1 | -3549 |
| RPS27L | -3238 |
| RPL12 | -3022 |
| CLTC | -3017 |
| NUP62 | -2956 |
| DNAJC3 | -2943 |
| POLR2J | -2719 |
| TPR | -2493 |
| KPNA5 | -2443 |
| RPL14 | -2377 |
| POM121C | -2353 |
| RPL3L | -2329 |
| CANX | -2175 |
| KPNA1 | -1902 |
| KPNA3 | -1784 |
| EIF2AK2 | -1265 |
| KPNA4 | -1222 |
| POM121 | -863 |
| NUP155 | -830 |
| POLR2K | -326 |
| POLR2E | -285 |
| NUP107 | -257 |
| NUP35 | -211 |
| RPLP0 | -196 |
| RPL39L | -143 |
| POLR2G | 121 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| NUP88 | 790 |
| NUP214 | 985 |
| TGFB1 | 1202 |
| SEH1L | 1613 |
| KPNA2 | 1909 |
| RPL26L1 | 2574 |
| AAAS | 2639 |
| POLR2D | 2746 |
| RPL3 | 3020 |
| PABPN1 | 3039 |
| CPSF4 | 4237 |
| NUP43 | 4730 |
| POLR2H | 5035 |
| NUP85 | 5357 |
| NDC1 | 6027 |
Formation of Fibrin Clot (Clotting Cascade)
| 408 | |
|---|---|
| set | Formation of Fibrin Clot (Clotting Cascade) |
| setSize | 20 |
| pANOVA | 5.36e-05 |
| s.dist | 0.522 |
| p.adjustANOVA | 0.000394 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TFPI | 7103 |
| F13A1 | 6621 |
| SERPINE2 | 6504 |
| A2M | 6271 |
| PF4 | 6150 |
| F2R | 5807 |
| F5 | 5478 |
| F3 | 5461 |
| F10 | 5355 |
| PRCP | 5033 |
| GP1BB | 4968 |
| THBD | 4047 |
| PROS1 | 3322 |
| VWF | 3201 |
| PROCR | 3157 |
| SERPINA5 | 2655 |
| SERPING1 | 1779 |
| F8 | -4842 |
| KLKB1 | -5366 |
| C1QBP | -6427 |
| GeneID | Gene Rank |
|---|---|
| TFPI | 7103 |
| F13A1 | 6621 |
| SERPINE2 | 6504 |
| A2M | 6271 |
| PF4 | 6150 |
| F2R | 5807 |
| F5 | 5478 |
| F3 | 5461 |
| F10 | 5355 |
| PRCP | 5033 |
| GP1BB | 4968 |
| THBD | 4047 |
| PROS1 | 3322 |
| VWF | 3201 |
| PROCR | 3157 |
| SERPINA5 | 2655 |
| SERPING1 | 1779 |
| F8 | -4842 |
| KLKB1 | -5366 |
| C1QBP | -6427 |
Branched-chain amino acid catabolism
| 123 | |
|---|---|
| set | Branched-chain amino acid catabolism |
| setSize | 21 |
| pANOVA | 3.89e-05 |
| s.dist | -0.519 |
| p.adjustANOVA | 0.000295 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| BCKDHB | -8636 |
| PPM1K | -8064 |
| ACAT1 | -7523 |
| HIBCH | -7345 |
| IVD | -7156 |
| BCAT2 | -6384 |
| HIBADH | -6289 |
| DBT | -6233 |
| MCCC1 | -5914 |
| ALDH6A1 | -5760 |
| DLD | -5637 |
| MCCC2 | -5416 |
| HSD17B10 | -5319 |
| ACAD8 | -5066 |
| ECHS1 | -4997 |
| BCKDHA | -4992 |
| BCKDK | -4893 |
| ACADSB | -4135 |
| AUH | -1884 |
| SLC25A44 | -1198 |
| GeneID | Gene Rank |
|---|---|
| BCKDHB | -8636 |
| PPM1K | -8064 |
| ACAT1 | -7523 |
| HIBCH | -7345 |
| IVD | -7156 |
| BCAT2 | -6384 |
| HIBADH | -6289 |
| DBT | -6233 |
| MCCC1 | -5914 |
| ALDH6A1 | -5760 |
| DLD | -5637 |
| MCCC2 | -5416 |
| HSD17B10 | -5319 |
| ACAD8 | -5066 |
| ECHS1 | -4997 |
| BCKDHA | -4992 |
| BCKDK | -4893 |
| ACADSB | -4135 |
| AUH | -1884 |
| SLC25A44 | -1198 |
| BCAT1 | 2281 |
Translation of Replicase and Assembly of the Replication Transcription Complex_9679504
| 1370 | |
|---|---|
| set | Translation of Replicase and Assembly of the Replication Transcription Complex_9679504 |
| setSize | 12 |
| pANOVA | 0.00196 |
| s.dist | -0.516 |
| p.adjustANOVA | 0.00834 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIK3C3 | -8581 |
| CHMP3 | -8379 |
| PIK3R4 | -7915 |
| CHMP2B | -6818 |
| CHMP7 | -6760 |
| CHMP2A | -6492 |
| CHMP4B | -5674 |
| UVRAG | -5296 |
| CHMP6 | -3052 |
| MAP1LC3B | -2392 |
| BECN1 | -1741 |
| CHMP4A | 120 |
| GeneID | Gene Rank |
|---|---|
| PIK3C3 | -8581 |
| CHMP3 | -8379 |
| PIK3R4 | -7915 |
| CHMP2B | -6818 |
| CHMP7 | -6760 |
| CHMP2A | -6492 |
| CHMP4B | -5674 |
| UVRAG | -5296 |
| CHMP6 | -3052 |
| MAP1LC3B | -2392 |
| BECN1 | -1741 |
| CHMP4A | 120 |
Beta-catenin phosphorylation cascade
| 114 | |
|---|---|
| set | Beta-catenin phosphorylation cascade |
| setSize | 17 |
| pANOVA | 0.000242 |
| s.dist | -0.514 |
| p.adjustANOVA | 0.00146 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AXIN1 | -9179 |
| AMER1 | -8922 |
| FRAT2 | -8670 |
| PPP2R5C | -8460 |
| APC | -7499 |
| CSNK1A1 | -6329 |
| PPP2CA | -6239 |
| PPP2R5D | -6188 |
| FRAT1 | -5993 |
| PPP2R5E | -5836 |
| PPP2R5B | -5648 |
| PPP2CB | -4090 |
| GSK3B | -3239 |
| CTNNB1 | -2957 |
| PPP2R5A | -2472 |
| PPP2R1A | -1738 |
| PPP2R1B | 4557 |
| GeneID | Gene Rank |
|---|---|
| AXIN1 | -9179 |
| AMER1 | -8922 |
| FRAT2 | -8670 |
| PPP2R5C | -8460 |
| APC | -7499 |
| CSNK1A1 | -6329 |
| PPP2CA | -6239 |
| PPP2R5D | -6188 |
| FRAT1 | -5993 |
| PPP2R5E | -5836 |
| PPP2R5B | -5648 |
| PPP2CB | -4090 |
| GSK3B | -3239 |
| CTNNB1 | -2957 |
| PPP2R5A | -2472 |
| PPP2R1A | -1738 |
| PPP2R1B | 4557 |
Regulation of expression of SLITs and ROBOs
| 1051 | |
|---|---|
| set | Regulation of expression of SLITs and ROBOs |
| setSize | 162 |
| pANOVA | 1.86e-29 |
| s.dist | -0.513 |
| p.adjustANOVA | 1.01e-27 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| MAGOH | -8779 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| GeneID | Gene Rank |
|---|---|
| RPL9 | -9193 |
| RPSA | -9069 |
| RPL8 | -9045 |
| RPS27 | -9023 |
| RPL39 | -9019 |
| RPL10 | -8958 |
| RPS21 | -8956 |
| RPL35 | -8896 |
| RPS29 | -8889 |
| RPL5 | -8844 |
| RPL19 | -8835 |
| RPS23 | -8794 |
| MAGOH | -8779 |
| FAU | -8778 |
| RPL37 | -8774 |
| RPL13 | -8760 |
| RPS16 | -8752 |
| RPS15A | -8723 |
| RPL26 | -8660 |
| RPS24 | -8637 |
| RPS3A | -8610 |
| RPL21 | -8604 |
| RPL22 | -8602 |
| PSMD9 | -8596 |
| RPL38 | -8575 |
| RPL30 | -8551 |
| RPS15 | -8544 |
| RPS6 | -8538 |
| RPL18A | -8510 |
| RPL32 | -8491 |
| RPL7A | -8488 |
| RPS10 | -8476 |
| RPL36 | -8458 |
| UPF3B | -8403 |
| RPL35A | -8364 |
| RPL27 | -8329 |
| RPL34 | -8283 |
| RPL4 | -8279 |
| RPS11 | -8273 |
| UPF2 | -8225 |
| RPL37A | -8193 |
| RPL29 | -8173 |
| RPL11 | -8081 |
| RPL24 | -8040 |
| UBA52 | -8015 |
| RPL15 | -7966 |
| RPL31 | -7935 |
| RPS20 | -7922 |
| RPL7 | -7911 |
| RPL41 | -7858 |
| RPS25 | -7825 |
| RPS17 | -7816 |
| RPL13A | -7782 |
| RPS12 | -7764 |
| RPL6 | -7750 |
| RPL23 | -7726 |
| RPL36AL | -7677 |
| RPS9 | -7651 |
| CASC3 | -7613 |
| RPLP2 | -7545 |
| RPS4Y1 | -7535 |
| RPS8 | -7427 |
| PSMC2 | -7403 |
| RPS4X | -7375 |
| RPS7 | -7364 |
| RPL10A | -7319 |
| PSMB3 | -7282 |
| RPL28 | -7270 |
| RPL18 | -7257 |
| USP33 | -7216 |
| ELOB | -7170 |
| RPS28 | -7167 |
| RPS27A | -7158 |
| RPS2 | -7146 |
| PSMA3 | -7105 |
| RPS13 | -7092 |
| PSMB10 | -6950 |
| PSMB1 | -6768 |
| RPS19 | -6727 |
| RPL17 | -6676 |
| RPS14 | -6574 |
| PSMF1 | -6454 |
| PSME3 | -6306 |
| RPS5 | -6187 |
| RPLP1 | -6159 |
| PSMB6 | -6137 |
| PSMD3 | -5977 |
| UBB | -5814 |
| RPL27A | -5778 |
| RPL36A | -5540 |
| PSMD8 | -5400 |
| NCBP1 | -5334 |
| PSMA6 | -5322 |
| PSMC6 | -5268 |
| GSPT1 | -5112 |
| PSMC5 | -5067 |
| PSMA2 | -5031 |
| CUL2 | -4996 |
| RPS3 | -4984 |
| PSMA7 | -4955 |
| RPS18 | -4906 |
| UBC | -4857 |
| PSMB7 | -4777 |
| SEM1 | -4750 |
| PSMA4 | -4631 |
| PSMD13 | -4372 |
| RPL23A | -4282 |
| PSMA1 | -4199 |
| PSMD6 | -4060 |
| RBM8A | -3948 |
| PSMD11 | -3874 |
| PSMD12 | -3731 |
| ELOC | -3489 |
| ETF1 | -3370 |
| RNPS1 | -3368 |
| HOXA2 | -3339 |
| RBX1 | -3249 |
| RPS27L | -3238 |
| PSMC4 | -3144 |
| PSMD4 | -3131 |
| UPF3A | -3033 |
| RPL12 | -3022 |
| PSMC3 | -2992 |
| PSMB5 | -2933 |
| PSMC1 | -2895 |
| PSMD7 | -2738 |
| EIF4A3 | -2560 |
| PSMA5 | -2419 |
| RPL14 | -2377 |
| RPL3L | -2329 |
| GSPT2 | -1860 |
| PSME2 | -1779 |
| PSME1 | -1715 |
| LDB1 | -1450 |
| PSME4 | -1447 |
| EIF4G1 | -1413 |
| ZSWIM8 | -1358 |
| PSMD2 | -768 |
| PSMD14 | -686 |
| PSMB2 | -661 |
| ROBO1 | -547 |
| PABPC1 | -423 |
| PSMD1 | -351 |
| RPLP0 | -196 |
| RPL39L | -143 |
| PSMB4 | -124 |
| LHX4 | 38 |
| DAG1 | 168 |
| PSMD10 | 323 |
| RPS26 | 577 |
| RPL22L1 | 602 |
| ROBO2 | 1984 |
| PSMB8 | 2089 |
| NCBP2 | 2415 |
| RPL26L1 | 2574 |
| RPL3 | 3020 |
| ROBO3 | 3477 |
| COL4A5 | 3912 |
| PSMD5 | 4392 |
| PSMB9 | 4445 |
| MAGOHB | 5294 |
| SLIT2 | 5948 |
Laminin interactions
| 626 | |
|---|---|
| set | Laminin interactions |
| setSize | 30 |
| pANOVA | 1.54e-06 |
| s.dist | 0.507 |
| p.adjustANOVA | 1.94e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LAMA5 | 7035 |
| NID1 | 6988 |
| LAMA3 | 6917 |
| COL18A1 | 6872 |
| LAMB1 | 6787 |
| ITGA3 | 6774 |
| COL4A1 | 6492 |
| HSPG2 | 6439 |
| COL4A2 | 6432 |
| ITGB4 | 6414 |
| LAMA2 | 5859 |
| ITGA1 | 4864 |
| COL4A6 | 4606 |
| ITGB1 | 4290 |
| COL4A5 | 3912 |
| ITGA6 | 3776 |
| LAMA4 | 3639 |
| LAMC1 | 3149 |
| COL4A4 | 2640 |
| ITGA7 | 2519 |
| GeneID | Gene Rank |
|---|---|
| LAMA5 | 7035 |
| NID1 | 6988 |
| LAMA3 | 6917 |
| COL18A1 | 6872 |
| LAMB1 | 6787 |
| ITGA3 | 6774 |
| COL4A1 | 6492 |
| HSPG2 | 6439 |
| COL4A2 | 6432 |
| ITGB4 | 6414 |
| LAMA2 | 5859 |
| ITGA1 | 4864 |
| COL4A6 | 4606 |
| ITGB1 | 4290 |
| COL4A5 | 3912 |
| ITGA6 | 3776 |
| LAMA4 | 3639 |
| LAMC1 | 3149 |
| COL4A4 | 2640 |
| ITGA7 | 2519 |
| NID2 | 2251 |
| COL7A1 | 967 |
| COL4A3 | 892 |
| LAMC2 | 582 |
| LAMB2 | 563 |
| LAMA1 | -56 |
| ITGA2 | -233 |
| ITGAV | -743 |
| LAMC3 | -5840 |
| LAMB3 | -9095 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.3.2 (2023-10-31)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_AU.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_AU.UTF-8 LC_COLLATE=en_AU.UTF-8
## [5] LC_MONETARY=en_AU.UTF-8 LC_MESSAGES=en_AU.UTF-8
## [7] LC_PAPER=en_AU.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_AU.UTF-8 LC_IDENTIFICATION=C
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] pkgload_1.3.3 GGally_2.2.0
## [3] beeswarm_0.4.0 gtools_3.9.5
## [5] echarts4r_0.4.5 kableExtra_1.3.4
## [7] topconfects_1.18.0 limma_3.58.1
## [9] eulerr_7.0.0 mitch_1.14.0
## [11] MASS_7.3-60 fgsea_1.28.0
## [13] gplots_3.1.3 DESeq2_1.42.0
## [15] SummarizedExperiment_1.32.0 Biobase_2.62.0
## [17] MatrixGenerics_1.14.0 matrixStats_1.2.0
## [19] GenomicRanges_1.54.1 GenomeInfoDb_1.38.5
## [21] IRanges_2.36.0 S4Vectors_0.40.2
## [23] BiocGenerics_0.48.1 reshape2_1.4.4
## [25] lubridate_1.9.3 forcats_1.0.0
## [27] stringr_1.5.1 dplyr_1.1.4
## [29] purrr_1.0.2 readr_2.1.4
## [31] tidyr_1.3.0 tibble_3.2.1
## [33] ggplot2_3.4.4 tidyverse_2.0.0
## [35] zoo_1.8-12 R.utils_2.12.3
## [37] R.oo_1.25.0 R.methodsS3_1.8.2
##
## loaded via a namespace (and not attached):
## [1] bitops_1.0-7 gridExtra_2.3 rlang_1.1.2
## [4] magrittr_2.0.3 compiler_4.3.2 systemfonts_1.0.5
## [7] vctrs_0.6.5 rvest_1.0.3 pkgconfig_2.0.3
## [10] crayon_1.5.2 fastmap_1.1.1 XVector_0.42.0
## [13] ellipsis_0.3.2 caTools_1.18.2 utf8_1.2.4
## [16] promises_1.2.1 rmarkdown_2.25 tzdb_0.4.0
## [19] xfun_0.41 cachem_1.0.8 zlibbioc_1.48.0
## [22] jsonlite_1.8.8 highr_0.10 later_1.3.2
## [25] DelayedArray_0.28.0 BiocParallel_1.36.0 parallel_4.3.2
## [28] R6_2.5.1 bslib_0.6.1 stringi_1.8.3
## [31] RColorBrewer_1.1-3 jquerylib_0.1.4 assertthat_0.2.1
## [34] Rcpp_1.0.11 knitr_1.45 httpuv_1.6.13
## [37] Matrix_1.6-4 timechange_0.2.0 tidyselect_1.2.0
## [40] yaml_2.3.8 rstudioapi_0.15.0 abind_1.4-5
## [43] codetools_0.2-19 lattice_0.22-5 plyr_1.8.9
## [46] shiny_1.8.0 withr_2.5.2 evaluate_0.23
## [49] ggstats_0.5.1 xml2_1.3.6 pillar_1.9.0
## [52] KernSmooth_2.23-22 generics_0.1.3 RCurl_1.98-1.13
## [55] hms_1.1.3 munsell_0.5.0 scales_1.3.0
## [58] xtable_1.8-4 glue_1.6.2 tools_4.3.2
## [61] data.table_1.14.10 webshot_0.5.5 locfit_1.5-9.8
## [64] fastmatch_1.1-4 cowplot_1.1.2 grid_4.3.2
## [67] colorspace_2.1-0 GenomeInfoDbData_1.2.11 cli_3.6.2
## [70] fansi_1.0.6 viridisLite_0.4.2 S4Arrays_1.2.0
## [73] svglite_2.1.3 gtable_0.3.4 sass_0.4.8
## [76] digest_0.6.33 SparseArray_1.2.3 htmlwidgets_1.6.4
## [79] htmltools_0.5.7 lifecycle_1.0.4 httr_1.4.7
## [82] statmod_1.5.0 mime_0.12
END of report